

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70677 A1

(51) International Patent Classification⁷: **C07C 311/07**,
311/09, 311/11, 311/14, 311/20, 311/24, 323/67, C07D
207/36, 211/14, 213/38, 213/70, 213/71, 213/81, 215/20,
233/84, 249/08, 275/02, 277/36, 277/42, 295/18, 295/22,
307/64, 307/81, 319/18, 333/20, 333/34, 409/12, 413/12,
413/14, 417/12, 487/04, 491/08, 491/10, A61K 31/18,
A61P 25/28

(21) International Application Number: **PCT/GB01/01154**

(22) International Filing Date: 15 March 2001 (15.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0006717.3 20 March 2000 (20.03.2000) GB
0026827.6 2 November 2000 (02.11.2000) GB

(71) Applicants (for all designated States except US):
MERCK SHARP & DOHME LIMITED [GB/GB];
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU
(GB). **MERCK FROSST CANADA & CO.** [CA/CA];
Purdy's Wharf Tower One, 1959 Upper Water Street,
Halifax, Nova Scotia B3J 2X2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BELANGER**,
Patrice, Charles [CA/CA]; 419 Davignon Drive, Dol-
lard-des-Ormeaux, Québec H9B 1Y4 (CA). **COLLINS**,
Ian, James [GB/GB]; Terlings Park, Eastwick Road,
Harlow, Essex CM20 2QR (GB). **HANNAM, Joanne**,
Claire [GB/GB]; Terlings Park, Eastwick Road, Har-
low, Essex CM20 2QR (GB). **HARRISON, Timothy**
[GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex
CM20 2QR (GB). **LEWIS, Stephen, John** [GB/GB];

Terlings Park, Eastwick Road, Harlow, Essex CM20
2QR (GB). **MADIN, Andrew** [GB/GB]; Terlings Park,
Eastwick Road, Harlow, Essex CM20 2QR (GB). **MC**
IVER, Edward, Giles [GB/GB]; Terlings Park, East-
wick Road, Harlow, Essex CM20 2QR (GB). **NADIN**,
Alan, John [GB/GB]; Terlings Park, Eastwick Road,
Harlow, Essex CM20 2QR (GB). **NEDUVELIL, Joseph**,
George [GB/GB]; Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB). **SHEARMAN, Mark, Steven**
[GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex
CM20 2QR (GB). **SMITH, Adrian, Leonard** [GB/GB];
Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR
(GB). **SPAREY, Timothy, Jason** [GB/GB]; Terlings
Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).
STEVENSON, Graeme, Irvine [GB/GB]; Terlings Park,
Eastwick Road, Harlow, Essex CM20 2QR (GB). **TEALL**,
Martin, Richard [GB/GB]; Terlings Park, Eastwick Road,
Harlow, Essex CM20 2QR (GB).


(74) Agent: **HORGAN, James, Michael, Frederic**; European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES



(57) Abstract: A class of compounds is disclosed, compris-
ing sulphonamido-substituted bridged bicycloalkyl structures
of formula (I) (where the variables are as defined in the claims).
The compounds are inhibitors of γ -secretase, and hence are use-
ful in the treatment of and/or prevention of Alzheimer's disease.

WO 01/70677 A1



Published:

with international search report

For two-letter codes and other abbreviations, refer to "Reference Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL
DERIVATIVES

The present invention relates to a novel class of compounds their
5 salts, pharmaceutical compositions comprising them, processes for making
them and their use in therapy of the human body. In particular, the
invention relates to compounds which are inhibitors of γ -secretase, and
hence are useful in the treatment or prevention of Alzheimer's disease.

Alzheimer's disease (AD) is the most prevalent form of dementia.
10 Although primarily a disease of the elderly, affecting up to 10% of the
population over the age of 65, AD also affects significant numbers of
younger patients with a genetic predisposition. It is a neurodegenerative
disorder, clinically characterized by progressive loss of memory and
cognitive function, and pathologically characterized by the deposition of
15 extracellular proteinaceous plaques in the cortical and associative brain
regions of sufferers. These plaques mainly comprise fibrillar aggregates of
 β -amyloid peptide ($A\beta$), and although their exact role in the onset and
progress of AD is not fully understood, it is generally accepted that
suppressing or attenuating their formation is a likely means of alleviating
20 or preventing the condition. (See, for example, ID *research alert* 1996
1(2):1-7; ID *research alert* 1997 2(1):1-8; Current Opinion in CPNS
Investigational Drugs 1999 1(3):327-332; and Chemistry in Britain, Jan.
2000, 28-31.)

$A\beta$ is a peptide comprising 39-43 amino acid residues, formed by
25 proteolysis of the much larger amyloid precursor protein. The amyloid
precursor protein (APP or $A\beta$ PP) has a receptor-like structure with a large
ectodomain, a membrane spanning region and a short cytoplasmic tail.
Different isoforms of APP result from the alternative splicing of three
exons in a single gene and have 695, 751 and 770 amino acids respectively.

30 The $A\beta$ domain encompasses parts of both extra-cellular and
transmembrane domains of APP, thus its release implies the existence of

two distinct proteolytic events to generate its NH₂- and COOH-termini. At least two secretory mechanisms exist which release APP from the membrane and generate the soluble, COOH-truncated forms of APP (APP_s). Proteases which release APP and its fragments from the
5 membrane are termed "secretases". Most APP_s is released by a putative α -secretase which cleaves within the A β domain (between residues Lys¹⁶ and Leu¹⁷) to release α -APP_s and precludes the release of intact A β . A minor portion of APP_s is released by a β -secretase, which cleaves near the NH₂-terminus of A β and produces COOH-terminal fragments (CTFs) which
10 contain the whole A β domain. Finding these fragments in the extracellular compartment suggests that another proteolytic activity (γ -secretase) exists under normal conditions which can generate the COOH-terminus of A β .


It is believed that γ -secretase itself depends for its activity on the
15 presence of presenilin-1. In a manner that is not fully understood presenilin-1 appears to undergo autocleavage.

There are relatively few reports in the literature of compounds with inhibitory activity towards β - or γ -secretase, as measured in cell-based assays. These are reviewed in the articles referenced above. Many of the
20 relevant compounds are peptides or peptide derivatives.

A limited number of phenylsulphonylamino-substituted bridged bicycloalkane derivatives are disclosed in a non-pharmaceutical context in *J. Org. Chem.*, **30**(12), 4205-11 (1965).

The present invention provides a novel class of non-peptidic
25 compounds which are useful in the treatment or prevention of AD by inhibiting the activity of the putative γ -secretase, thus arresting the production of A β and preventing the formation of insoluble plaques.




According to the invention, there is provided a pharmaceutical
30 composition comprising, in a pharmaceutically acceptable carrier, a therapeutically effective amount of one or more compounds of formula I:



wherein:

A and B are independently selected from $-(CXY)_p-$; -

5. $(CXY)_qCY = CY(CXY)_r-$; $-(CXY)_xNR^{13}(CXY)_y-$;



X represents halogen, R^9 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where t is 1 or 2,
 10 $-OSO_2R^9$, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-OCO_2R^{10}$, $-CON(R^9)_2$,
 $-SO_2N(R^9)_2$, $-OSO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$ or $-NR^9SO_2R^{10}$;

Y represents H or C_{1-6} alkyl;

or X and Y together represent $=O$, $=S$, $=N-OR^{11}$ or $=CHR^{11}$;

provided neither A nor B comprises more than one $-CXY-$ moiety
 15 which is other than $-CH_2-$;

Z completes an aromatic ring system of 5 to 10 atoms, of which 0 to 3 are selected from nitrogen, oxygen and sulfur and the remainder are carbon, or Z completes a non-aromatic ring system of 5 to 10 atoms, of

which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon;

Z^1 completes a non-aromatic ring system of 5 to 10 atoms, of which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and
5 the remainder are carbon;

Z^2 completes a 5- or 6-membered heteroaryl ring;

m and n are independently 1 or 0;

p is an integer from 1-6;

q and r are independently 0, 1 or 2;

10 x and y are independently 0, 1 or 2;

provided that when $m = n = 0$, at least one of A and B comprises a chain of 2 or more atoms, such that the ring completed by A and B contains at least 5 atoms;

R^1 represents H, C_{1-4} alkyl, or C_{2-4} alkenyl;

15 R^2 represents H, C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl C_{1-6} alkyl, C_{3-6} cycloalkyl or C_{2-6} acyl which is optionally substituted with a carboxylic acid group or with an amino group;

R^3 represents C_{1-16} alkyl, C_{3-10} cycloalkyl, C_{2-16} alkenyl, C_{2-16} alkynyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{6-10} aryl C_{2-6} alkenyl, heteroaryl C_{2-6} alkenyl, C_{6-10} aryl, bi(C_{6-10} aryl), heteroaryl, bi(heteroaryl) or heterocyclyl; wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups represented by R^3 or forming part of a group represented by R^3 optionally bear up to 3 substituents independently selected from halogen, CN, NO_2 , $-OR^7$, $-SR^7$, $-S(O)_tR^8$ where t is 1 or 2, $-N(R^7)_2$, $-COR^7$, $-CO_2R^7$, $-OCOR^8$, $-CON(R^7)_2$, $-NR^7COR^8$, $-C_{1-6}$ alkyl NR^7COR^8 , $-NR^7CO_2R^8$ and $-NR^7SO_2R^8$; and the aryl, heteroaryl and heterocyclic groups represented by R^3 or forming part of a group represented by R^3 optionally bear up to 5 substituents independently selected from R^8 , halogen, CN, NO_2 , $-OR^7$, $-SR^7$, $-S(O)_tR^8$ where t is 1 or 2, $-N(R^7)_2$, $-COR^7$, $-CO_2R^7$, $-OCOR^8$, $-CON(R^7)_2$, $-NR^7COR^8$, $-C_{1-6}$ alkyl NR^7COR^8 , $-NR^7CO_2R^8$ and $-NR^7SO_2R^8$;
25
30

R^4 , R^5 and R^6 independently represent R^9 , halogen, CN, NO_2 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where t is 1 or 2, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-CON(R^9)_2$, $-SO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$, $-NR^9SO_2R^{10}$, $-CH=CHCH_2N(R^{16})_2$, $-CH_2OR^{10}$, $-CH_2N(R^{16})_2$, $-NHCOCH_2OR^{10}$ or

5 $-NHCOCH_2N(R^{16})_2$;

R^7 represents H or R^8 ; or two R^7 groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring;

R^8 represents C_{1-10} alkyl, perfluoro C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{3-6} cycloalkyl C_{1-6} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, Ar or $-C_{1-6}$ alkylAr;

10

R^9 represents H or R^{10} ; or two R^9 groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring which is optionally substituted by R^{12} , $-COR^{12}$ or $-SO_2R^{12}$;

R^{10} represents C_{1-10} alkyl, perfluoro C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{3-6} cycloalkyl C_{1-6} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{6-10} aryl, heteroaryl, heterocyclyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{6-10} aryl C_{2-6} alkenyl, or heteroaryl C_{2-6} alkenyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups optionally bear one substituent selected from halogen, CF_3 , NO_2 , CN, $-OR^{11}$, $-SR^{11}$, $-SO_2R^{12}$, $-COR^{11}$, $-CO_2R^{11}$, $-CON(R^{11})_2$, $-OCOR^{12}$, $-N(R^{11})_2$ and $-NR^{11}COR^{12}$; and the aryl, heteroaryl and heterocyclic groups optionally bear up to 3 substituents independently selected from halogen, NO_2 , CN, R^{12} , $-OR^{11}$, $-SR^{11}$, $-SO_2R^{12}$, $-COR^{11}$, $-CO_2R^{11}$, $-CON(R^{11})_2$, $-OCOR^{12}$, $-N(R^{11})_2$ and $-NR^{11}COR^{12}$;

15

20

R^{11} represents H or R^{12} ;

25

R^{12} represents C_{1-6} alkyl, perfluoro C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, Ar, $-C_{1-6}$ alkylAr or $ArOC_{1-6}$ alkyl; or two R^{12} groups together with a nitrogen atom to which they are mutually attached may complete a heterocyclic ring system of 3-10 atoms, 0-2 of which (in addition to said nitrogen atom) are selected from O, N and S, said ring system

30

bearing 0-2 substituents selected from halogen, CN, NO₂, R¹², OR¹¹, NHR¹¹, and COR¹¹.

R¹³ represents R⁹, -COR¹⁰, -CO₂R¹⁰, -SO₂R¹⁰, -CON(R⁹)₂ or -SO₂N(R⁹)₂;

5 each R¹⁶ independently represents H or R¹⁰, or two R¹⁶ groups together with the nitrogen to which they are mutually attached complete a mono- or bicyclic heterocyclic ring system of 5-10 ring atoms selected from C, N, O and S, said ring system optionally having an additional aryl or heteroaryl ring fused thereto, said heterocyclic system and/or additional
10 fused ring bearing 0-3 substituents independently selected from halogen, NO₂, CN, R¹², -OR¹¹, -SR¹¹, -SO₂R¹², -COR¹¹, -CO₂R¹¹, -CON(R¹¹)₂, -OCOR¹², -N(R¹¹)₂ and -NR¹¹COR¹²;

Ar represents phenyl or heteroaryl either of which optionally bears up to 3 substituents independently selected from halogen, CF₃, NO₂, CN,
15 OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;

"heterocyclyl" at every occurrence thereof means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein none of the constituent rings is aromatic and wherein at least one ring atom is other than C; and


20 "heteroaryl" at every occurrence thereof means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein at least one of the constituent rings is aromatic and wherein at least one ring atom is other than C;

or a pharmaceutically acceptable salt thereof.

25 In a subset of the compounds according to formula I,
R¹² represents C₁₋₆alkyl, perfluoroC₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Ar, -C₁₋₆alkylAr or ArOC₁₋₆alkyl.

In a further subset of the compounds of formula I,

A represents -(CXY)_p; -(CXY)_qCY = CY(CXY)_r;



B represents $\text{-(CXY)}_s\text{-}$ or $\text{-(CXY)}_q\text{CY}=\text{CY(CXY)}_r\text{-}$;

X represents halogen, R^9 , -OR^9 , -SR^9 , $\text{-S(O)}_t\text{R}^{10}$ where t is 1 or 2,
 5 $\text{-N(R}^9)_2$, -COR^9 , $\text{-CO}_2\text{R}^9$, -OCOR^{10} , $\text{-CON(R}^9)_2$, $\text{-SO}_2\text{N(R}^9)_2$, $\text{-NR}^9\text{COR}^{10}$,
 $\text{-NR}^9\text{CO}_2\text{R}^{10}$ or $\text{-NR}^9\text{SO}_2\text{R}^{10}$;

Y represents H or C_{1-6} alkyl;

or X and Y together represent $=\text{O}$ or $=\text{CH}_2$;

provided neither A nor B comprises more than one -CXY- moiety
 10 which is other than $\text{-CH}_2\text{-}$;

Z completes an aromatic ring system of 6 to 10 atoms, of which 0 to 2 are nitrogen and the remainder are carbon, or Z completes a non-aromatic ring system of 5 to 10 atoms, of which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon;

15 Z^1 completes a non-aromatic ring system of 5 to 10 atoms, of which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon;

m and n are independently 1 or 0;

p is an integer from 1-6;

20 q and r are independently 0, 1 or 2;

s is an integer from 1-6;

provided that when $m = n = 0$, at least one of p and s is greater than 1;

R^1 represents H or C_{1-4} alkyl;

R^2 represents H, C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl C_{1-6} alkyl or
 25 C_{3-6} cycloalkyl;

R^3 represents C_{1-16} alkyl, C_{3-10} cycloalkyl, C_{2-16} alkenyl, C_{2-16} alkynyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{6-10} aryl, bi(C_{6-10} aryl), heteroaryl, bi(heteroaryl) or heterocyclyl; wherein the alkyl, cycloalkyl, alkenyl and

alkynyl groups represented by R^3 or forming part of a group represented by R^3 optionally bear up to 3 substituents independently selected from halogen, CN, NO_2 , $-\text{OR}^7$, $-\text{SR}^7$, $-\text{S}(\text{O})_t\text{R}^8$ where t is 1 or 2, $-\text{N}(\text{R}^7)_2$, $-\text{COR}^7$, $-\text{CO}_2\text{R}^7$, $-\text{OCOR}^8$, $-\text{CON}(\text{R}^7)_2$, $-\text{NR}^7\text{COR}^8$, $-\text{C}_{1-6}\text{alkylNR}^7\text{COR}^8$, $-\text{NR}^7\text{CO}_2\text{R}^8$ and $-\text{NR}^7\text{SO}_2\text{R}^8$; and the aryl, heteroaryl and heterocyclic groups represented by R^3 or forming part of a group represented by R^3 optionally bear up to 5 substituents independently selected from R^8 , halogen, CN, NO_2 , $-\text{OR}^7$, $-\text{SR}^7$, $-\text{S}(\text{O})_t\text{R}^8$ where t is 1 or 2, $-\text{N}(\text{R}^7)_2$, $-\text{COR}^7$, $-\text{CO}_2\text{R}^7$, $-\text{OCOR}^8$, $-\text{CON}(\text{R}^7)_2$, $-\text{NR}^7\text{COR}^8$, $-\text{C}_{1-6}\text{alkylNR}^7\text{COR}^8$, $-\text{NR}^7\text{CO}_2\text{R}^8$ and $-\text{NR}^7\text{SO}_2\text{R}^8$;

R^4 , R^5 and R^6 are independently R^9 , halogen, CN, NO_2 , $-\text{OR}^9$, $-\text{SR}^9$, $-\text{S}(\text{O})_t\text{R}^{10}$ where t is 1 or 2, $-\text{N}(\text{R}^9)_2$, $-\text{COR}^9$, $-\text{CO}_2\text{R}^9$, $-\text{OCOR}^{10}$, $-\text{CON}(\text{R}^9)_2$, $-\text{SO}_2\text{N}(\text{R}^9)_2$, $-\text{NR}^9\text{COR}^{10}$, $-\text{NR}^9\text{CO}_2\text{R}^{10}$ or $-\text{NR}^9\text{SO}_2\text{R}^{10}$;

R^7 is H or R^8 ; or two R^7 groups together with a nitrogen atom to which they are mutually attached may complete a piperidine, piperazine or morpholine ring;

R^8 is $\text{C}_{1-10}\text{alkyl}$, perfluoro $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkylC}_{1-6}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, Ar or $-\text{C}_{1-6}\text{alkylAr}$;

R^9 is H or R^{10} ; or two R^9 groups together with a nitrogen atom to which they are mutually attached may complete a piperidine, piperazine or morpholine ring which is optionally substituted by R^{12} , $-\text{COR}^{12}$ or $-\text{SO}_2\text{R}^{12}$;

R^{10} is $\text{C}_{1-10}\text{alkyl}$, perfluoro $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkylC}_{1-6}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, $\text{C}_{6-10}\text{aryl}$, heteroaryl, heterocyclyl, $\text{C}_{6-10}\text{arylC}_{1-6}\text{alkyl}$, or heteroaryl $\text{C}_{1-6}\text{alkyl}$, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups optionally bear one substituent selected from halogen, CF_3 , NO_2 , CN, $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{12}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{OCOR}^{12}$, $-\text{N}(\text{R}^{11})_2$ and $-\text{NR}^{11}\text{COR}^{12}$; and the aryl, heteroaryl and heterocyclic groups optionally bear up to 3 substituents independently selected from halogen, NO_2 , CN, R^{12} , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{12}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{OCOR}^{12}$, $-\text{N}(\text{R}^{11})_2$ and $-\text{NR}^{11}\text{COR}^{12}$;

R¹¹ is H or R¹²;

R¹² is C₁₋₆alkyl, perfluoroC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Ar or -C₁₋₆alkylAr; and

Ar is phenyl or heteroaryl either of which optionally bears up to 3
5 substituents independently selected from halogen, CF₃, NO₂, CN, C₁₋₆alkyl and C₁₋₆alkoxy;

where "heterocyclyl" and "heteroaryl" are as defined previously.

In a further aspect, the invention provides a compound of formula I
as defined above, or a pharmaceutically acceptable salt thereof, with the
10 proviso that:

when A = B = -CH₂CH₂-, R¹ = R² = H, R³ = phenyl and m = 0, (CXY)_n
is other than -CH₂-, -CH(Br)- or -CH(SPh)-; and

when m = n = 0, R¹ = R² = H, R³ = phenyl and B = -CH₂CH₂-, A is
other than -CH(Br)CH₂CH₂-.

15 Where a variable occurs more than once in formula I or in a
substituent thereof, the individual occurrences of that variable are
independent of each other, unless otherwise specified.

As used herein, the expression "C_{1-x}alkyl" where x is an integer
greater than 1 refers to straight-chained and branched alkyl groups
20 wherein the number of constituent carbon atoms is in the range 1 to x.
Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
Derived expressions such as "C₂₋₆alkenyl", "hydroxyC₁₋₆alkyl",
"heteroaryl"C₁₋₆alkyl, "C₂₋₆alkynyl" and "C₁₋₆alkoxy" are to be construed in
an analogous manner.

25 The expression "perfluoroC₁₋₆alkyl" as used herein refers to alkyl
groups as defined above comprising at least one -CF₂- or -CF₃ group.

The expression "C₃₋₁₀cycloalkyl" as used herein refers to
nonaromatic monocyclic or fused bicyclic hydrocarbon ring systems
comprising from 3 to 10 ring atoms. Examples include cyclopropyl,
30 cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl and decalinyl.

The expression "C₃₋₆ cycloalkyl(C₁₋₆)alkyl" as used herein includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.

The expression "C₂₋₆acyl" as used herein refers to (C₁₋₅alkyl)carbonyl groups, such as acetyl, propanoyl and butanoyl, including cycloalkyl derivatives such as cyclopentanecarbonyl and cyclobutanecarbonyl.

C₆₋₁₀aryl groups include phenyl and naphthyl, preferably phenyl.

The expression "bi(C₆₋₁₀aryl)" refers to two aryl groups as defined above linked by a single bond, an example being biphenyl.

The expression "C₆₋₁₀arylC₁₋₆alkyl," as used herein includes benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

The expression "heterocyclyl" as used herein means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein none of the constituent rings is aromatic and wherein at least one ring atom is other than carbon. Preferably not more than 3 ring atoms are other than carbon. Suitable heterocyclyl groups include azetidiny, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl.

Further examples of heterocyclic ring systems include 2,5-diazabicyclo[2.2.1]heptane and 2-aza-5-oxabicyclo[2.2.1]heptane.

The expression "heteroaryl" as used herein means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein at least one of the constituent rings is aromatic and wherein at least one ring atom is other than carbon. Preferably not more than 3 ring atoms are other than carbon. Where a heteroaryl ring comprises two or more atoms which are not carbon, not more than one of said atoms may be other than nitrogen. Examples of heteroaryl groups include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, triazolyl and thiadiazolyl groups and benzo-fused analogues thereof. Further examples of suitable heteroaryl ring systems include

1,2,4-triazine, 1,3,5-triazine, 1,2,3,4-tetrahydroisoquinoline, imidazo[2,1-*b*]thiazole and benzo[1,4]dioxin.

A heteroaryl or heterocyclic group containing a nitrogen atom may be in the form of the corresponding N-oxide.

5 The term "bi(heteroaryl)" as used herein refers to two heteroaryl groups as defined above (which may be the same or different) linked by a single bond, for example 5-(pyridin-2-yl)thiophene-2-yl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.

10 For use in medicine, the compounds of formula I may advantageously be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention
15 include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or
20 phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

25 Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion
30 are encompassed within the scope of the present invention.

Regardless of the presence or absence of asymmetric centres, certain compounds in accordance with the invention exist as enantiomers by virtue of the asymmetry of the molecule as a whole. For example, many of the compounds of formula I in which A comprises a monosubstituted fused
5 benzene ring lack a plane of symmetry, and hence exist as pairs of enantiomers, the interconversion of which is prevented by the rigidity of the bridged bicycloalkyl ring structure. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention, and that structural formulae depicting
10 asymmetric molecules of this type shall be representative of both of the possible enantiomers, unless otherwise indicated.

The compounds of formula I are sulphonamido-substituted bridged bicycloalkyl derivatives, optionally comprising a further fused ring system.

In formula I, m and n are independently 0 or 1, but preferably at
15 least one of m and n is 0, and most preferably m and n are both 0.

p is an integer from 1 to 6, preferably from 2 to 5, and most preferably is 3 or 4.

q and r are independently 0, 1 or 2 but are preferably both 1 or both
0.

20 s is an integer from 1 to 4, and is preferably 2 or 3, most preferably 2.

x and y are independently 0, 1 or 2, but are preferably not both 0.

When $m = n = 0$, at least one of A and B comprises a chain of 2 or more atoms, such that the ring completed by A and B contains at least 5
25 atoms. Thus, for example, if $m = n = 0$ and A and B represent $-(CXY)_p-$ and $-(CXY)_x-NR^{13}-(CXY)_y-$ respectively, then p must be greater than 1 or at least one of x and y must be greater than 0.

X represents halogen, R^9 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where t is 1 or 2, $-OSO_2R^9$, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-OCO_2R^{10}$, $-CON(R^9)_2$,
30 $-SO_2N(R^9)_2$, $-OSO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$ or $-NR^9SO_2R^{10}$; wherein R^9 and R^{10} are as defined above. Alternatively, X and Y together may

represent =O, =S, =N-OR¹¹ or =CHR¹¹. In a subset of the compounds of the invention, X represents halogen, R⁹, -OR⁹, -SR⁹, -S(O)_tR¹⁰, -N(R⁹)₂, -COR⁹, -CO₂R⁹, -OCOR¹⁰, -CON(R⁹)₂, -SO₂N(R⁹)₂, -NR⁹COR¹⁰, -NR⁹CO₂R¹⁰ or -NR⁹SO₂R¹⁰; or together with Y represents =O or =CH₂. Typically, X represents H, C₁₋₄alkyl, substituted C₁₋₄alkyl, -OR^{9a}, -COR^{9a}, -CO₂R^{9a}, -OCOR^{10a}, -N(R^{9a})₂, -CON(R^{9a})₂, -OCO₂R^{10a}, -OSO₂R^{10a} or (in combination with Y) =O, =S, =N-OR¹¹, =CHAr or =CH₂, where R^{9a} is H or R^{10a}, and R^{10a} is C₁₋₆alkyl, C₂₋₆alkenyl, Ar (especially phenyl) or benzyl. Preferred embodiments of X include H, methyl, hydroxymethyl, -CO₂Et, -CONHCH₂Ph, -OCOMe, -OCO₂Me, methanesulfonyloxy, p-toluenesulfonyloxy, 2-nitrobenzoyloxy, 3,4-dimethoxybenzoyloxy, 2-methylthionicotinoyloxy, and (in combination with Y) =O, =S, =N-OMe, =N-OEt, =N-OPh, =N-OCH₂Ph, =CHPh and =CH₂.


Y may represent H or C₁₋₆alkyl, or may combine with X as indicated above. Preferably, Y represents H or together with X represents =O, =S, =N-OMe, =N-OEt, =N-OPh, =N-OCH₂Ph, =CHPh or =CH₂.

Neither A nor B may comprise more than one -CXY- moiety which is other than -CH₂-.

When A and/or B comprises a -NR¹³- moiety, R¹³ preferably represents H, optionally-substituted C₁₋₆alkyl, C₂₋₆alkenyl or C₆₋₁₀arylC₁₋₆alkyl. Particular values for R¹³ include H, methyl, ethyl, allyl, cyanomethyl, carbamoylmethyl, methoxycarbonylmethyl, benzyl, chlorobenzyl and methoxybenzyl. Preferably, A and B do not both comprise a -NR¹³- moiety.


Suitable embodiments of A and B include:

-CXY-, -CH₂CXY-, -CH₂CXYCH₂-, -CH₂CH₂CXYCH₂-, -CH=CH-, -CH₂CH=CHCXY-, -CH₂NR¹³CXY-, -CH₂CH₂NR¹³CXY-, -CH₂CXYNR¹³CH₂-, -CXYCH₂NR¹³CH₂-, -NR¹³CXY-,




Preferred embodiments of A include $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}=\text{CHCH}_2-$,

5



and



10

Typical embodiments of B include $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{NR}^{13}\text{CH}_2-$, $-\text{NR}^{13}\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, and $-\text{CH}_2\text{CH}=\text{CHCH}_2-$, and preferred embodiments of B include $-\text{CH}_2\text{CH}_2-$ and $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

15

Z completes an aromatic ring system containing 5-10 atoms, of which 0-3 are selected from nitrogen, oxygen and sulfur and the remainder













are carbon (in particular, an aromatic ring system containing 6-10 atoms, of which 0-2 are nitrogen and the remainder are carbon), or Z completes a non-aromatic ring system containing 5-10 atoms, of which 0-3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon. Examples of aromatic ring systems completed by Z include benzene, naphthalene, pyridine, quinoline, isoquinoline, pyrazine, pyrimidine, pyrrole, furan, thiophene, indole, benzofuran, benzothiophene, oxazole, isoxazole, thiazole, isothiazole and triazole. Examples of non-aromatic ring systems completed by Z include cyclohexane, cyclopentane, indane, tetralin, decalin, piperidine, piperazine, morpholine, tetrahydrofuran and tetrahydrothiophene. Preferably, Z completes a benzene ring or a pyridine ring.

Z¹ completes a non-aromatic ring system containing 5-10 atoms, of which 0-3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon. Examples of ring systems completed by Z¹ include cyclohexane, cyclopentane, indane, tetralin, decalin, piperidine, piperazine, morpholine, tetrahydrofuran and tetrahydrothiophene.




Z² completes a heteroaromatic ring comprising 5 or 6 atoms, such as imidazole, triazole or pyrimidine.


A fused ring (as indicated by Z, Z¹ or Z²) may form part of A or B, but A and B preferably do not both comprise such a ring. Typically, such fused rings (if present) form part of A.

Examples of structures completed by A and B include (but are not restricted to):



5





where w is 1 or 2, and X , Y , $R^1 - R^6$ and R^{13} have the same meanings as before.

5 R^1 represents H, C_{1-4} alkyl (such as methyl, ethyl, isopropyl or *t*-butyl), or C_{2-4} alkenyl (such as allyl). In a subset of the compounds of formula I, R^1 represents H or C_{1-4} alkyl. Preferably, R^1 represents H, methyl or allyl. Most preferably, R^1 represents H.

10 R^2 represents H, C_{1-6} alkyl (such as methyl, ethyl, propyl or butyl), C_{6-10} aryl (such as phenyl or naphthyl), C_{6-10} aryl C_{1-6} alkyl (such as benzyl), C_{3-6} cycloalkyl (such as cyclopropyl, cyclopentyl or cyclohexyl), or C_{2-6} acyl which is optionally substituted with $-CO_2H$ (such as acetyl, malonyl, succinoyl or glutaroyl), or with an amino group, in particular a primary amino group or an alkyl- or dialkylamino group in which the alkyl group(s) 15 comprise(s) up to 4 carbons. Preferably, R^2 is H.

R^3 represents C_{1-16} alkyl, C_{3-10} cycloalkyl, C_{2-16} alkenyl, C_{2-16} alkynyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{6-10} aryl C_{2-6} alkenyl, heteroaryl C_{2-6} alkenyl, C_{6-10} aryl, C_{6-10} aryloxy C_{6-10} aryl, bi(C_{6-10} aryl), heteroaryl, bi(heteroaryl), or heterocyclyl. In a subset of the compounds of 20 formula I, R^3 represents C_{1-16} alkyl, C_{3-10} cycloalkyl, C_{2-16} alkenyl, C_{2-16} alkynyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryloxy C_{6-10} aryl, bi(C_{6-10} aryl), heteroaryl, bi(heteroaryl) or heterocyclyl.

25 Alkyl, cycloalkyl, alkenyl and alkynyl groups represented by R^3 or forming part of a group represented by R^3 may bear up to 3 substituents (but preferably not more than one substituent) independently selected

from halogen, CN, NO₂, -OR⁷, -SR⁷, -S(O)_tR⁸ where t is 1 or 2, -N(R⁷)₂, -COR⁷, -CO₂R⁷, -OCOR⁸, -CON(R⁷)₂, -NR⁷COR⁸, -C₁₋₆alkylNR⁷COR⁸, -NR⁷CO₂R⁸ and -NR⁷SO₂R⁸; where R⁷ and R⁸ are as defined previously. Typical substituents include halogen, -OR⁷, -SR⁷ and -SO₂R⁸.

5 Aryl, heteroaryl and heterocyclic groups represented by R³ or forming part of a group represented by R³ may bear up to 5 substituents independently selected from halogen, R⁸, CN, NO₂, -OR⁷, -SR⁷, -S(O)_tR⁸ where t is 1 or 2, -N(R⁷)₂, -COR⁷, -CO₂R⁷, -OCOR⁸, -CON(R⁷)₂, -NR⁷COR⁸, -C₁₋₆alkylNR⁷COR⁸, -NR⁷CO₂R⁸ and -NR⁷SO₂R⁸; where R⁷ and R⁸ are as
10 defined previously. Generally not more than 3 (preferably not more than two) such substituents are present. Typical substituents include halogen, R⁸, CN, NO₂, -OR⁷, -SR⁷, -S(O)₂R⁸, -N(R⁷)₂, -COR⁷, -CO₂R⁷, -NR⁷COR⁸ and -C₁₋₆alkylNR⁷COR⁸. Preferred substituents include F, Cl, methyl, methoxy and NO₂.

15 R⁷ represents H or R⁸; or two R⁷ groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring, while R⁸ represents C₁₋₁₀alkyl, perfluoroC₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, Ar or -C₁₋₆alkylAr, where Ar represents phenyl or heteroaryl
20 either of which optionally bears up to 3 substituents independently selected from halogen, CF₃, NO₂, CN, C₁₋₆alkyl and C₁₋₆alkoxy. Preferably, R⁷ and R⁸ are independently selected from H, C₁₋₆alkyl (especially methyl, ethyl, n-propyl or isopropyl), perfluoroC₁₋₆alkyl (especially trifluoromethyl or 2,2,2-trifluoroethyl), Ar (especially phenyl optionally bearing up to 3
25 substituents independently selected from halogen, CF₃, NO₂, CN, C₁₋₆alkyl and C₁₋₆alkoxy) and -C₁₋₆alkylAr (especially benzyl optionally bearing up to 3 substituents independently selected from halogen, CF₃, NO₂, CN, C₁₋₆alkyl and C₁₋₆alkoxy), with the proviso that R⁸ cannot be H.

Typical examples of alkyl and substituted alkyl groups represented
30 by R³ include methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-octyl, n-dodecyl, n-decyl, n-butyl, methanesulphonylmethyl, 2-ethoxyethyl, 2-

ethanethioethyl, 3-chloropropyl, 2,2,2-trichloroethyl and 2,2,2-tifluoroethyl.

Typical examples of cycloalkyl groups represented by R^3 include cyclopropyl, cyclopentyl and cyclohexyl.

5 Typical examples of alkenyl and substituted alkenyl groups represented by R^3 include vinyl, allyl and 2-phenylethenyl.

Typical examples of alkynyl groups represented by R^3 include propargyl.

10 Typical examples of arylalkyl groups represented by R^3 include benzyl, 2-nitrobenzyl, and 2-phenylethyl.

Typical examples of heteroarylalkyl groups represented by R^3 include pyridylmethyl, 2-(2-thienyl)ethyl and 2-furylethyl.

Typical examples of aryl groups represented by R^3 include phenyl, 1-naphthyl, 2-naphthyl, 2,5-dichlorophenyl, 2-nitrophenyl, 3-nitrophenyl, 15 4-nitrophenyl, 2,4,6-trimethylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 4-acetylphenyl, 5-dimethylaminonaphth-1-yl, pentafluorophenyl, 2,4,6-tris(isopropyl)phenyl, 4-bromophenyl, *o*-tolyl, 20 *m*-tolyl, *p*-tolyl, pentamethylphenyl, 2,3,5,6-tetramethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 2,3,4-trichlorophenyl, 2,5-dimethoxyphenyl, 3-chloro-4-fluorophenyl, 4-ethylphenyl, 4-*n*-propylphenyl, 4-isopropylphenyl, 4-bromo-2,5-difluorophenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 2,4-difluorophenyl, 25 4-chloro-2,5-dimethylphenyl, 2-methyl-5-nitrophenyl, 2-trifluoromethylphenyl, 3,5-dichlorophenyl, 2-chloro-6-methylphenyl, 2,3-dichlorophenyl, 2-bromophenyl, 3-chloro-2-methylphenyl, 2,6-dichlorophenyl, 3-bromophenyl, 2-cyanophenyl, 4-*n*-butoxyphenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 3-fluoro-6-methylphenyl, 30 2,4,6-trichlorophenyl, 4-iodophenyl, 4-*t*-butylphenyl, 2-methoxycarbonylphenyl, 4-methylsulphonylphenyl,

2-methylsulphonylphenyl, 4-(1,1-dimethylpropyl)phenyl, 2-chloro-5-trifluoromethylphenyl, 2-trifluoromethoxyphenyl, 4-acetamido-3-chlorophenyl, 5-chloro-2-methoxyphenyl, 2,6-difluorophenyl, 4-methyl-3-nitrophenyl, 4-*n*-butylphenyl, 4-(2-chloro-6-nitrophenoxy)phenyl, 4-(3-chloro-2-cyanophenoxy)phenyl, 2,5-bis(trifluoromethoxy)phenyl, 2-chloro-4-trifluoromethylphenyl, 3-carboxy-4-hydroxyphenyl, 2,3,4-trifluorophenyl, 3,4-difluorophenyl, 4-*n*-pentylphenyl, 3-chloro-4-methylphenyl, 4-bromo-2-ethylphenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2-iodophenyl and 4-cyanophenyl.

10 Typical examples of biaryl groups represented by R³ include 4-biphenyl.

Heterocyclyl groups represented by R³ may be bonded through carbon or nitrogen (if present). Typical examples of heterocyclyl groups represented by R³ include 1-pyrrolidinyl, 4-morpholinyl, 1-piperidinyl, 1-piperazinyl, tetrahydrothiophenyl and tetrahydrofuryl.

15 Typical examples of heteroaryl groups represented by R³ include 2-thienyl and 3-thienyl, 4,5-dibromo-2-thienyl, 4-bromo-2,5-dichloro-3-thienyl, 2,5-dichloro-3-thienyl, 4,5-dichloro-2-thienyl, 2-trifluoroacetyl-1,2,3,4-tetrahydro-7-isoquinolinyl, 3,5-dimethyl-4-isoxazolyl, 5-bromo-2-thienyl, 4-bromo-5-chloro-2-thienyl, 3-bromo-5-chloro-2-thienyl, 5-chloro-1,3-dimethyl-1*H*-pyrazol-4-yl, benzo[1,2,5]thiadiazol-4-yl, 1-methyl-1*H*-imidazol-4-yl, benzo[1,2,5]oxadiazol-4-yl, 2-methoxycarbonyl-3-thienyl, 5-(*N*-(4-chlorobenzoyl)aminomethyl)-2-thienyl, 6-chloro-imidazo[2,1-*b*]thiazol-5-yl, 1,2-dimethyl-1*H*-imidazol-4-yl, 4-ethoxycarbonyl-3-pyridyl, 2,5-dichloro-4-nitro-3-thienyl, 2-pyridyl, 3-pyridyl, 5-chloro-2-thienyl, 2-furyl, 2-thiazolyl and 2-chlorothiazol-5-yl.

Further examples of heteroaryl groups represented by R³ include 2-(morpholin-4-yl)thiazol-5-yl, 6-chloropyrid-3-yl, pyrrol-3-yl, 1-methylpyrrol-3-yl and isothiazol-5-yl.

30 Typical examples of bi(heteroaryl) groups represented by R³ include 5-(1-methyl-5-trifluoromethyl-1*H*-pyrazol-3-yl)-2-thienyl, 5-pyridin-2-yl-2-

thienyl, 5-isoxazol-3-yl-2-thienyl, 5-(2-methylthiopyrimidin-4-yl)-2-thienyl, 5-(2-methylthiazol-4-yl)-2-thienyl, 5-(2-methyl-5-trifluoromethyl-2*H*-pyrazol-3-yl)-2-thienyl and 5-(5-trifluoromethylisoxazol-3-yl)-2-thienyl.

5 Examples of preferred groups represented by R^3 include phenyl, thiophene, substituted thiophene (in particular 5-chloro-2-thienyl) and *n*-butyl.

Further examples of preferred groups represented by R^3 include 2-, 3- and 4-fluorophenyl, 2,4-difluorophenyl, 2,3,4-trifluorophenyl, 4-chlorophenyl, pyrid-3-yl, 6-chloropyrid-3-yl and isothiazol-5-yl.

10 R^4 , R^5 and R^6 are independently R^9 , halogen, CN, NO_2 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where *t* is 1 or 2, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-CON(R^9)_2$, $-SO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$, $-CH=CHCH_2N(R^{16})_2$, $-NR^9SO_2R^{10}$, $-CH_2OR^9$, $-CH_2N(R^{16})_2$, $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$; where R^9 , R^{10} and R^{16} are as defined previously. When the group A or B comprises a
15 non-aromatic ring completed by Z or Z^1 , R^4 , R^5 and R^6 preferably all represent hydrogen. When A or B comprises an aromatic ring completed by Z, R^4 , R^5 and R^6 are preferably independently selected from R^9 , halogen, CN, NO_2 , $-OR^9$, $-N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$, $-CH=CHCH_2N(R^{16})_2$, $-CH_2OR^9$, $-CH_2N(R^{16})_2$, $-NHCOCH_2OR^{10}$ and $-NHCOCH_2N(R^{16})_2$, but
20 preferably at least one of R^5 and R^6 represents H, and most preferably both R^5 and R^6 represent H.

When A or B comprises a heteroaromatic ring completed by Z^2 , R^4 preferably represents H.

25 R^9 represents H or R^{10} ; or two R^9 groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring which is optionally substituted by R^{12} , $-COR^{12}$ or $-SO_2R^{12}$, while R^{10} represents C_{1-10} alkyl, perfluoro C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{3-6} cycloalkyl C_{1-6} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{6-10} aryl, heteroaryl, heterocyclyl, C_{6-10} aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl,
30 C_{6-10} aryl C_{2-6} alkenyl or heteroaryl C_{2-6} alkenyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups optionally bear one substituent

- selected from halogen, CF_3 , NO_2 , CN , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{12}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{CON}(\text{R}^{11})_2$, $-\text{OCOR}^{12}$, $-\text{N}(\text{R}^{11})_2$ and $-\text{NR}^{11}\text{COR}^{12}$; and the aryl, heteroaryl and heterocyclic groups optionally bear up to 3 substituents independently selected from halogen, NO_2 , CN , R^{12} , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{12}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{CON}(\text{R}^{11})_2$, $-\text{OCOR}^{12}$, $-\text{N}(\text{R}^{11})_2$ and $-\text{NR}^{11}\text{COR}^{12}$, where R^{11} and R^{12} are as defined previously. Preferably, R^9 and R^{10} independently represent H, C_{1-10} alkyl, perfluoro C_{1-6} alkyl, C_{3-6} cycloalkyl C_{1-6} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{6-10} aryl, heteroaryl, C_{6-10} aryl C_{1-6} alkyl, C_{6-10} aryl C_{2-6} alkenyl, heteroaryl C_{2-6} alkenyl or heteroaryl C_{1-6} alkyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups are unsubstituted or substituted by CN , $-\text{OR}^{11}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$ or $-\text{CON}(\text{R}^{11})_2$, and wherein the aryl and heteroaryl groups bear not more than two substituents selected from halogen, NO_2 , CN , R^{12} , $-\text{OR}^{11}$ and $-\text{SO}_2\text{R}^{12}$, with the proviso that R^{10} cannot represent H.
- R^{11} represents H or R^{12} , while R^{12} represents C_{1-6} alkyl, C_{3-7} cycloalkyl, perfluoro C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, ArOC_{1-6} alkyl, Ar or $-\text{C}_{1-6}$ alkyl Ar , where Ar represents phenyl or heteroaryl either of which optionally bears up to 3 substituents independently selected from halogen, CF_3 , NO_2 , CN , OCF_3 , C_{1-6} alkyl and C_{1-6} alkoxy, or two R^{12} groups together with a nitrogen atom to which they are mutually attached may complete a heterocyclic ring system of 3-10 atoms, 0-2 of which (in addition to said nitrogen atom) are selected from O, N and S, said ring system bearing 0-2 substituents selected from halogen, CN , NO_2 , R^{12} , OR^{11} , NHR^{11} , and COR^{11} . Preferably, R^{11} and R^{12} independently represent H, C_{1-6} alkyl, perfluoro C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl (optionally bearing up to 2 substituents independently selected from halogen, CF_3 , NO_2 , CN , C_{1-6} alkyl and C_{1-6} alkoxy), heteroaryl (especially thiazolyl, optionally substituted by halogen, CF_3 or C_{1-6} alkyl) or benzyl (optionally bearing up to 2 substituents independently selected from halogen, CF_3 , NO_2 , CN , C_{1-6} alkyl and C_{1-6} alkoxy), with the proviso that R^{12} cannot represent H.

Examples of heterocyclic rings represented by $N(R^{12})_2$ include pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 2,5-diazabicyclo[2.2.1]heptane and 2-aza-5-oxabicyclo[2.2.1]heptane, any of which may be substituted, e.g. by halogen, CF_3 , methyl, hydroxymethyl, methoxymethyl or hydroxy.

Each R^{16} independently represents H or R^{10} , or two R^{16} groups together with the nitrogen to which they are mutually attached complete a mono- or bicyclic heterocyclic ring system of 5-10 ring atoms selected from C, N, O and S, said ring system optionally having an additional aryl or heteroaryl ring fused thereto, said heterocyclic system and/or additional fused ring bearing 0-3 substituents independently selected from halogen, NO_2 , CN, R^{12} , $-OR^{11}$, $-SR^{11}$, $-SO_2R^{12}$, $-COR^{11}$, $-CO_2R^{11}$, $-CON(R^{11})_2$, $-OCOR^{12}$, $-N(R^{11})_2$ and $-NR^{11}COR^{12}$. Examples of heterocyclic ring systems represented by $-N(R^{16})_2$ include pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 2,5-diazabicyclo[2,2,1]heptane, 5,6-dihydro-8H-imidazo[1,2- α]pyrazine and spiro[isobenzofuran-1(3H),4'-piperidine]. Preferably, the heterocyclic ring system bears at most one substituent. Preferred substituents are halogen and R^{12} groups, in particular alkyl, CF_3 , phenoxyalkyl and phenyl, wherein the phenyl groups optionally bear up to 2 substituents selected from halogen (especially chlorine or fluorine), C_{1-6} alkyl and C_{1-6} alkoxy.

R^4 very aptly represents halogen (especially chlorine, bromine or fluorine), nitro, CN, phenyl, substituted phenyl (such as 3,5-bis(trifluoromethyl)phenyl, *o*-anisyl, 2-fluorophenyl, 3-fluorophenyl and 4-fluorophenyl), heteroaryl (such as 5-phenyl-1,2,4-oxadiazol-3-yl, 5-pyridyl-1,2,4-oxadiazol-3-yl, 3-thienyl, 2-thienyl, 2-benzofuryl, 2-pyridyl, 4-pyridyl, 3-pyridyl and 6-methoxy-3-pyridyl), amino represented by $-N(R^9)_2$, amido represented by $-NR^9COR^{10}$, carbamate represented by $-NR^9CO_2R^{10}$, alkoxy, aryloxy or heteroaryloxy represented by $-OR^{10}$, optionally substituted alkenyl, including $-CH=CHCH_2N(R^{16})_2$ C_{6-10} aryl C_{2-6} alkenyl

and heteroarylC₂₋₆alkenyl, substituted acetamido represented by -NHCOCH₂(NR¹⁶)₂, and substituted methyl represented by -CH₂OR⁹.

Preferred amino groups represented by R⁴ include N(R⁹)₂ wherein the two R⁹ groups complete a piperidine or piperazine ring which is optionally substituted in the 4-position by Ar, and NHR¹⁰ wherein R¹⁰ is selected from C₆₋₁₀arylC₁₋₆alkyl (especially benzyl or substituted benzyl), heteroarylC₁₋₆alkyl, and C₁₋₆alkyl which is substituted by OR¹⁰ or N(R¹¹)₂ (especially ethyl which is substituted by OAr or N(R¹²)₂ wherein the R¹² groups complete a heterocyclic ring).

Typical examples of amino groups represented by R⁴ include NH₂, (3-pyridylmethyl)amino, 4-phenoxybenzylamino, 4-benzyloxybenzylamino, 2-methoxybenzylamino, 3-methoxybenzylamino, 4-methoxybenzylamino, 3,3-dimethylbutylamino, (cyclohexylmethyl)amino, 3-methylbutylamino, (4-pyridylmethyl)amino, 2-benzyloxyethylamino, 2-phenylpropylamino, (2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)amino, 4-*t*-butylbenzylamino, 3-phenylbutylamino, 4-isopropoxybenzylamino, (benzofuran-2-ylmethyl)amino, 3-phenylpropylamino, 4-*n*-pentylbenzylamino, 4-methanesulphonylbenzylamino, 3-(4-*t*-butylphenoxy)benzylamino, 3-(4-methoxyphenoxy)benzylamino, 3-trifluoromethoxybenzylamino, 4-cyanobenzylamino, 3-fluorobenzylamino, 4-fluorobenzylamino, 3-chlorobenzylamino, 3-trifluoromethylbenzylamino, 3-(3,4-dichlorophenoxy)benzylamino, 4-(4-*t*-butylthiazol-2-yl)benzylamino, 4-(hex-1-ynyl)benzylamino, 3-benzyloxybenzylamino and 4-phenylpiperidin-1-yl.

Further examples of amino groups represented by R⁴ include 2-(4-fluorophenoxy)ethylamino, 2-(4-chlorophenoxy)ethylamino, 2-(4-fluoroanilino)ethylamino, 2-(4-morpholinyl)ethylamino, 4-(4-fluorophenyl)piperazin-1-yl, 4-(2-methoxyphenyl)piperazin-1-yl and 4-(pyridin-2-yl)piperazin-1-yl.

Typical examples of amido groups represented by R⁴ include benzamido, phenylacetamido, 3,5-difluorophenylacetamido, 4-

fluorobenzamido, acetamido, propionamido, butyramido, pentanamido, hexanamido, isobutyramido, 3-methylbutyramido, 2-methylbutyramido, 2-methylpentanamido, 3-methylpentanamido, 4-methylpentanamido, 2,2-dimethylbutyramido, 2-ethylbutyramido, cyclopentylacetamido, 2,2-dimethylpent-4-enamido, cyclopropylacetamido, 4-methyloctanamido, 3,5,5-trimethylhexanamido, 2-methylhexanamido, 2,2-dimethylpentanamido, 5-methylhexanamido, 3-phenylpropionamido, isonicotinamido, pyridine-2-carboxamido and nicotinamido.

Typical examples of carbamate groups represented by R^4 include phenoxycarbonylamino, 4-chlorophenoxycarbonylamino, methoxycarbonylamino, benzyloxycarbonylamino, isobutoxycarbonylamino, allyloxycarbonylamino, 4-methylphenoxycarbonylamino, 4-bromophenoxycarbonylamino, 4-fluorophenoxycarbonylamino, 4-methoxyphenoxycarbonylamino and 2,2-dimethylpropoxycarbonylamino.

When R^4 represents an alkoxy, aryloxy or heteroaryloxy group $-OR^{10}$, R^{10} preferably represents C_{6-10} aryl C_{1-6} alkyl (such as benzyl, chlorobenzyl, fluorobenzyl and methoxybenzyl), heteroaryl C_{1-6} alkyl (such as pyridylmethyl), C_{1-6} alkyl (such as methyl), heterocyclyl (such as 1-*t*-butoxycarbonylpiperidin-4-yl), heteroaryl (such as pyridin-4-yl), or C_{1-6} alkyl which is substituted by $-OR^{11}$, $-CON(R^{11})_2$ or $-N(R^{11})_2$, especially an ethyl group substituted by $-OAr$. Particularly preferred alkoxy groups represented by R^4 include phenoxyethoxy, 4-chlorophenoxyethoxy and 4-fluorophenoxyethoxy. Further preferred alkoxy groups represented by R^4 include methoxy substituted with $-CON(R^{12})_2$ and ethoxy or propoxy substituted with $-N(R^{12})_2$, in particular 2-(morpholin-4-yl)ethoxy, 2-(2-methylpyrrolidin-1-yl)ethoxy, 2-(2-hydroxymethyl)pyrrolidin-1-ylethoxy, 2-(2-methoxymethyl)pyrrolidin-1-ylethoxy, 2-(3-hydroxypyrrolidin-1-yl)ethoxy, 2-(2-aza-5-oxa-[2.2.1]bicyclohept-2-yl)ethoxy, 2-(piperidin-1-yl)ethoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy and 2-(2-methylpiperidin-1-yl)ethoxy and 3-(morpholin-4-yl)propoxy.

Typical examples of C_{6-10} aryl C_{2-6} alkenyl groups represented by R^4 include 4-phenylbut-1-enyl, styryl, 4-methoxystyryl, 4-fluorostyryl, 4-chlorostyryl and 4-bromostyryl.

Typical examples of heteroaryl C_{2-6} alkenyl groups represented by R^4 include 3-(imidazol-1-yl)propenyl and 3-(1,2,4-triazol-1-yl)propenyl.

Typical examples of alkenyl and substituted alkenyl groups represented by R^4 include, vinyl, cyanovinyl, 3-(N,N-dimethylamino)prop-1-enyl, 3-hydroxyprop-1-enyl, methoxycarbonylethenyl and benzoylethenyl.


A special class of alkenyl groups represented by R^4 have the formula $-\text{CH}=\text{CHCH}_2\text{N}(\text{R}^{16})_2$. Typical examples include 3-(N,N-dimethylamino)propenyl, 3-(piperidin-1-yl)propenyl, 3-(morpholin-4-yl)propenyl and the corresponding N-oxide, 3-(4-methylpiperazin-1-yl)propenyl, 3-(4-phenylpiperazin-1-yl)propenyl and 3-(N-2-methoxyethyl-N-methylamino)propenyl.

Typical examples of substituted acetamido groups represented by $-\text{NHCOCH}_2(\text{NR}^{16})_2$ include 2-(diethylamino)acetamido, 2-(N-benzyl-N-methylamino)acetamido, 2-(pyrrolidin-1-yl)acetamido, 2-[4-(4-fluorophenyl)piperazin-1-yl]acetamido, 2-[5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]acetamido, 2-(4-phenylpiperazin-1-yl)acetamido, 2-(piperidin-1-yl)acetamido, 2-(4-methylpiperazin-1-yl)acetamido, 2-(morpholin-4-yl)acetamido, 2-(4-phenylpiperidin-1-yl)acetamido, 2-[4-(2-methoxyphenyl)piperidin-1-yl]acetamido, 2-(2-phenoxyethylmorpholin-4-yl)acetamido, 2-[(4-phenylmorpholin-2-ylmethyl)amino]acetamido, 2-(3-phenyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)acetamido and 2-[4-(2-methoxyphenyl)piperazin-1-yl]acetamido.

Typical examples of substituted acetamido groups represented by $-\text{NHCOCH}_2\text{OR}^{10}$ include 2-methoxyacetamido, 2-phenoxyacetamido, and the corresponding 2-, 3- and 4-fluorophenoxy derivatives and 2-, 3- and 4-chlorophenoxy derivatives.

Typical examples of substituted methyl groups represented by -CH₂OR⁹ include hydroxymethyl, phenoxymethyl, 2-, 3- and 4-chlorophenoxymethyl, 2-, 3- and 4-fluorophenoxymethyl, 2-, 3- and 4-methoxyphenoxymethyl, 4-trifluoromethylphenoxymethyl, 4-t-butylphenoxymethyl, 4-[1,2,4]triazol-1-ylphenoxymethyl, quinolin-5-yloxymethyl, 4-trifluoromethoxyphenoxymethyl and 4-(4-acetylpiperazin-1-yl)phenoxymethyl.

A subclass of the compounds of formula I is defined by formula II:



II

10

wherein:

w is 1 or 2;

A¹ represents -CH₂CXY-, -CH₂CH₂CH₂CH₂-, -CH₂CH=CHCH₂- or -CH₂CXYCH₂-; and

15 X, Y, R¹, R² and R³ have the same meanings as before.

In a subset of the compounds of formula II, A¹ represents -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH₂CH=CHCH₂- or -CH₂CXYCH₂-.

In preferred compounds of formula II, w is 1; R¹ and R² are both H; Y is H or together with X represents =O, =N-OR¹¹ or =CH₂; and X is
20 selected from H, C₁₋₆alkyl, -CO₂R⁹, -OCOR¹⁰, -OCO₂R¹⁰, -OSO₂R⁹, and -CON(R⁹)₂, or together with Y represents =O, =N-OR¹¹ or =CH₂, where R⁹ and R¹¹ have the same meaning as before.

Examples of compounds within this subclass include:

endo-N-bicyclo[4.2.1]non-3-en-9-yl-4-methyl-benzenesulfonamide;

- endo-N*-bicyclo[4.2.1]non-3-en-9-yl-4-fluoro-benzenesulfonamide;
endo-N-bicyclo[4.2.1]non-3-en-9-yl-benzenesulfonamide;
endo-thiophene-2-sulfonic acid bicyclo[4.2.1]non-3-en-9-ylamide;
endo-5-chloro-thiophene-2-sulfonic acid bicyclo[4.2.1]non-3-en-9-ylamide;
5 *endo*-5-chloro-thiophene-2-sulfonic acid bicyclo[4.2.1]non-9-ylamide; and
endo-8-(5-chloro-thiophene-2-sulfonylamino)-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester.

Further examples of compounds within this sub class include:

- 10 (*syn, exo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl
acetate;
(*syn, exo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl
2-(methylthio)nicotinate;
(*syn, exo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl
3,4-dimethoxybenzoate;
15 (*syn, exo*)-7-(5-chlorothiophene-2-sulfonylamino)-bicyclo[2.2.1]hept-2-yl
2-nitrobenzoate;
(*syn, exo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl
methyl carbonate;
(*syn, exo*)-7-(5-chlorothiophene-2-sulfonylamino)-bicyclo[2.2.1]hept-2-yl
20 methanesulfonate;
(*syn, exo*)-7-(5-chlorothiophene-2-sulfonylamino)-bicyclo[2.2.1]hept-2-yl
toluene-4-sulfonate;
(*syn*)-5-chloro-*N*-(2-methylenebicyclo[2.2.1]hept-7-yl)thiophene-2-
sulfonamide;
25 (*syn, endo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl
acetate;
[9-*endo*]-*N*-(9-methylbicyclo[4.2.1]non-3-en-9-yl)benzenesulfonamide;
[9-*endo*]-5-chloro-*N*-(9-methylbicyclo[4.2.1]non-3-en-9-yl)thiophene-2-
sulfonamide; and

[9-*endo*]-*N*-(9-allylbicyclo[4.2.1]non-3-en-9-yl)-5-chlorothiophene-2-sulfonamide.

Still further compounds within this subclass include:

5-chloro-thiophene-2-sulfonic acid (3-methylbicyclo[3.2.1]oct-8-yl)-amide;

5 *endo*-5-chloro-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide;

endo-5-chloro-thiophene-2-sulfonic acid (3-oxo-bicyclo[3.2.1]oct-8-yl)-amide;

endo-5-chloro-thiophene-2-sulfonic acid (3-methoxyimino-bicyclo[3.2.1]oct-8-yl)-amide;

10 *endo*-butane-1-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide;

endo-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

endo-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide;

endo-4-methyl-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

endo-4-fluoro-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

15 *endo*-2-fluoro-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

endo-3-fluoro-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

endo-4-chloro-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

endo-4-bromo-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;


20 *endo*-5-bromo-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide;

endo-4-iodo-*N*-(3-methylene-bicyclo[3.2.1]oct-8-yl)-benzenesulfonamide;

and

endo-5-chloro-thiophene-2-sulfonic acid (3-benzylidene-bicyclo[3.2.1]oct-8-yl)-amide.


25 A second subclass of the compounds of formula I is defined by formula IIA:



IIA

wherein:

A² represents -CH₂-NR¹³-CXY-CH₂- or




5

and w, X, Y, Z², R¹, R², R³ and R¹³ have the same meanings as before.

In preferred embodiments of formula IIA, R¹ and R² are both H, w is 1, X and Y are both H or together represent =S, Z² completes an imidazole ring, and R¹³ is selected from H, 2,2,2-trifluoroethyl, benzyl, chlorobenzyl, methoxybenzyl, methoxycarbonylbzyl, methoxycarbonylmethyl, benzoylmethyl and aminocarbonylmethyl.

Examples of compounds within this subclass include:



15

and


in which X, Y and R¹³ are as indicated in the following table:

| X | Y | R ¹³ |
|---|---|-----------------|
| H | H | Benzyl |

| | | |
|------|---|--|
| $=O$ | | H |
| $=S$ | | H |
| H | H | H |
| H | H | CF_3CH_2 |
| H | H | $PhCOCH_2$ |
| H | H | $MeOCOCH_2$ |
| H | H | $PhCH_2CH_2$ |
| H | H | $PhCH_2CH_2CH_2$ |
| H | H | H_2NCOCH_2 |
| H | H | 2-chlorobenzyl |
| H | H | 3-chlorobenzyl |
| H | H | 4-chlorobenzyl |
| H | H | 2-methoxybenzyl |
| H | H | 3-methoxybenzyl |
| H | H | 4-methoxybenzyl |
| H | H | 3-MeOCOC ₆ H ₄ CH ₂ |
| H | H | 4-MeOCOC ₆ H ₄ CH ₂ |

A third subclass of the compounds of formula I is defined by formula

III:




III

wherein w, Z, R¹, R², R³, R⁴, R⁵ and R⁶ have the same meanings as before.

In this subclass, w is preferably 1; R¹ is preferably H or methyl; R² is preferably H; R⁵ and R⁶ are preferably H; and Z preferably completes an aromatic ring system.

- 5 A fourth subclass of the compounds of formula I is defined by formula IIIA:




wherein:

- 10 B¹ represents $-(CH_2)_u-NR^{13}-CXY-(CH_2)_v-$;
 u and v are independently 0 or 1; and
 X, Y, R¹, R², R³, R⁴, R⁵, R⁶ and R¹³ have the same meanings as before.

- 15 Preferably, R¹ and R² are both H, R⁵ and R⁶ are both H, Z completes an aromatic ring, X and Y are both H and one of u and v is 0 and the other is 1.

A preferred subclass of the compounds of formula III is defined by formula IV:



wherein w, R¹, R³ and R⁴ have the same meanings as before.

Examples of compounds within this subclass include:

- 5 *endo*-4-methyl-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4-fluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4-chloro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-
- 10 benzenesulfonamide;
- endo*-4-nitro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-propane-1-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- 15 *endo*-4-bromo-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4-iodo-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4,5-dibromo-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-
- 20 3(8),4,6-trien-13-ylamide;
- endo*-3-chloro-4-fluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4-ethyl-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;







- endo*-2,3,4,5,6-pentafluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-4-trifluoromethyl-benzenesulfonamide;
- 5 *endo*-2,4-difluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-2-chloro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-2,5-dichloro-thiophene-3-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- 10 *endo*-2,3-dichloro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4,5-dichloro-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- 15 *endo*-2-cyano-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-3-fluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- 20 *endo*-5-bromo-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-2,6-difluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- 25 *endo*-4-bromo-5-chloro-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-3-bromo-5-chloro-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-2,3,4-trifluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- 30

- endo*-3,4-difluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-4-cyano-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- 5 *endo*-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-2-fluoro-*N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide;
- endo*-pyridine-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- 10 *endo*-butane-1-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-5-chloro-thiophene-2-sulfonic acid tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamide;
- endo*-*N*-(5-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- 15 *endo*-5-chloro-thiophene-2-sulfonic acid (5-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide;
- endo*-5-chloro-thiophene-2-sulfonic acid (4-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide;
- 20 *endo*-5-chloro-thiophene-2-sulfonic acid (5-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide;
- endo*-5-chloro-thiophene-2-sulfonic acid (4-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide;
- endo*-4-methyl-*N*-tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-yl-benzenesulfonamide;
- 25 *endo*-thiophene-2-sulfonic acid tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-ylamide;
- endo*-*N*-(13-methyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- 30 *endo*-*N*-(5-nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;

- endo-N*-(4-nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- endo-N*-(4-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- 5 *endo-N*-(5-bromo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- endo-N*-(5-phenyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- endo-N*-(5-thiophen-3-yl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-
- 10 benzenesulfonamide;
- endo-N*-[5-(2-methoxy-phenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-(4-fluoro-phenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 15 *endo-N*-[5-(3-fluoro-phenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-(5-benzofuran-2-yl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- endo-N*-(5-thiophen-2-yl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-
- 20 benzenesulfonamide;
- endo-N*-[5-(2-fluoro-phenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-(5-pyridin-4-yl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;
- 25 *endo-N*-(5-pyridin-3-yl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide; and
- endo-N*-[5-(6-methoxy-pyridin-3-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide.


Further compounds in accordance with Formula IV are as shown in

30 the table below. (In all cases, w = 1, R¹ = H and R⁴ is in the β -position with respect to the ring junction).

| R ³ | R ⁴ |
|----------------------|--|
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl | CN |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl | 2-pyridyl |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| vinyl | H |
| 2-ethoxyethyl | H |
| 2-ethanethioethyl | H |
| 3-chloropropyl | H |
| 2,2,2-trifluoroethyl | H |
| cyclopentyl | H |
| 2-furyl | H |
| 2-thiazolyl | H |
| 3-thienyl | H |
| 2-chloro-5-thiazolyl | H |
| 3-pyridyl | H |
| 6-chloro-3-pyridyl | H |

| | |
|---------------------|---|
| n-pentyl | H |
| 3-pyrrolyl | H |
| 1-methyl-3-pyrrolyl | H |
| 5-isothiazolyl | H |

A preferred subclass of the compounds of formula IV is defined by formula V:



V

wherein R^{4a} represents $-N(R^9)_2$, $-NR^9COR^{10}$ or $-NR^9CO_2R^{10}$, and R^1 , R^3 , R^9 and R^{10} have the same meanings as before.

In a subset of the compounds of Formula V, R^1 represents H.

Examples of compounds within this subclass include:

endo-N-(5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide;

endo-N-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-benzamide;

endo-N-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-2-phenyl-acetamide;

endo-N-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-2-phenoxy-acetamide;

endo-N-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-2-(3,5-difluoro-phenyl)-acetamide;

- endo-N*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-4-fluoro-benzamide;
- endo-N*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-acetamide;
- 5 *endo*-hexanoic acid (13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-amide;
- endo*-3-methyl-pentanoic acid (13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-amide;
- endo-N*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-2-cyclopentyl-acetamide;
- 10 *endo*-4-methyl-octanoic acid (13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-amide;
- endo*-5-methyl-hexanoic acid (13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-amide;
- 15 *endo-N*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-2-methoxy-acetamide;
- endo-N*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-3-phenyl-propionamide;
- endo*-pyridine-2-carboxylic acid (13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-amide;
- 20 *endo-N*-[13-(5-chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-2-phenoxy-acetamide;
- endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid phenyl ester;
- 25 *endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid benzyl ester;
- endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid isobutyl ester;
- endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid p-tolyl ester;
- 30

- endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid 4-fluoro-phenyl ester;
- endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid 4-methoxy-phenyl ester;
- 5 *endo*-(13-benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid 2,2-dimethyl-propyl ester;
- endo-N*-{5-[(pyridin-3-ylmethyl)-amino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-benzenesulfonamide;
- endo-N*-[5-(4-phenoxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 10 *endo-N*-[5-(4-benzyloxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-(3-methoxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 15 *endo-N*-[5-(4-methoxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-(cyclohexylmethyl-amino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-(3-methyl-butylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 20 *endo-N*-{5-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-benzenesulfonamide;
- endo-N*-[5-(4-tert-butyl-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 25 *endo-N*-[5-(3-phenyl-butylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-(4-isopropoxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- endo-N*-[5-[(benzofuran-2-ylmethyl)-amino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;
- 30

endo-N-[5-(3-phenyl-propylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

endo-N-[5-(4-pentyl-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

5 *endo-N*-[5-(3-trifluoromethoxy-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

endo-N-[5-(4-cyano-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

10 *endo-N*-[5-(3-fluoro-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

endo-N-[5-(4-fluoro-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide;

endo-N-[5-(3-chloro-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide; and

15 *endo-N*-[5-(3-trifluoromethyl-benzylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide.

Further examples of compounds in accordance with formula V include:

20 *endo*-5-chloro-thiophene-2-sulfonic acid {5-[2-(4-fluoro-phenoxy)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide;

endo-5-chloro-thiophene-2-sulfonic acid {5-[2-(4-chloro-phenoxy)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide;

endo-5-chloro-thiophene-2-sulfonic acid {5-[4-(4-fluoro-phenyl)-piperazin-1-yl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide;


25 *endo*-5-chloro-thiophene-2-sulfonic acid {5-[2-(4-fluoro-phenylamino)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide;

endo-5-chloro-thiophene-2-sulfonic acid {5-[4-(2-methoxy-phenyl)-piperazin-1-yl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide; and

30 *endo*-5-chloro-thiophene-2-sulfonic acid {5-(4-pyridin-2-yl-piperazin-1-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide.

In preferred compounds in accordance with formula V, R^1 represents H and R^{4a} represents $N(R^9)_2$ wherein the two R^9 groups complete a piperidine or piperazine ring which is optionally substituted in the 4-position by Ar, or NHR^{10} wherein R^{10} is selected from $C_{6-10}arylC_{1-6}alkyl$ (especially benzyl or substituted benzyl), heteroaryl $C_{1-6}alkyl$, and $C_{1-6}alkyl$ which is substituted by OR^{10} or $N(R^{11})_2$ (especially ethyl which is substituted by OAr or $N(R^{12})_2$ wherein the two R^{12} groups complete a heterocyclic ring).

Another preferred subclass of the compounds of formula IV is defined by formula VA:














wherein R^{4b} represents $C_{2-6}alkenyl$ (which is optionally substituted by halogen, CN, OR^{11} , $-CO_2R^{11}$, $-COR^{11}$ or $-CON(R^{11})_2$), $C_{6-10}arylC_{2-6}alkenyl$, heteroaryl $C_{2-6}alkenyl$, $-CH=CHCH_2N(R^{16})_2$, $-OR^{10}$, $-CH_2OR^9$, $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$; and R^1 , R^3 , R^9 , R^{10} , R^{11} and R^{16} have the same meanings as before.


















In particular, R^{4b} represents $-CH=CH_2$, $-CH=CHCN$, $-CH=CH-CH_2OR^{11}$, $-CH=CH-CO-Ar$, $-CH=CH-CO_2R^{11}$, $-CH=CHAr$, $-CH=CHCH_2N(R^{16})_2$, $-OCH_2Ar$, $-OCH_2CH_2OR^{12}$, $-OCH_2CON(R^{12})_2$, $-OCH_2CH_2N(R^{12})_2$, $-CH_2OR^9$, $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$, where Ar and R^{12} have the same meanings as before.

Examples of compounds within this subclass include the compounds of formula VA wherein R^1 is H and R^3 and R^{4b} are as follows:

| R^3 | R^{4b} |
|-------|----------|
| Ph | |
| Ph | |
| Ph | |
| Ph | |
| Ph | |
| Ph | |

| R^3 | R^{4b} |
|----------------|----------|
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |














| R^3 | R^{4b} |
|----------------|--|
| 5-Cl-2-thienyl | HOCH_2^- |
| Ph | HOCH_2^- |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |
| Ph |  |












| R^3 | R^{4b} |
|----------------|--|
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |












Further suitable compounds in accordance with formula VA are those in which R¹ is H and R³ and R^{4b} are as follows:

5


| R ³ | R ^{4b} |
|------------------|----------------------|
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 5-Cl-2-thienyl | |
| 3-pyridyl | PhCH ₂ O- |
| 2-Cl-5-thiazolyl | PhCH ₂ O- |
| 2-thienyl | |
| 4-fluorophenyl | |
| 4-chlorophenyl | |
| 4-nitrophenyl | |
| 4-methoxyphenyl | |

| | |
|-------------------------------------|--|
| n-propyl |  |
| 3,5-(bistrifluoromethyl)phenyl |  |
| 2-fluorophenyl |  |
| 2,4-difluorophenyl |  |
| 3-fluorophenyl |  |
| 5-Br-2-thienyl |  |
| 1-Me-1 <i>H</i> -imidazol-4-yl |  |
| 1,2-di-Me-1 <i>H</i> -imidazol-4-yl |  |
| 4-cyanophenyl |  |
| 3-pyridyl |  |
| n-butyl |  |
| 3-pyridyl |  |
| 5-Cl-2-thienyl |  |

| | |
|----------------|--|
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |

| | |
|---|--|
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 3-pyridyl |  |
|  |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |
| 5-Cl-2-thienyl |  |

Another subclass of the compounds of formula I is defined by formula IIIC:



III C

wherein

V represents CR⁴ or N;

W represents CH or N;

5 a is 0 or 1;

b is 0 or 1;



w is 1 or 2;

and X, Y, R¹, R³ and R⁴ have the same meanings as before.

Preferably, b is 0, R¹ is H and V and W are not both N.

10 Examples of compounds within this subclass are as indicated in the following table:

| V | W | a | b | w | X,Y | R ³ | R ⁴ |
|-----------------|----|---|---|---|---------------------|----------------|----------------|
| CR ⁴ | CH | 1 | 1 | 1 | H,H | 5-Cl-2-thienyl | H |
| CR ⁴ | CH | 0 | 0 | 2 | H,H | 5-Cl-2-thienyl | H |
| CR ⁴ | N | 1 | 0 | 1 | H,H | 5-Cl-2-thienyl | H |
| N | CH | 1 | 0 | 1 | H,H | 5-Cl-2-thienyl | - |
| CR ⁴ | CH | 1 | 0 | 1 | =CH ₂ | 3-pyridyl | H |
| CR ⁴ | CH | 1 | 0 | 1 | CH ₃ ,OH | 3-pyridyl | H |
| CR ⁴ | CH | 1 | 0 | 1 | =O | 5-Cl-2-thienyl | |
| CR ⁴ | CH | 1 | 0 | 1 | =O | 3-pyridyl | |
| CR ⁴ | CH | 1 | 0 | 1 | H,OH | 3-pyridyl | |

| | | | | | | | |
|-----------------|----|---|---|---|-------------------|-----------|---|
| CR ⁴ | CH | 1 | 0 | 1 | H,CH ₃ | 3-pyridyl |  |
| CR ⁴ | CH | 1 | 0 | 1 | =CH ₂ | 3-pyridyl |  |

Preferred compounds in accordance with the invention include those of formula IV wherein:

w is 1;

5 R¹ is H;

R³ is selected from n-propyl, n-butyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-chlorophenyl, 2-thienyl, 5-chloro-2-thienyl, 5-bromo-2-thienyl, 3-pyridyl, 6-chloro-2-pyridyl and 5-isothiazolyl; and

10 R⁴ is in the β -position with respect to the ring junction and is selected from pyridine-2-carboxamido, phenoxyacetamido, 4-chlorophenoxyacetamido, 2,4-dichlorophenoxyacetamido, 4-fluorophenoxyacetimido, morpholin-4-ylacetamido, pyrrolidin-1-ylacetamido, piperidin-1-ylacetamido, 4-phenylpiperazin-1-ylacetamido, 15 4-(4-fluorophenyl)piperazin-1-ylacetamido, 2-(4-fluorophenoxy)ethoxy, 2-(morpholin-4-yl)ethoxy, 2-(morpholin-4-yl)ethylamino, 2-(4-fluorophenoxy)ethylamino, 2-(4-chlorophenoxy)ethylamino, 3-(4-fluorophenoxy)propenyl, 3-(imidazol-1-yl)propenyl, 3-(morpholin-4-yl)propenyl, 5-(pyridin-2-yl)-1,2,4-oxadiazol-3-yl, 5-(pyridin-3-yl)-1,2,4-oxadiazol-3-yl, 5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl, 3-(2-aza-5-oxabicyclo[2.2.1]hept-2-yl)propenyl, 2-(2-aza-5-oxabicyclo[2.2.1]hept-2-yl)ethoxy, 3-(4-fluoropiperidin-1-yl)propenyl, 2-(4-fluoropiperidin-1-yl)ethoxy, 3-(4-trifluoromethylpiperidin-1-yl)propenyl and 2-(4-trifluoromethylpiperidin-1-yl)ethoxy;

25 and the pharmaceutically acceptable salts thereof.

The compounds of the present invention have an activity as inhibitors of γ secretase.

The invention provides pharmaceutical compositions comprising one or more compounds of Formula I or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, 5 powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the 10 principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a solid preformulation 15 composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into 20 equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the 25 active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be 30 separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the

duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

5 The present invention also provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition associated with the deposition of β -amyloid. Preferably the condition is a neurological disease having associated β -amyloid deposition such as
10 Alzheimer's disease.

 The present invention further provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing Alzheimer's disease.


15 Also disclosed is a method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to Formula I or a pharmaceutically acceptable salt thereof.

 The liquid forms in which the novel compositions of the present
20 invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for
25 aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(vinylpyrrolidone) or gelatin.


 For treating or preventing Alzheimer's Disease, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100
30 mg/kg per day, and especially about 0.01 to 5 mg/kg of body weight per

day. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.

Compounds of formula IA in accordance with the invention (corresponding to formula I in which R^1 and R^2 are both H) may be prepared by reaction of the amines (VI) with R^3SO_2-Hal , where Hal represents halogen (preferably Cl) and A, B, X, Y, R^3 , n and m have the same meanings as before:




IA




VI

The reaction is advantageously carried out in an aprotic solvent such as dichloromethane in the presence of a base such as pyridine at ambient temperature.

The amines VI may be prepared by reduction of the oximes VII, derived from the ketones VIII:



VII




VIII


wherein A, B, X, Y, n and m have the same meanings as before.

The reduction of VII to VI may be effected by conventional means, such as hydrogenation in a solvent such as acetic acid in the presence of a catalyst such as PtO_2 , or reaction with sodium cyanoborohydride in ethanolic solution. Conversion of the ketones VIII to the oximes VII is readily achieved by condensation of the ketones with hydroxylamine hydrochloride in refluxing ethanolic solution in the presence of a mild base such as sodium acetate.

Compounds of formula IB in accordance with the invention (corresponding to formula I in which R^1 is an alkyl group and R^2 is H) may be prepared by reaction of the sulphonylimine IX with RLi :



IB



IX


wherein R represents C_{1-4} alkyl, and A, B, X, Y, R^3 , n and m have the same meanings as before. The reaction is advantageously carried out at reduced temperature in a hydrocarbon solvent, with quenching by aqueous acid.

The sulphonylimines IX are obtained by condensation of the ketones VIII with a sulphonamide $\text{R}^3\text{SO}_2\text{NH}_2$, where R^3 has the same meaning as before. The condensation may be effected by refluxing the reagents in toluene in the presence of an acid catalyst with azeotropic removal of water.

Compounds of formula I in which R^2 is other than H may be obtained by appropriate transformations of the compounds of formulae IA, IB and ID, for example by N-alkylation or N-acylation using standard methods. Alternatively, the primary amines VI may be converted to

secondary amines by N-alkylation or N-arylation using standard methods, prior to reaction with $R^3SO_2\text{-Hal}$.

The ketones VIII, sulphonyl halides $R^3SO_2\text{-Hal}$ and sulphonamides $R^3SO_2NH_2$ are commercially available or accessible by the application of known synthetic methods to commercially available materials. For example, a convenient route to ketones VIIIA, synthetic precursors of the compounds of formula IV, is illustrated in the following scheme:



10


wherein w and R^4 have the same meanings as before.

The dibromide X reacts exothermically with the enamine XI in acetonitrile solution to form the salt XII, which may be hydrolysed in aqueous acid to form the ketone VIIIA, which may be converted to the oxime VIIA in the manner described previously. Alternatively, the salt XII may be reacted directly with hydroxylamine hydrochloride under similar conditions to provide oxime VIIA. Although the above illustration is with regard to monosubstituted benzo-fused derivatives, the process may readily be adapted to provide ketones of formula VIII in which A comprises a different fused ring system.

20

Individual compounds in accordance with formula I may be converted to different compounds in accordance with formula I by application of known synthetic techniques. Alternatively, such transformations may be carried out on the precursors of the compounds of formula I. For example, a compound in which A or B comprises an olefinic double bond may be converted to the corresponding alkane derivative by catalytic hydrogenation. Similarly, an exocyclic olefinic double bond may be converted to an oxo substituent by ozonolysis. Alternatively, an oxo substituent on A or B may be converted to an exocyclic olefin by means of a Wittig reaction, or an oxo substituent may be converted to a thioxo substituent by treatment with Lawesson's reagent.

Compounds of formula I wherein A or B comprises a $-\text{CH}_2\text{-NR}^{13}$ - moiety may be prepared from the corresponding compounds comprising a $-\text{CO}-$ moiety as illustrated in the scheme below:



Treatment of ketone XV with hydroxylamine-O-sulfonic acid in refluxing formic acid yields the lactam XVI, which may be reduced to the amine XVII by reaction with aluminium hydride in refluxing THF. If desired, N-

alkylation may be carried out by standard methods to provide XVIII where R^{13a} is R^{13} which is other than H and R^{13} has the same meaning as before.

Likewise, compounds of formula I or their precursors comprising aryl or heteroaryl groups may have substituents attached thereto by conventional synthetic means, and said substituents may be converted to other substituents by known techniques.

As an illustration of this principle, compounds of formula IV in which R^4 is H may be nitrated under standard conditions (such as reaction with sodium nitrate in trifluoroacetic acid) to provide the nitro derivatives (IV, $R^4 = NO_2$). Generally, a mixture of positional isomers is obtained, from which the individual isomers may be separated by conventional techniques of chromatography or fractional crystallisation. The nitro derivatives may be reduced to the corresponding anilines (IV, $R^4 = NH_2$) by conventional methods, such as reaction with tin in hydrochloric acid. The anilines may be converted to the corresponding diazonium salts (e.g. by treatment with sodium nitrite and hydrochloric acid) and thence to a variety of derivatives by displacement of the diazonium group. Examples of substituents R^4 introducible by this route include F, Cl, Br, I, OH, CN and SH. A phenol group introduced by this process may be alkylated by standard procedures, for example by reaction with an alkyl halide (such as a phenoxyethyl bromide) in the presence of a base such as potassium carbonate. Such a reaction may be carried out at about 120 °C in DMF. An alternative alkylation method is a Mitsunobu reaction with an alcohol in the presence of diethyl azodicarboxylate and triphenylphosphine.

Alternatively, the anilines IV ($R^4 = NH_2$) may be reacted with $R^{10}CO-Hal$, $R^{10}OCO-Hal$ or $R^{10}SO_2-Hal$ to form the corresponding amides ($R^4 = -NHCOR^{10}$), carbamates ($R^4 = -NHCO_2R^{10}$) or sulphonamides ($R^4 = -NHSO_2R^{10}$) respectively, where Hal and R^{10} have the same meanings as before. In another alternative, the anilines may be alkylated, e.g. by reaction with $R^{10}CHO$ and sodium cyanoborohydride to form IV ($R^4 = -NHCH_2R^{10}$) where R^{10} has the same meaning as before.

The bromo derivatives IV ($R^4 = \text{Br}$) may be subjected to substitution by $R^9R^{10}\text{NH}$ to form secondary or tertiary amines IV ($R^4 = -\text{NR}^9R^{10}$), where R^9 and R^{10} have the same meanings as before. The reaction may be carried out at elevated temperature in a sealed tube in the presence of a
5 Pd^0 catalyst. In the case of secondary amines thus formed (i.e. if R^9 is hydrogen), subsequent reaction with $R^{10}\text{CO-Hal}$, $R^{10}\text{OCO-Hal}$ or $R^{10}\text{SO}_2\text{-Hal}$ provides the corresponding amides, carbamate and sulphonamides respectively, where R^{10} and Hal have the same meanings as before.

Alternatively, the bromo derivatives IV ($R^4 = \text{Br}$) may react with
10 boronic acids $R^{10}\text{B}(\text{OH})_2$ to form IV ($R^4 = R^{10}$), where R^{10} has the same meaning as before, the reaction taking place in the presence of base and a $(\text{Ph}_3\text{P})_4\text{Pd}^0$ catalyst.

Compounds of formula IV (or their precursors) in which R^4 is alkoxy carbonyl (available by elaboration of the compounds X in which R^4
15 is alkoxy carbonyl as described above) are particularly useful intermediates. Reduction of the alkoxy carbonyl group (e.g. by treatment with diisobutylaluminium hydride [DIBAL-H]) provides the corresponding benzyl alcohol ($R^4 = -\text{CH}_2\text{OH}$), which may be converted to the tosylate, mesylate or similar, or to the corresponding bromide, and subjected to
20 nucleophilic displacement by an amine or ArO^- where Ar has the same meaning as before, especially by a phenoxide. Alternatively, the benzyl alcohol may be oxidised to the corresponding aldehyde ($R^4 = -\text{CHO}$) (e.g. by treatment with pyridinium dichromate at room temperature in dichloromethane), and coupled with a variety of ylides to form olefinic
25 derivatives, including propenoic acid derivatives ($R^4 = -\text{CH}=\text{CHCO}_2\text{R}$ where R is alkyl such as methyl or ethyl). Reduction of the propenoic esters (e.g. by treatment with DIBAL-H) provides the corresponding allyl alcohols ($R^4 = -\text{CH}=\text{CHCH}_2\text{OH}$ which may be elaborated in the same way as the benzyl alcohols discussed above. In particular, the alcohol may be
30 converted to the corresponding bromide ($R^4 = -\text{CH}=\text{CHCH}_2\text{Br}$) by treatment with phosphorus tribromide in dichloromethane at low

temperature (e.g. -20°C), and the bromine atom may be displaced by a variety of nucleophiles, in particular the amines $\text{NH}(\text{R}^{16})_2$ such as morpholine, piperidine and pyrrolidine, thereby providing the corresponding compounds in which R^4 is $-\text{CH}=\text{CHCH}_2\text{N}(\text{R}^{16})_2$ where R^{16} has the same meaning as before. The displacement is typically carried out at about 80°C in DMF in the presence of potassium carbonate.

The above mentioned aldehydes ($\text{R}^4 = -\text{CHO}$) may also be reacted with hydroxylamine hydrochloride in refluxing formic acid to provide the corresponding nitriles ($\text{R}^4 = -\text{CN}$), which in turn may be reacted with hydroxylamine hydrochloride and triethylamine in refluxing ethanol to provided the corresponding N-hydroxycarboximidamides ($\text{R}^4 = -\text{C}(\text{NH}_2)=\text{NOH}$), which may be condensed with aryl or heteroaryl carboxylic acids to yield the corresponding compounds in which R^4 is 5-aryl- or 5-heteroaryl-1,2,4-oxadiazol-3-yl.

It will also be appreciated that where more than one isomer can be obtained from a reaction then the resulting mixture of isomers can be separated by conventional means.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

A typical assay which can be used to determine the level of activity of compounds of the present invention is as follows:

- (1) Mouse neuroblastoma neuro 2a cells expressing human app695 are cultured at 50-70% confluency in the presence of sterile 10mM sodium butyrate.
- (2) Cells are placed in 96-well plates at 30,000/well/100 μ L in minimal essential medium (MEM) (phenol red-free) + 10% foetal bovine serum (FBS), 50mM HEPES buffer (pH7.3), 1% glutamine, 0.2mg/ml G418 antibiotic, 10mM sodium butyrate.
- (3) Make dilutions of the compound plate. Dilute stock solution to 5.5% DMSO/110 μ M compound. Mix compounds vigorously and store at 4°C until use.
- (4) Add 10 μ L compound/well. Mix plate briefly and leave for 18h in 37°C incubator.
- (5) Remove 90 μ L of culture supernatant and dilute 1:1 with ice-cold 25mM HEPES (pH.3), 0.1% BSA, 1.0mM EDTA (+ broad spectrum protease inhibitor cocktail; pre-aliquotted into a 96-well plate). Mix and keep on ice or freeze at -80°C.
- (6) Add back 100 μ L of warm MEM + 10% FBS, 50mM HEPES (pH7.3), 1% glutamine, 0.2mg/ml G418, 10mM sodium butyrate to each well, and return plate to 37°C incubator.
- (7) Prepare reagents necessary to determine amyloid peptide levels, for example by ELISA assay.

(8) To determine if compounds are cytotoxic, cell viability following compound administration is assessed by the use of redox dye reduction. A typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.

(9) Quantitate amyloid beta 40 and 42 peptides using an appropriate volume of diluted culture medium by standard ELISA techniques.

(10) Add 15 μ L/well MTS/PES solution to the cells; mix and leave at 37°C.


(11) Read plate when the absorbance values are approximately 1.0 (mix briefly before reading to disperse the reduced formazan product).

Alternative assays are described in *Biochemistry*, 2000, 39(30), 8698-8704.


The Examples of the present invention all had an ED₅₀ of less than 10 μ M, preferably less than 1 μ M and most preferably less than 100nM in at least one of the above assays.

Nomenclature.

Many of the compounds of formula I, and in particular those in which A comprises a fused aryl or heteroaryl ring, may be named according to two or more different protocols which are equally valid. Thus, for example, a compound of formula V may be treated as a sulphonamide derived from a 5-substituted *endo*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine:



or as a sulphonamide derived from a 2-substituted 11-*endo*-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-amine:



In both cases, “endo” refers to the configuration of the sulphonamido group
5 relative to the ring to which the benzene ring is fused.

Such systems are used interchangeably herein.

The following examples illustrate the present invention.


EXAMPLES

General Procedures

All products capable of existing in enantiomeric form were obtained as racemic mixtures unless otherwise stated.

- 5 Where stated, purification by mass-directed preparative HPLC refers to preparative reversed phase HPLC using a Platform LCZ mass spectrometer running under MassLynx 3.3 / FractionLynx control [Micromass, UK] to trigger fraction collection when a compound of the molecular weight corresponding to the desired compound was detected. A
10 generic acetonitrile / water gradient of 20% → 100% with a constant 0.1% trifluoroacetic acid was used for the preparative HPLC, and the mass spectrometer was operated with an APcI probe in positive and negative ionization mode. Solvent was removed from the resulting purified samples by lyophilization.
- 15 All examples were analyzed by analytical LC-MS utilizing diode array detection (210 – 250 nm) and APcI detection (150 – 850 amu) using a full 5% → 95% MeCN gradient with 0.1% aqueous TFA.

20 **1-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylidene-pyrrolidinium bromide**



- 1,2-Bis-bromomethyl-benzene (66.4 g, 0.25 mol) was added to a mixture of 1-cyclopent-1-enyl-pyrrolidine (29.4 g, 0.25 mol) and Hünig's base (87 mL, 0.50 mol) in MeCN (200 mL) with vigorous stirring. An exothermic
25 reaction ensued, bringing the mixture to reflux. The mixture was refluxed for 16 h, cooled, the product was filtered off and washed with MeCN to give the pure title compound as a white crystalline solid (48.14 g, 60%). ¹H NMR (d₆-DMSO, 360 MHz) δ 7.29 – 7.22 (4 H, m, aromatic), 4.16 – 4.11 (2 H, m, CH-N⁺), 4.04 – 3.99 (2 H, m, CH-N⁺), 3.60 (2 H, bs, bridgehead CH),

3.05 (4 H, d, benzylic), 2.17 – 2.05 (4 H, m, N⁺-C-CH₂), 1.92 – 1.88 (2 H, m), 1.25 – 1.20 (2 H, m). *m/z* 240 (M⁺).

Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one oxime




5

1-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylidene-pyrrolidinium bromide (48.14 g, 0.15 mol) was suspended in EtOH (200 mL) and H₂O (100 mL) and stirred. Hydroxylamine hydrochloride (31.27 g, 0.45 mol) was added, resulting in the starting material dissolving. Sodium acetate trihydrate (61.2 g, 0.45 mol) was added to the solution. After a few minutes a thick white precipitate formed. The mixture was heated to reflux until a clear solution was obtained and then allowed to cool to room temperature. The product oxime crystallized from solution and was filtered off, washing with water. The resulting pure oxime was dried to give 27.18 g (90%) of a pure white crystalline solid. ¹H NMR (d₆-DMSO, 360 MHz) δ 10.17 (1 H, s, N-OH), 7.19 – 7.12 (4 H, m, aromatic), 3.51 (1 H, bt, bridgehead CH), 3.01 – 2.87 (2 H, m, benzylic), 2.80 (1 H, bt, bridgehead CH), 2.77 (2 H, t, J = 14 Hz, benzylic), 1.68 – 1.63 (2 H, m), 1.10 – 1.05 (2 H, m). *m/z* 202 (M+H⁺).

20 A similar procedure may be used to synthesise oximes from the corresponding ketones when they are available.

***endo*-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine**



25 Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one oxime (27.18 g, 0.135 mol) was dissolved in AcOH (170 mL), PtO₂ (785 mg) was added, and the mixture was hydrogenated in a Parr reactor at 30 psi for 2 h, at which point hydrogen uptake had ceased. The mixture was filtered through Celite®, washing with AcOH, and the filtrate was concentrated by

lyophilization to give a white solid. The solid was treated with aqueous 2 N NaOH (200 mL) and extracted into DCM. The organic extracts were dried (MgSO₄) and concentrated to give the pure product amine (20.1 g, 80%) [single *endo* stereoisomer] as a pale yellow oil which crystallized upon standing. ¹H NMR (d₆-DMSO, 360 MHz) δ 7.08 – 6.99 (4 H, m, aromatic), 3.39 (2 H, d, J = 15.0 Hz, benzylic), 3.23 (1 H, t, J = 6.1 Hz, CH-N), 2.37 (2 H, dd, J = 15.0 & 7.8 Hz, benzylic), 2.15 – 2.09 (2 H, m, bridgehead CH), 1.73 (2 H, bs, -NH₂), 1.64 – 1.53 (2 H, m), 1.03 – 0.94 (2 H, m). *m/z* 188 (M+H⁺).

10

The following derivatives were similarly prepared by use of a suitably substituted o-xylyl dibromide:


endo-4-Fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine

endo-5-Fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine

15 *endo*-4-Chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine


endo-5-Chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine

endo-Tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-ylamine




20 This was synthesized in an analogous manner to *endo*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine using 1-cyclohex-1-enylpyrrolidine as a starting material. *m/z* 202 (M+H⁺).

25 **Example 1. *endo*-4-Methyl-N-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide**



endo-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine (325 mg, 1.74 mmol) was dissolved in DCM (10 mL) and treated with pyridine (300 μL,

- 3.7 mmol) and *p*-toluenesulfonyl chloride (497 mg, 2.6 mmol). The mixture was stirred for 16 h, 900 mg of polyamine scavenger resin (4.5 mmol/g) was added to remove excess sulfonyl chloride and the mixture stirred for 24 h. The mixture was filtered, concentrated, dissolved in EtOAc (100 mL) and washed with 2 M aqueous HCl followed by saturated aqueous NaHCO₃. The solution was concentrated and recrystallized from EtOAc / diethyl ether to give the pure product (168 mg) as a white crystalline solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 7.88 (1 H, d, *J* = 7.1 Hz, N-H), 7.77 (2 H, d, *J* = 8.2 Hz, tosyl), 7.41 (2 H, d, *J* = 8.2 Hz, tosyl), 7.03 (4 H, s, aromatic), 3.42 (1 H, dd, *J* = 7.1 & 6.2 Hz, CH-N), 3.17 (2 H, d, *J* = 15.6 Hz, benzylic), 2.40 (3 H, s, tosyl), 2.35 (2 H, dd, *J* = 15.6 & 7.8 Hz, benzylic), 2.12 (2 H, m, bridgehead CH), 1.49 – 1.46 (2 H, m), 0.90 – 0.87 (2 H, m). *m/z* 342 (M+H⁺).
- 15 Following the procedure of Example 1, and using the appropriate sulfonyl chloride, the following compounds of formula H were prepared. In each case, purification was by mass-directed HPLC.



H

| Example | R ³ | <i>m/z</i> (M+H ⁺) |
|---------|------------------|--------------------------------|
| 2 | 4-fluorophenyl | 346 |
| 3 | 4-chlorophenyl | 362 |
| 4 | 4-nitrophenyl | 373 |
| 5 | <i>n</i> -propyl | 294 |
| 6 | 4-bromophenyl | 406 |
| 7 | 4-iodophenyl | 454 |

| Example | R ³ | m/z (M+H ⁺) |
|---------|----------------------------|-------------------------|
| 8 | 4,5-dibromo-2-thienyl | 490 |
| 9 | 3-chloro-4-fluorophenyl | 380 |
| 10 | 4-ethylphenyl | 356 |
| 11 | pentafluorophenyl | 418 |
| 12 | 4-trifluoromethylphenyl | 396 |
| 13 | 2,4-difluorophenyl | 364 |
| 14 | 2-chlorophenyl | 362 |
| 15 | 2,5-dichloro-3-thienyl | 402 |
| 16 | 2,3-dichlorophenyl | 396 |
| 17 | 4,5-dichloro-2-thienyl | 402 |
| 18 | 2-cyanophenyl | 353 |
| 19 | 2-thienyl | 334 |
| 20 | 3-fluorophenyl | 346 |
| 21 | 5-bromo-2-thienyl | 412 |
| 22 | 2,6-difluorophenyl | 364 |
| 23 | 4-bromo-5-chloro-2-thienyl | 446 |
| 24 | 3-bromo-5-chloro-2-thienyl | 446 |
| 25 | 2,3,4-trifluorophenyl | 382 |
| 26 | 3,4-difluorophenyl | 364 |
| 27 | 4-cyanophenyl | 353 |
| 28 | phenyl | 328 |
| 29 | 2-fluorophenyl | 346 |
| 30 | 2-pyridyl | 329 |
| 31 | n-butyl | 308 |
| 32 | 5-chloro-2-thienyl | 368 |

Example 33. *endo-N*-(5-Fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide

The title compound was prepared by an analogous route to Example 1 using *endo*-5-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine and purified by mass-directed preparative HPLC. *m/z* 346 (M+H⁺).

5 **Example 34. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide**

The title compound was prepared by an analogous route to Example 1 using *endo*-5-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine and purified by mass-directed preparative HPLC. *m/z* 386 (M+H⁺).

10

Example 35. *endo*-5-Chloro-thiophene-2-sulfonic acid (4-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide

The title compound was prepared by an analogous route to Example 1 using *endo*-4-fluoro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine and purified by mass-directed preparative HPLC. *m/z* 386 (M+H⁺).

15

Example 36. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide

The title compound was prepared by an analogous route to Example 1 using *endo*-5-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine and purified by mass-directed preparative HPLC. *m/z* 402 (M+H⁺).

20

Example 37. *endo*-5-Chloro-thiophene-2-sulfonic acid (4-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide

The title compound was prepared by an analogous route to Example 1 using *endo*-4-chloro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine and purified by mass-directed preparative HPLC. *m/z* 402 (M+H⁺).

25

Example 38. *endo*-4-Methyl-N-tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-yl-benzenesulfonamide

30


The title compound was prepared by an analogous route to Example 1 using *endo*-tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-ylamine and purified by mass-directed preparative HPLC. *m/z* 356 (M+H⁺).

5 **Example 39. *endo*-Thiophene-2-sulfonic acid
tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-ylamide**

The title compound was prepared by an analogous route to Example 1 using *endo*-tricyclo[8.3.1.0^{3,8}]tetradeca-3(8),4,6-trien-14-ylamine and purified by mass-directed preparative HPLC. *m/z* 348 (M+H⁺).

10

Example 40. *endo*-N-(13-Methyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide



15 Step 1. Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one

1-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylidene-pyrrolidinium bromide (225 mg, 0.70 mmol) was dissolved in water (5 mL) and 2 M aqueous HCl (5 mL) was added. The mixture was heated at reflux for 16 h, cooled and extracted into DCM. The organic extracts were concentrated to give tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (130 mg) as a white crystalline solid. ¹H NMR (CDCl₃, 360 MHz) δ 7.19 (4 H, s, aromatic), 2.99 – 2.86 (4 H, m, benzylic), 2.61 – 2.57 (2 H, m, bridgehead H), 1.90 – 1.80 (2 H, m), 1.33 – 1.26 (2 H, m).

20 Step 2. N-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylidene-
25 benzenesulfonamide


Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (130 mg, 0.70 mmol) and benzenesulfonamide (110 mg, 0.70 mmol) were mixed in toluene (6 mL). Amberlyst-15 ion exchange resin (35 mg) was added, and the mixture was heated at reflux under Dean Stark conditions for 36 h. The mixture was

concentrated and the crude sulfonylimine was used directly in the next step.

Step 3. *endo-N*-(13-Methyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide

- 5 The crude *N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylidene-benzenesulfonamide above was dissolved in THF (2 mL), cooled to -78 °C, and treated dropwise with 1.0 M MeLi in THF / cumene (5.0 mL). The mixture was allowed to slowly warm to 20 °C, quenched with water (10 mL) followed by 5 M aqueous HCl (2 mL) and extracted into DCM. The
10 mixture was concentrated and purified by mass-directed preparative HPLC to give 10 mg of the pure product. ¹H NMR (d₆-DMSO, 360 MHz) δ 7.84 (2 H, m, aromatic), 7.58 (1 H, s, N-H), 7.50 (3 H, m, aromatic), 6.98 (4 H, m, aromatic), 3.32 (2 H, benzylic), 2.39 (2 H, benzylic), 2.21 (2 H, m, bridgehead H), 1.52 (2 H, m), 0.91 (3 H, s, Me), 0.90 (2 H, m). *m/z* 342
15 (M+H⁺).

Example 41. *endo-N*-(5-Nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide and *endo-N*-(4-nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide




- Sodium nitrate (10.1 g, 118.8 mmol) was added portionwise to a stirred solution of *endo-N*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl-benzenesulfonamide (Example 28) (13.0 g, 39.8 mmol) in trifluoroacetic acid (260 mL) with ice-cooling. The cooling was removed 10 minutes after
25 the addition was complete. The reaction mixture was stirred at rt for 1 h and then added to ice. Stirring was continued until the ice had melted. The mixture was filtered, the solid washed with water until the washings were neutral and dried under vacuum. The crude product was recrystallized from ethanol four times to give pure *endo-N*-(5-nitro-

tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (5.75g, 39%) as a yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ 1.02 - 1.11 (m, 2 H), 1.58 - 1.66 (m, 2 H), 2.33 - 2.40 (m, 2 H), 2.57 - 2.66 (m, 2 H), 3.11 - 3.18 (m, 2 H), 3.60 (m, 1 H) 5.45 (bd, 1 H), 7.17 (d, 1 H, J = 9 Hz) 7.52 - 7.64 (m, 3 H), 7.90 - 7.96 (m, 4 H). *m/z* 373 (M+H⁺).

endo-N-(4-Nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide was isolated pure from the above recrystallization mother liquors by mass-directed preparative HPLC. *m/z* 373 (M+H⁺).

10


Example 42. *endo-N*-(5-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide



A solution of tin (II) chloride (4.86 g, 25.6 mmol) in concentrated hydrochloric acid (25 mL) was added dropwise to an ice-cooled solution of *endo-N*-(5-nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 41) (2.8 g, 7.5 mmol) in THF (40 mL). The reaction mixture was stirred at room temperature for 18 h, cooled in an ice-bath and basified carefully with 4N sodium hydroxide solution. The mixture was then extracted with ethyl acetate. The organic phase was washed with brine and concentrated to give an orange oil. The crude product was dissolved in the minimum quantity of ethyl acetate and diluted with diethyl ether. 2M HCl in ether (5.6 mL, 11.2 mmoles) was added with stirring. The mixture was filtered and the solid washed with ethyl acetate and then diethyl ether. The solid was dispersed between DCM and 1 N NaOH solution and mixed thoroughly. The organic phase was separated, dried over sodium sulphate and evaporated to give the title compound as a yellow solid (2.4 g, 93%). ¹H NMR (CDCl₃, 400 MHz) δ 1.13 - 1.19 (m, 2 H), 1.50 - 1.58 (m, 2 H), 2.15 - 2.25 (m, 2 H), 2.30 - 2.40 (m, 2


H), 2.82 - 2.92 (m, 2 H), 3.66 (m, 1 H), 5.04 (bd, 1 H), 6.38-6.42 (m, 2 H), 6.79 (d, 1 H, $J = 9$ Hz), 7.50 - 7.61 (m, 3 H), 7.91 - 7.94 (m, 2 H). m/z 343 ($M+H^+$).

5 **Example 43. *endo-N*-(4-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide**



The title compound was prepared from the crude mother liquors resulting from the recrystallization described in Example 41 using an analogous
10 route to Example 42. A pure sample was obtained by mass-directed preparative HPLC as its TFA salt. ¹H NMR (CDCl₃, 400 MHz) δ 0.96 - 1.09 (m, 2 H), 1.43 - 1.56 (m, 2 H), 2.19 - 2.27 (m, 1 H), 2.38 - 2.49 (m, 2 H), 2.80 - 2.88 (m, 1 H), 2.95-3.10 (m, 2 H), 3.48 - 3.41 (m, 1 H), 6.16 (bd, 1 H), 6.93 - 7.01 (m, 2 H), 7.10 (bd, 1 H), 7.49-7.53 (m, 2 H), 7.57 - 7.61 (m, 1 H),
15 7.90 - 7.94 (m, 2 H). m/z 343 ($M+H^+$).


Example 44. *endo-N*-(13-Benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-benzamide





20 Benzoic acid (5.0 mg, 0.041 mmol) was weighed into a test tube and treated with *N,N'*-carbonyldiimidazole (4.1 mg, 0.025 mmol) in THF (0.5 mL). The solution was heated at 70 °C for 2 h, cooled, and a solution of *endo-N*-(5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 42) (6.0 mg, 0.0175 mmol) in THF (0.5 mL)
25 was added. The solution was heated at 70 °C for 16 h, concentrated, and


the crude product purified by mass-directed preparative HPLC. m/z 447 ($M+H^+$).

- 5 Following the procedure of Example 44, and using the appropriate carboxylic acid, the following compounds of formula J were prepared. In each case, purification was by mass-directed HPLC.



J

| Example | R ⁴ | m/z ($M+H^+$) |
|---------|---|-------------------|
| 45 | PhCH ₂ CONH- | 461 |
| 46 | PhOCH ₂ CONH- | 477 |
| 47 |  | 497 |
| 48 |  | 465 |
| 49 | CH ₃ CONH- | 385 |
| 50 | CH ₃ (CH ₂) ₄ CONH- | 441 |
| 51 | CH ₃ CH ₂ CH(CH ₃)CH ₂ CONH- | 441 |
| 52 | cyclopentyl-CH ₂ CONH- | 453 |
| 53 | CH ₃ (CH ₂) ₃ CH(CH ₃)(CH ₂) ₂ CONH- | 483 |
| 54 | (CH ₃) ₂ CH(CH ₂) ₃ CONH- | 455 |
| 55 | MeOCH ₂ CONH- | 415 |
| 56 | Ph(CH ₂) ₂ CONH- | 475 |


| Example | R ⁴ | m/z (M+H ⁺) |
|---------|---|-------------------------|
| 57 |  | 448 |

Example 58. *endo-N*-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-2-phenoxy-acetamide

5 The title compound was prepared by an analogous route to Example 44 and purified by mass-directed preparative HPLC. *m/z* 517 (M+H⁺).

Example 59. *endo*-(13-Benzenesulfonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl)-carbamic acid phenyl ester

10






Phenyl chloroformate (10 μ L, 0.08 mmol) was added to a test tube and treated with a solution of *endo-N*-(5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 42) (6.0 mg, 0.0175 mmol) in THF (0.5 mL) followed by pyridine (10 μ L). The solution was allowed to stand at 20 °C for 16 h, concentrated, and the crude product purified by mass-directed preparative HPLC. *m/z* 463 (M+H⁺).

15


Following the procedure of Example 59, and using the appropriate chloroformate, the following compounds of formula J were prepared. In each case, purification was by mass-directed HPLC.

20

| Example | R ⁴ | m/z (M+H ⁺) |
|---------|--|-------------------------|
| 60 | PhCH ₂ OCONH- | 477 |
| 61 | (CH ₃) ₂ CHCH ₂ OCONH- | 443 |

| Example | R ⁴ | m/z (M+H ⁺) |
|---------|--|-------------------------|
| 62 | Me-  -OCONH- | 477 |
| 63 | F-  -OCONH- | 481 |
| 64 | MeO-  -OCONH- | 493 |
| 65 | (CH ₃) ₃ CCH ₂ OCONH- | 457 |

Example 66. *endo*-N-Bicyclo[4.2.1]non-3-en-9-yl-4-methyl-benzenesulfonamide



Step 1. Bicyclo[4.2.1]non-3-en-9-one oxime

Hydroxylamine hydrochloride (1.53 g, 22.0 mmol) and sodium acetate (2.99g, 36.4 mmol) were added to a solution of bicyclo[4.2.1]non-3-en-9-one (Synthesis, 1976, 453) (1.0 g, 7.3 mmol) and the resulting solution warmed to reflux overnight. The reaction was then cooled to room temperature and the solvent removed under reduced pressure. The residue was partitioned between EtOAc (50 mL) and NaOH solution (1N aq 50 mL), the organic layer separated, dried over MgSO₄, filtered and the solvent removed under reduced pressure to give the title compound (1.02 g, 93%).
¹H NMR (CDCl₃) δ 1.22-1.63 (2H, m), 1.88-1.95 (2H, m), 1.99-2.09 (3H, m), 2.45-2.49 (1H, m), 2.88 (1H, m), 3.55 (1H, m), 5.54 (1H, d, J = 2 Hz). m/z 152 (M+H)⁺.

Step 2. *endo*-Bicyclo[4.2.1]non-3-en-9-ylamine

NaCNBH₃ (451 mg, 7.3 mmol) was added to a solution of bicyclo[4.2.1]non-3-en-9-one oxime (550 mg, 3.6 mmol) in MeOH (10 mL) at -30°C containing methyl orange indicator (20 µl of 0.1 % solution) followed by enough HCl (5N, Aq) to turn the solution pink. As the reaction proceeded
5 sufficient HCl was added to maintain a pink colour. After two hours the reaction was allowed to warm to room temperature and poured onto ice/NaOH (4N, aq), and extracted into EtOAc (30 mL), dried over MgSO₄, filtered and the solvent removed under reduced pressure. The recovered hydroxylamine was taken up in AcOH (2 mL) and added to a stirred
10 suspension of activated Zn dust (4.72 g 72.6 mmol) in AcOH (50 mL). After 30 min TLC (2N NH₃/MeOH: DCM 5:95) showed complete reduction of the hydroxylamine to a more polar product. The solution was filtered through Celite® to remove the zinc and the solvent removed under reduced pressure. The residue was basified with NaHCO₃ and extracted
15 into EtOAc (50 mL), dried over MgSO₄, filtered and the solvent removed under reduced pressure to afford the title product (220 mg 46%). ¹H NMR (CDCl₃) δ 1.33-1.43 (2H, m), 1.48 (2H bs, NH₂), 1.78-1.81 (2H, m), 1.82 (2H, bd, J = 16 Hz), 2.09-2.32 (4H, m), 3.39 (1H, t, J = 8.0 Hz), 5.48 (2H, d, J = 4 Hz). *m/z* 138 (M+H)⁺.

20 Step 3. *endo*-N-Bicyclo[4.2.1]non-3-en-9-yl-4-methyl-benzenesulfonamide
p-Toluenesulphonyl chloride (41.94 mg, 0.22 mmol) was added to a solution of *endo*-bicyclo[4.2.1]non-3-en-9-ylamine (157 mg, 0.22 mmol) and N-Methyl morpholine (NMM, 48 µL, 0.44 mmol) in dry DCM (2.0 mL). The resulting mixture was stirred for 18 hrs at room temperature, followed
25 by the addition of polyamine resin (100 mg of 2.46 mmol/g) and stirred for a further 18 h. The reaction was then filtered and the resin washed with MeOH (2 x 5 mL). The filtrates were combined and the solvent removed under reduced pressure. The residue was purified by mass-directed preparative HPLC to afford the title compound. ¹H NMR (d₆-DMSO) δ
30 1.22 (2H, bd, J = 8.0 Hz), 1.62 (2H, m), 1.94 (2H, m), 2.1 (2H, m), 2.29 (1H, m), 2.31 (1H, m), 2.39 (3H, s), 3.34 (1H, m), 5.42 (2H, d, J = 4.0 Hz), 7.14

(1H, bd, J = 4.0 Hz), 7.39 (2H, d, J = 8.0 Hz), 7.76 (2H, d, J = 8.0 Hz). m/z 292 (M+H)⁺.

**Example 67. *endo*-N-Bicyclo[4.2.1]non-3-en-9-yl-4-fluoro-
5 benzenesulfonamide**

The title compound was prepared by an analogous route to Example 66 and purified by mass-directed preparative HPLC. ¹H NMR (d₆-DMSO) δ 1.21 (2H, m), 1.6 (2H, m), 1.85 (2H, m), 2.05 (2H, m), 2.20 (2H, m), 3.40 (1H, dd, J = 8.0, 4.0 Hz), 5.32 (2H, d, J = 4.0 Hz), 7.15 (1H, d, J = 4.0 Hz),
10 7.31 (2H, m), 7.82 (2H, m). m/z 296 (M+H)⁺.

**Example 68. *endo*-N-Bicyclo[4.2.1]non-3-en-9-yl-
benzenesulfonamide**

The title compound was prepared by an analogous route to Example 66
15 and purified by mass-directed preparative HPLC. ¹H NMR (d₆-DMSO) δ 1.23 (2H, m), 1.55 (2H, m), 1.9 (2H, m), 2.1 (2H, m), 2.3 (2H, m), 3.49 (1H, dd, J = 8.0, 4.0 Hz), 5.41 (2H, d, J = 4.0 Hz), 7.2 (1H, d, J = 4.0 Hz), 7.6 (3H, m), 7.84 (2H, m). m/z 278 (M+H)⁺.


**Example 69. *endo*-Thiophene-2-sulfonic acid bicyclo[4.2.1]non-3-
20 en-9-ylamide**

The title compound was prepared by an analogous route to Example 66 and purified by mass-directed preparative HPLC. ¹H NMR (d₆-DMSO) δ 1.25 (2H, m), 1.7 (2H, m), 1.9 (2H, m), 2.2 (2H, m), 2.3 (2H, m), 3.55 (1H, dd, J = 8.0, 4.0 Hz), 5.51 (2H, d, J = 4.0 Hz), 7.19 (1H, t, J = 4.0 Hz), 7.49 (1H, d, J = 4.0 Hz), 7.63 (1H, d, J = 1.5 Hz), 7.93 (1H, d, J = 1.5 Hz). m/z 284 (M+H)⁺.
25

**Example 70. *endo*-5-Chloro-thiophene-2-sulfonic acid
30 bicyclo[4.2.1]non-3-en-9-ylamide**

The title compound was prepared by an analogous route to Example 66 and purified by mass-directed preparative HPLC. ^1H NMR (d_6 -DMSO) δ 1.26 (2H, dd, $J = 8.0, 1.0$ Hz), 1.73 (2H, m), 1.97 (2H, m), 2.23-2.33 (4H, m), 3.59 (1H, m), 5.43 (2H, brs), 7.26 (1H, d, $J = 1.5$ Hz), 7.5 (1H, d, $J = 1.5$ Hz), 7.65 (1H, bs). m/z 318 ($M+H$) $^+$.

Example 71. *endo*-5-Chloro-thiophene-2-sulfonic acid bicyclo[4.2.1]non-9-ylamide



Step 1. *Endo*-Bicyclo[4.2.1]non-9-ylamine

A solution of bicyclo[4.2.1]non-3-en-9-one oxime (220 mg, 1.46 mmol) in AcOH (50 mL) was hydrogenated over PtO_2 (25 mg) at 50 psi for 4 h. The reaction mixture was filtered through Celite® and the solvent removed under reduced pressure. The residue was partitioned between EtOAc (50 mL) and NaOH solution (1N aq, 50 mL), the organic layer separated, dried over MgSO_4 , filtered and the solvent removed under reduced pressure to give the title compound as an oil (201 mg, 98%). ^1H NMR (CDCl_3) δ 1.39-1.65 (8H, bm), 1.70-1.75 (4H, brm), 1.82 (2H, m), 2.17 (2H, m), 3.29 (1H, t, $J = 8\text{Hz}$). m/z 140 ($M+H$) $^+$.


Step 2. *endo*-5-Chloro-thiophene-2-sulfonic acid bicyclo[4.2.1]non-9-ylamide

5-Chlorothiophene-2-sulphonyl chloride (313 mg, 1.4 mmol) was added in a single portion to a solution of *endo*-bicyclo[4.2.1]non-9-ylamine (201 mg, 1.4 mmol) and *N*-methyl morpholine (461 μL , 4.2 mmol) in dry DCM (20 mL). The resulting mixture was stirred at room temperature for 3 h, at which time polyamine resin (500 mg, 2.46 mmol/g) was added and stirring continued for one hour. The reaction mixture was then filtered to remove the resin and the resin pad washed with MeOH (4 x 20 mL). The filtrates were combined and the solvent removed under reduced pressure to afford

a white solid. Recrystallisation from EtOH afforded the pure title compound as white needles. (382 mg, 85%) ^1H NMR (CDCl_3) δ 1.37-1.60 (10H, m), 1.79 (2H, m), 2.29 (2H, m), 3.69 (1H, m), 4.77 (1H, brd, $J = 8.0$ Hz), 6.90 (1H, d, $J = 4$ Hz), 7.40 (1H, d, $J = 4.0$ Hz). m/z 320 ($\text{M}+\text{H}$) $^+$.

5

Example 72. *endo*-8-(5-Chloro-thiophene-2-sulfonylamino)-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester



Step 1. 8-Hydroxyimino-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester

10

3-Bromo-2-bromomethyl-propionic acid ethyl ester (5.48 g, 20 mmol) was added to a mixture of 1-cyclopent-1-enyl-pyrrolidine (2.74 g, 20 mmol) and Hünig's base (3.5 mL) in MeCN (15 mL) with vigorous stirring. An exothermic reaction ensued, bringing the mixture to reflux. The mixture was refluxed for 16 h, cooled, and poured into 100 mL of EtOAc with stirring. The resulting solid (3.33 g) was collected by filtration, dissolved in 0.5 M aqueous HCl (100 mL) and stirred with EtOAc (100 mL) for 48 h.

15

The organic layer was separated and concentrated to give 8-oxo-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester (1.0 g, 5.1 mmol) as a colourless oil. This was dissolved in EtOH (50 mL), treated with a solution of hydroxylamine hydrochloride (1.04 g, 15 mmol) and sodium acetate trihydrate (2.04 g, 15 mmol) in water (10 mL) and heated at reflux for 16 h. The solution was cooled, concentrated, diluted with water (100 mL) and extracted with DCM. The DCM extracts were dried (MgSO_4), concentrated and purified by flash chromatography (20 \rightarrow 30% EtOAc / hexane) to give the oxime (270 mg) as a colourless oil. ^1H NMR (CDCl_3 , 360 MHz) δ 9.85 (1 H, bs, N-OH), 4.20 (2 H, q, $J = 7.1$ Hz, $\text{CH}_2\text{-O}$), 3.36 (1 H, bs, bridgehead H), 2.63 – 2.56 (4 H, m), 2.15 – 2.04 (2 H, m), 1.76 – 1.69 (4 H, m), 1.30 (3 H, t, $J = 7.1$ Hz, -Me). m/z 212 ($\text{M}+\text{H}$) $^+$.

25


Step 2. *endo*-8-Amino-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester

8-Hydroxyimino-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester (270 mg, 1.28 mmol) was dissolved in AcOH (5 mL), treated with PtO₂ (34 mg) and stirred under an atmosphere of H₂ for 1 h [catalyst clumps together when reaction complete]. The mixture was filtered, concentrated, basified (aqueous 4 N NaOH) and extracted into DCM to give the title compound which was sufficiently pure for use in the next step. *m/z* 198 (M+H)⁺.

Step 3. *endo*-8-(5-Chloro-thiophene-2-sulfonylamino)-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester

endo-8-Amino-bicyclo[3.2.1]octane-*endo*-3-carboxylic acid ethyl ester (21.2 mg, 0.108 mmol) in DCM (2 mL) was treated with 5-chlorothiophene-2-sulphonyl chloride (43 mg, 2.0 mmol) and pyridine (40 μ L, 0.5 mmol). The mixture was stirred for 16 h, diluted with DCM (50 mL) and washed with aqueous 2 M HCl. The organic extracts were dried and purified by flash chromatography (10 \rightarrow 25% EtOAc / hexane) to give pure title compound (12.6 mg) as a colourless crystalline solid. ¹H NMR (CDCl₃, 360 MHz) δ 7.42 (1 H, d, *J* = 3.9 Hz, thiophene), 6.93 (1 H, d, *J* = 3.9 Hz, thiophene), 5.29 (1 H, bd, *J* = 6.7 Hz, N-H), 4.16 (2 H, q, *J* = 7.0 Hz, CH₂-O), 3.27 (1 H, q, *J* = 6.7 Hz, CH-N), 2.50 (1 H, t, *J* = 8.3 Hz, CH-COOEt), 2.21 (2 H, dd, *J* = 14.9 & 3.0 Hz, CH_{eq}-C-COOEt), 2.03 (2 H, bs, bridgehead H), 1.88 (2 H, ddd, *J* = 15.0, 8.4 & 2.3 Hz, CH_{ax}-C-COOEt), 1.66 – 1.51 (4 H, m), 1.28 (3 H, t, *J* = 7.0 Hz, -Me). *m/z* 378 (M+H)⁺.


Example 73. *endo*-N-{5-[(Pyridin-3-ylmethyl)-amino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-benzenesulfonamide













endo-N-(5-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 42) (25 mg, 0.073 mmol), pyridine-3-carbaldehyde (7.9 mg, 0.073 mmol) and acetic acid (4.4 mg, 0.073 mmol) in 1,2-dichloroethane (0.5 mL) were added to a test-tube. A solution of



5 tetramethylammonium triacetoxyborohydride (27 mg, 0.102 mmol) in 1,2-dichloroethane (0.5 mL) was added and the mixture stirred at room temperature for 64 h. Water (1 mL) was added with stirring, the organic phase was separated and concentrated to dryness. The crude product was purified by mass-directed preparative HPLC. *m/z* 434 (M+H⁺).

10 Following the procedure of Example 73, and using the appropriate aldehyde, the following compounds of formula J were prepared. In each case, purification was by mass-directed HPLC.


**J**

| Example | R ⁴ | <i>m/z</i> (M+H ⁺) |
|---------|----------------|--------------------------------|
| 74 | | 525 |
| 75 | | 539 |
| 76 | | 463 |
| 77 | | 463 |

| Example | R ⁴ | m/z (M+H ⁺) |
|---------|--|-------------------------|
| 78 |  | 439 |
| 79 | (CH ₃) ₂ CHCH ₂ CH ₂ NH- | 413 |
| 80 |  | 491 |
| 81 | t-Bu-  -CH ₂ NH- | 489 |
| 82 | PhCH(CH ₃)CH ₂ CH ₂ NH- | 475 |
| 83 | i-PrO-  -CH ₂ NH- | 491 |
| 84 |  | 473 |
| 85 | Ph(CH ₂) ₃ NH- | 461 |
| 86 | CH ₃ (CH ₂) ₄ -  -CH ₂ NH- | 503 |
| 87 | CF ₃ O-  -CH ₂ NH- | 517 |
| 88 | NC-  -CH ₂ NH- | 458 |
| 89 | F-  -CH ₂ NH- | 451 |
| 90 | F-  -CH ₂ NH- | 451 |

| Example | R ⁴ | m/z (M+H ⁺) |
|---------|--|-------------------------|
| 91 |  | 467 |
| 92 |  | 501 |

Example 93. *endo*-N-(5-Bromo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide




5 A solution of sodium nitrite (223 mg, 3.23 mmol) in water (4 mL) was added dropwise to a stirred suspension of *endo*-N-(5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 42) (465 mg, 1.36 mmol) in water (16 mL) and 2 N HCl (4 mL) with ice-cooling. The reaction mixture was stirred at room temperature for 20 min and then saturated sodium tetrafluoroborate solution (4 mL) was added. The mixture was stirred with ice-cooling for 20 min followed by 30 min at room temperature. The mixture was filtered and the solid washed with water and then DCM. A solution of the filtered solid in 15 acetone (16 mL) was added dropwise to a stirred suspension of copper (I) bromide (5.6 g, 39.15 mmol) in water (16 mL) and conc. HBr (16 mL). The reaction was stirred at room temperature for 3 h and then added to ethyl acetate and water. The organic phase was washed with brine, dried over sodium sulphate and concentrated to give a brown oil. The crude product was purified by flash chromatography over silica eluting with 3:1 DCM : 20 isohexane increasing in polarity to 1% methanol in DCM to give the title compound as a white solid (220 mg, 40%). ¹H NMR (CDCl₃, 400 MHz) δ

1.06 – 1.14 (m, 2 H), 1.54 – 1.64 (m, 2 H), 2.24 – 2.29 (m, 2 H), 2.37 – 2.47 (m, 2 H), 2.94 – 3.20 (m, 2 H), 3.62 (m, 1 H), 5.22 (bd, 1 H), 6.88 (d, 1 H, $J = 9$ Hz), 7.16 (m, 2 H), 7.51 – 7.61 (m, 3 H), 7.93 (m, 2 H). m/z 406/408 ($M+H^+$).

5


Example 94. *endo-N*-[5-(4-Phenyl-piperidin-1-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-benzenesulfonamide



endo-N-(5-Bromo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 93) (25 mg, 0.062 mmol), sodium *tert*-butoxide (14 mg, 0.148 mmol), tris(dibenzylideneacetone)dipalladium (0) (1.4 mg, 0.0015 mmol), tri-*o*-tolylphosphine (1.9 mg, 0.0061 mmol) and 4-phenylpiperidine (11.9 mg, 0.074 mmol) in degassed 1,4-dioxane (1.2 mL) were added to a test-tube and sealed under an atmosphere of nitrogen. The mixture was stirred and heated at 90 °C for 18 h, allowed to cool to room temperature and diluted with ethyl acetate. The mixture was washed with water and brine, the organic phase separated, dried over sodium sulphate and concentrated to dryness. The crude product was purified by mass-directed preparative HPLC. m/z 487 ($M+H^+$).

20

Example 95. *endo-N*-(5-Phenyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide




A mixture of *endo-N*-(5-bromo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 93) (24 mg, 0.059 mmol),

25

benzeneboronic acid (9 mg, 0.074 mmol) and sodium carbonate (25 mg, 0.296 mmol) in water (0.25 mL) and dimethoxyethane (1 mL) was thoroughly degassed. Tetrakis(triphenylphosphine)palladium (0) (5 mg) was added and the mixture was stirred and heated at reflux under
 5 nitrogen for 3 h. The mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic phase was washed with brine, dried over sodium sulphate and concentrated to dryness. The crude product was purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) δ 1.16 - 1.21 (m, 2 H), 1.59 - 1.64 (m, 2 H), 2.30 (m, 2 H),
 10 2.51 - 2.60 (m, 2 H), 3.00 - 3.07 (m 2 H), 3.72 (m, 1 H), 5.01 (bd, 1 H), 7.10 (d, 1 H, J = 8 Hz), 7.26 - 7.33 (m, 3 H), 7.39 - 7.43 (m, 2 H), 7.52 - 7.63 (m, 5 H), 7.94 - 7.97 (m, 2 H). *m/z* 404 (M+H⁺).


Following the procedure of Example 95, and using the appropriate boronic
 15 acid, the following compounds of formula J were prepared. In each case, purification was by mass-directed HPLC.

**J**

| Example | R ⁴ | <i>m/z</i> (M+H ⁺) |
|---------|-----------------|--------------------------------|
| 96 | 3-thienyl | 410 |
| 97 | 2-methoxyphenyl | 434 |
| 98 | 4-fluorophenyl | 422 |
| 99 | 3-fluorophenyl | 422 |
| 100 | benzofuran-2-yl | 444 |
| 101 | 2-thienyl | 410 |
| 102 | 2-fluorophenyl | 422 |

| Example | R ⁴ | m/z (M+H ⁺) |
|---------|-----------------------|-------------------------|
| 103 | 4-pyridyl | 405 |
| 104 | 3-pyridyl | 405 |
| 105 | 6-methoxypyridin-3-yl | 435 |

**Example 106. *endo*-5-Chloro-thiophene-2-sulfonic acid
tricyclo[6.2.2.0^{2,7}]dodeca-2(7),3,5-trien-9-ylamide**



5

Step 1. Tricyclo[6.2.2.0^{2,7}]dodeca-2,4,6-trien-9-one oxime

Tricyclo[6.2.2.0^{2,7}]dodeca-2,4,6-trien-9-one (*Can.J.Chem.*, **71**, 1290-6, 1993) (440 mg, 2.56 mmol) was dissolved in ethanol (3 mL) and water (1.5 mL) was added, followed by hydroxylamine hydrochloride (484 mg, 6.97 mmol) and sodium acetate trihydrate (948 mg, 6.97 mmol). The reaction was stirred at room temperature overnight. Water (40 mL) was added, a precipitate formed and this was filtered. The precipitate was dissolved in DCM (20 mL) and washed with water. The aqueous washings were extracted into DCM (20 mL) and the organic layer was dried (MgSO₄) and concentrated to give the desired oxime (475 mg, 100%). ¹H NMR (CDCl₃, 360 MHz) δ 7.25 - 7.18 (4 H, m), 3.73 - 3.70 (1 H, m), 3.34 - 3.30 (1 H, m), 2.61, (1 H, dd, J = 18 & 2.5 Hz), 2.39 - 2.31 (1 H, m), 2.04 - 1.96 (1 H, m), 1.87 - 1.79 (1 H, m), 1.66 - 1.49 (2 H, m). m/z 188 (M+H⁺).

15

Step 2. *endo*-Tricyclo[6.2.2.0^{2,7}]dodeca-2,4,6-trien-9-ylamine


Tricyclo[6.2.2.0^{2,7}]dodeca-2,4,6-trien-9-one oxime (20 mg, 0.107 mmol) was dissolved in glacial acetic acid (5 mL), platinum (IV) oxide (5 mg) was added, and the mixture was hydrogenated in a Parr reactor at 32 psi for 4 h. The mixture was filtered, freeze dried and used crude in the next reaction step.

20

Step 3. *endo*-5-Chloro-thiophene-2-sulfonic acid tricyclo[6.2.2.0^{2,7}]dodeca-2(7).3.5-trien-9-ylamide

endo-Tricyclo[6.2.2.0^{2,7}]dodeca-2,4,6-trien-9-ylamine (prepared above, 0.107 mmol) was dissolved in CDCl₃ (2 mL) and treated with 5-chlorothiophenesulphonyl chloride (46.5 mg, 0.214 mmol) followed by pyridine (200 µL). The reaction was heated at 45 °C for 48 hours. The product was purified by mass-directed preparative HPLC to give the desired product (1.8 mg, 5%) ¹H NMR (CDCl₃, 360 MHz) δ 7.37 (1 H, d, J = 4 Hz), 7.27 - 7.07 (4 H, m), 6.93 (1 H, d, J = 4 Hz), 4.01 - 3.97 (1 H, br d), 3.88 - 3.79 (1 H, m), 3.02 - 2.96 (2 H, m), 2.29 - 2.21 (1 H, m), 1.79 - 1.58 (2 H, m), 1.49 - 1.39 (1 H, m), 1.36 - 1.25 (1 H, m), 1.14 - 1.08 (1 H, m). *m/z* 354 (M+H⁺).

Example 107. 5-Chloro-thiophene-2-sulfonic acid (3-methyl-bicyclo[3.2.1]oct-8-yl)-amide



Step 1. 3-Methylene-bicyclo[3.2.1]octan-8-one oxime

3-Methylene-bicyclo[3.2.1]octan-8-one (*Tetrahedron Lett.*, **29**, 5663-4, 1988) (408 mg, 3 mmol) was dissolved in ethanol (3 mL) and water (1.5 mL) was added, followed by hydroxylamine hydrochloride (534 mg, 9 mmol) and sodium acetate trihydrate (1.224 g, 9 mmol). The reaction was stirred at room temperature overnight. Water (20 mL) was added and the mixture was extracted into DCM (3 x 30 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated to give a viscous yellow oil which was purified by column chromatography on silica using 10 → 20% ethyl acetate in isohexane to yield the oxime (284 mg, 63%). ¹H NMR (CDCl₃, 360 MHz) δ 4.91 - 4.87 (2 H, m), 3.42 - 3.38 (1 H, m), 2.66 - 2.64 (1 H, m), 2.55 - 2.48 (2 H, m), 2.37 - 2.24 (2 H, m), 1.87 - 1.51 (4 H, m). *m/z* 152 (M+H⁺).


Step 2. 3-Methyl-bicyclo[3.2.1]oct-8-ylamine

3-Methylene-bicyclo[3.2.1]octan-8-one oxime (25 mg, 0.165 mmol) was dissolved in ethanol (5 mL), 10% palladium on carbon (15 mg) was added, and the mixture was hydrogenated in a Parr reactor at 40 psi for 2 h and then 50 psi for 20 h. The mixture was filtered and the catalyst was
5 washed with further ethanol (25 mL). The filtrate was evaporated to give the product amine as a mixture of 4 isomers which was used crude in the next step.

Step 3. 5-Chloro-thiophene-2-sulfonic acid (3-methyl-bicyclo[3.2.1]oct-8-yl)-amide

10 3-Methyl-bicyclo[3.2.1]oct-8-ylamine (prepared in Step 2, 0.165 mmol) was dissolved in DCM (1.5 mL) and treated with 5-chlorothiophenesulphonyl chloride (53.7 mg, 0.248 mmol) followed by pyridine (100 μ L). The reaction was stirred at room temperature for 66 h, followed by heating at 60 °C for 18 h. The reaction mixture was evaporated and purified by mass-directed
15 preparative HPLC to give the desired product (5.3 mg, 10%) as a mixture of four isomers. m/z 320 ($M+H^+$).

Example 108. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide



20

Step 1. *endo*-N-(3-Methylene-bicyclo[3.2.1]oct-8-yl)-hydroxylamine

Sodium cyanoborohydride (165 mg, 2.62 mmol) was added to a solution of 3-methylene-bicyclo[3.2.1]octan-8-one oxime (200 mg, 1.32 mmol) in
25 methanol (4 mL) containing methyl orange indicator (10 μ L of a 0.1% aqueous solution) at -30 °C followed by enough 5 N hydrochloric acid to turn the solution pink. After 90 min the reaction mixture was allowed to warm to 0 °C and the reaction mixture was basified using 4 N sodium hydroxide solution. The mixture was extracted into DCM (3 x 30 mL) and

the combined organic extracts were dried (Na_2SO_4) and concentrated to give the desired hydroxylamine (185 mg, 91%). ^1H NMR (CDCl_3 , 360 MHz) δ 4.73 - 4.71 (2 H, m), 3.25 (1 H, t, $J = 4.5$ Hz), 2.57 - 2.53 (2 H, br d), 2.25 - 2.22 (2 H, m), 1.91 - 1.85 (2 H, br dd), 1.75 - 1.66 (2 H, m), 1.55 - 1.42 (2 H, m). m/z 154 ($\text{M}+\text{H}^+$).

Step 2. *endo*-3-Methylene-bicyclo[3.2.1]oct-8-ylamine

endo-*N*-(3-Methylene-bicyclo[3.2.1]oct-8-yl)-hydroxylamine (25 mg, 0.16 mmol) in 50% acetic acid (1 mL) was treated with activated zinc dust (110 mg) and heated at 55 °C for 2 h. The reaction was allowed to cool to room temperature, filtered and basified using 4 N sodium hydroxide solution. The reaction mixture was extracted into DCM (3 x 30 mL) and the combined organic extracts were dried (Na_2SO_4) and concentrated. The crude product was used directly in the next step.

Step 3. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide


endo-3-Methylene-bicyclo[3.2.1]oct-8-ylamine (prepared as above, 0.16 mmol) was dissolved in CDCl_3 (2.1 mL) and treated with 5-chlorothiophenesulphonyl chloride (53 mg, 0.244 mmol) followed by pyridine (100 μL). The reaction was heated at 50 °C for 18 h followed by 65 °C for a further 24 h. The product was purified by mass-directed preparative HPLC followed by column chromatography on silica using 20% diethyl ether in isohexane as the eluant to give the desired product (14.1 mg, 27%). ^1H NMR (CDCl_3 , 360 MHz) δ 7.42 (1 H, d, $J = 4$ Hz), 6.92 (1 H, d, $J = 4$ Hz), 4.92 - 4.85 (1 H, br d), 4.78 - 4.75 (2 H, m), 3.47 - 3.42 (1 H, m), 2.40 - 2.35 (2 H, br d), 2.15 - 2.10 (2 H, m), 1.99 - 1.93 (2 H, br dd), 1.68 - 1.63 (2 H, m), 1.48 - 1.41 (2 H, m). m/z 318 ($\text{M}+\text{H}^+$).

Alternative Procedure for Step 3

A solution of *endo*-3-methylene-bicyclo[3.2.1]oct-8-ylamine [Step 2] (0.50 g, 3.65 mmol), triethylamine (0.56 mL, 4.03 mmol) and 5-chlorothiophenesulphonyl chloride (0.87 g, 4.03 mmol) in CH_2Cl_2 (20 mL) was stirred at room temperature for 1 h. The reaction mixture was diluted with


CH_2Cl_2 and washed with water, and dried (MgSO_4), filtered and evaporated. Trituration gave *endo*-5-chloro-thiophene-2-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide (1.2g, ca 100%).

5 **Example 109. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-oxo-bicyclo[3.2.1]oct-8-yl)-amide**



A solution of the sulfonamide from Example 108 (0.60 g, 1.89 mmol) in methanol (12 ml), CH_2Cl_2 (50 ml) was cooled to -78°C , and treated with
10 ozone until a blue color persisted. The reaction mixture was treated with dimethyl sulfide (0.5 ml) and allowed to warm to room temperature overnight. The reaction mixture was evaporated in vacuo and purified by column chromatography to yield *endo*-5-Chloro-thiophene-2-sulfonic acid (3-oxo-bicyclo[3.2.1]oct-8-yl)-amide (0.5g, 83%) as a colorless foam.
15 ^1H NMR (CDCl_3 , 360 MHz), 7.46 (1H, d, $J = 4.0$), 6.97 (1H, d, $J = 4.0$), 5.12 (1H, d, $J = 3.1$), 3.45-3.42 (1H, m), 2.68-2.63 (2H, m), 2.50 (2H, m), 2.26-2.21 (2H, m), 1.87-1.84 (2H, m), 1.62-1.56 (2H, m). $m/z = 320$ (MH^+).


20 **Example 110. *endo*-5-Chloro-thiophene-2-sulfonic acid (4-oxo-3-azabicyclo[4.2.1]non-9-yl)-amide**



A solution of the ketone from Example 109 (0.80 g, 2.51 mmol) in 98% formic acid (15 ml) was treated with hydroxylamine-O-sulfonic acid (450
25 mg, 3.98 mmol) and refluxed for 7h. The reaction mixture was evaporated


in vacuo, and diluted with ethyl acetate and brine. The organic layer was separated, dried (MgSO_4), filtered and evaporated in vacuo. Purification by column chromatography gave *endo*-5-Chloro-thiophene-2-sulfonic acid (4-oxo-3-aza-bicyclo[4.2.1]non-9-ylmethyl)-amide (412 mg, 49%). ^1H NMR (d_6 -DMSO, 400 MHz) 8.34 (1H, brs), 7.52 (1H, d, $J = 4.0$), 7.26 (1H, d, $J = 4.0$), 7.18 (1H, d, $J = 7.0$), 3.47-3.36 (2H, m), 2.71 (1H, d, $J = 15.5$), 2.64-2.57 (1H, m), 2.11-1.94 (3H, m), 1.76-1.33 (4H, m). $m/z = 335$ (MH^+).

Example 111. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-aza-bicyclo[4.2.1]non-9-yl)-amide




A solution of the lactam from Example 110 (100 mg, 0.29 mmol) in THF (3 ml) was treated with a freshly prepared solution of AlH_3 (H. C. Brown et al, *J. Am. Chem. Soc.*, 1968, 2927) (0.66M in THF, 1.4 ml, 0.92 mmol) and refluxed for 10 min. The reaction mixture was cooled to 0°C , and quenched carefully with ice cold H_2O -THF (1:1) (ca. 1 ml). The reaction mixture was warmed to room temperature and treated with 4 N NaOH solution until a precipitate formed. The supernatant was collected by decantation, and the precipitate was washed several times with ethyl acetate. The combined organic fractions were dried (MgSO_4), filtered and evaporated in vacuo. Purification by column chromatography gave *endo*-5-chloro-thiophene-2-sulfonic acid (3-aza-bicyclo[4.2.1]non-9-ylmethyl)-amide (60 mg, 63%) as a white solid. ^1H NMR (d_6 -DMSO, 400 MHz) 7.54 (1H, d, $J = 4.0$), 7.24 (1H, d, $J = 4.0$), 3.68 (1H, dd, $J = 7.1, 7.1$), 3.5 (2H, obscured), 2.92-2.85 (2H, m), 2.54-2.38 (2H, m), 2.21-2.16 (2H, m), 1.92-1.26 (6H, m). $m/z = 321$ (MH^+).

Example 112. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-benzyl-3-aza-bicyclo[4.2.1]non-9-yl)-amide



A solution of the amine from Example 111 (35 mg, 0.11 mmol) in CH₂Cl₂ (1 ml) was treated with triethylamine (0.034 ml) and benzyl bromide (0.042 ml). The reaction mixture was stirred for 4h, then diluted with CH₂Cl₂, washed with water, dried (MgSO₄), filtered and evaporated in vacuo. Purification by column chromatography gave *endo*-5-Chloro-thiophene-2-sulfonic acid (3-benzyl-3-aza-bicyclo[4.2.1]non-9-yl)methyl)-amide (35 mg, 78%). ¹H NMR (CDCl₃, 400 MHz) 7.41-7.26 (6H, m), 7.04 (1H, d J = 3.7), 6.77 (1H, d, J = 4.0), 3.83-3.80 (1H, m), 3.58-3.48 (2H, m), 2.84-2.76 (2H, m), 2.38-2.17 (3H, m), 2.09-1.95 (2H, m), 1.82-1.71 (2H, m), 1.54-1.26 (3H, m). *m/z* = 411 (MH⁺).

Example 113. *endo*-5-chloro-N-(4-thioxo-3-azabicyclo[4.2.1]non-9-yl)thiophene-2-sulfonamide




A mixture of the product from Example 110 (250 mg) and Lawesson's reagent (227 mg) in toluene (10 ml) was heated to reflux for 20 mins. On cooling, the mixture was basified with NaOH (1M 10 ml) and extracted with EtOAc (3x20 ml). The combined organic phases were dried and concentrated, then recrystallised from EtOAc/ether to give the title compound as a white solid (58 mg, 22%), (360MHz ¹H δ, d₆-DMSO) 1.43

(1H, m), 1.56 (1H, m), 1.68 (2H, m), 2.09 (1H, m), 2.15 (1H, m), 2.83 (1H, dd, $J=7.2, 14.4$), 2.93 (1H, m), 3.04 (1H, d, $J=14.4$), 3.44 (1H, dd, $J=3.6, 10.8$), 3.54 (1H, dd, $J=2.4, 14.4$), 7.22 (1H, d, $J=4$), 7.53 (1H, d, $J=4$), 8.39 (1H, d, $J=7.2$), 9.89 (1H, brs); MS(ES⁺): MH⁺ 351.


5

Example 114. *endo*-5-chloro-*N*-[5,6,7,8,9,10-hexahydro-6,9-methanoimidazo[1,2-*a*]azocin-11-yl]thiophene-2-sulfonamide



10

Step 1: *endo*-*N*-[4-(benzylthio)-3-azabicyclo[4.2.1]non-3-en-9-yl]-5-chlorothiophene-2-sulfonamide – HBr salt.



15

The product from Example 113 (50 mg) was suspended in CHCl₃ (3 ml), benzyl bromide (20 μl) added and the mixture heated to reflux for 8 hrs. Cooled, added ether and filtered. Recrystallisation from EtOAc/ether gave the title sulfide (44mg, 59%) as a white solid.

20 Step 2


The above intermediate (30 mg), aminoacetaldehyde dimethyl acetal (10 μl) and triethylamine (24 μl) in THF (1 ml) were heated to reflux for 24 hrs. The cooled mixture was concentrated, added to saturated aqueous NaHCO₃ (5 ml) and extracted with DCM (3x20 ml). The extracts were dried, concentrated and the residue dissolved in DCM (2 ml). TFA (0.2 ml) was added and heated to reflux for 24 hrs. The mixture was concentrated

25

in vacuo, 1M NaOH (5 ml) added and extracted with DCM (3x5 ml).

Drying, concentration and column chromatography on silica eluting with 1% NH₃ in EtOAc gave the title imidazole (8 mg, 39%) as a white solid, (360MHz ¹H d₆-DMSO) 1.04 (2H, m), 1.74 (2H, m), 2.32 (1H, dd, J=6.2, 12.2), 2.40 (1H, dd, J=7.1, 13.3), 2.89 (1H, dd, J=6.4, 13.7), 3.04 (1H, d, J=16.5), 3.70 (1H, dd, J=6.3, 6.3), 4.01 (1H, dd, J=5.6, 14.4), 4.18 (1H, d, J=14.7), 7.09 (1H, d, J=0.9), 7.23 (1H, s), 7.30 (1H, d, J=4.1), 7.60 (1H, d, J=4), 8.52 (1H, brs); MS(ES⁺): M+Na 358.

10 **Example 115. [9-*endo*]-N-(9-methylbicyclo[4.2.1]non-3-en-9-yl)benzenesulfonamide**




To a solution of bicyclo[4.2.1]non-3-en-9-one (1.55g), triethylamine (4.8ml) and benzenesulfonamide (1.79g) in dry DCM (50ml) at 0°C was added TiCl₄ (1.0M in DCM, 6.3ml). The reaction was stirred for 30 min at 0°C then at RT for 16h. Filtered through Celite® then concentrated *in vacuo*, the resulting solid was suspended in ether and heated under reflux for 5min then filtered. The filtrate was concentrated *in vacuo* and the crude imine extracted into hexane at reflux, concentrated *in vacuo* to give an off white solid (1.706g, 54%). The imine was used without further purification.

A solution of the imine (0.138g) in dry THF (10ml) was cooled to -78°C and MeLi (1.0M in ether, 0.6ml) was added dropwise. The reaction was stirred at -78°C for 10 min then at RT for 3h. The reaction was cooled to 0°C, quenched with water and extracted with EtOAc, washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The product was purified by column chromatography (silica, 15% EtOAc in hexane) to give a white

solid (0.108g, 74%), (360MHz ^1H , $\delta\text{-CDCl}_3$) 1.22 (3H, s), 1.39 (2H, m), 1.88 (2H, m), 2.16 (4H, m), 2.42 (2H, m), 4.71 (1H, brs), 5.53 (2H, m), 7.51 (3H, m), 7.92 (2H, m); (^{13}C $\delta\text{-CDCl}_3$) 26.8, 28.9, 35.2, 47.8, 69.5, 128.8, 129.1, 130.6, 134.0, 145.4. MS(CI+): [M+Na+MeCN]+ 355.

5


Example 116. [9-endo]-5-chloro-N-(9-methylbicyclo[4.2.1]non-3-en-9-yl)thiophene-2-sulfonamide



10 An imine was prepared by a similar procedure to the previous example using 5-chlorothiophene-2-sulfonamide instead of benzenesulfonamide. A solution of the imine (0.158g) in dry THF (10ml) was cooled to 0°C and MeMgCl (3.0M in THF, 0.2ml) was added dropwise. The reaction was stirred at 0°C for 30 min then heated under reflux for 2h. The reaction
15 was cooled to 0°C, quenched with saturated ammonium chloride solution, extracted with ether, washed with brine, dried over MgSO_4 and concentrated *in vacuo* to give a pale yellow solid (0.150g, 90%), (360MHz ^1H , $\delta\text{-CDCl}_3$) 1.38 (3H, s), 1.41 (2H, m), 1.92 (2H, m), 2.20 (4H, m), 2.36 (2H, m), 4.80 (1H, brs), 5.53 (2H, m), 6.87 (1H, d, $J=3.9$), 7.40 (1H, d, $J=3.9$); (^{13}C $\delta\text{-CDCl}_3$) 26.5, 28.9, 35.1, 47.9, 70.0, 128.1, 129.1, 132.9, 138.5,
20 144.8.


Example 117. [9-endo]-N-(9-allylbicyclo[4.2.1]non-3-en-9-yl)-5-chlorothiophene-2-sulfonamide

25



A solution of the imine prepared as described in the previous example (0.158g) in dry THF (10ml) was cooled to 0°C and allylmagnesium bromide (1.0M in ether, 0.6ml) was added dropwise. The reaction was stirred at
 5 0°C for 1h then at RT for 2h. The reaction was cooled to 0°C, quenched with 2N HCl and extracted with EtOAc, washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The product was recrystallized (hexane/EtOAc) to give a white solid (0.118g, 66%), (360MHz ¹H, δ-CDCl₃) 1.42 (2H, m), 1.83 (2H, m), 2.19 (2H, m), 2.35 (4H, m), 2.54 (2H, m), 4.59
 10 (1H, brs), 4.94 (2H, m), 5.34 (1H, m), 5.53 (2H, m), 6.86 (1H, d, J=3.9), 7.39 (1H, d, J=3.9); (¹³C δ-CDCl₃) 29.1, 35.0, 41.5, 45.3, 73.1, 119.7, 128.0, 129.0, 133.2, 135.4, 138.8, 144.1. MS(Cl⁺): [M-allyl]⁺ 316.

Example 118. (*syn, exo*)-7-[[5-Chlorothiophen-2-yl)sulfonyl]amino)bicyclo[2.2.1]hept-2-yl acetate
 15




(a) A solution of (*syn, exo*)-7-azidobicyclo[2.2.1]hept-2-yl acetate (E. Zibral; A. Stuetz, *Tetrahedron*, 1974, **27**, 4953-4963) (1.2 g, 6.15 mmol) in
 20 EtOAc (20 mL) was hydrogenated over 5% Pd-C at 30 psi H₂ for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to give (*syn, exo*)-7-aminobicyclo[2.2.1]hept-2-yl acetate as a colourless oil (0.95 g, 91%). ¹H NMR (CDCl₃, 400 MHz) δ 1.08–1.12 (2 H, m), 1.56–1.64
 25 (2 H, m), 1.88–1.96 (2 H, m), 2.01–2.04 (4 H, m), 2.10 (1 H, d, J 5), 3.06 (1 H, s), 4.75–4.77 (1 H, m).

(b) The amine was dissolved in dry CH_2Cl_2 (20 mL) and 5-chlorothiophene-2-sulfonyl chloride (1.22 g, 5.62 mmol) and Et_3N (1.2 mL, 8.4 mmol) were added. The solution was stirred at room temperature under N_2 for 60 h. The solution was washed with H_2O (20 mL) and the washings were extracted with CH_2Cl_2 (20 mL). The combined organic extracts were dried (Na_2SO_4), filtered and concentrated. Flash column chromatography, eluting 15% EtOAc -isohexane, then 30% EtOAc -isohexane, gave the product as a pink oil. Trituration and washing with Et_2O gave the title compound as white crystals (1.12 g, 57%). A sample was recrystallised from EtOAc -isohexane. ^1H NMR (CDCl_3 , 360 MHz) δ 1.10–1.16 (2 H, m), 1.55–1.64 (2 H, m), 1.68–1.75 (1 H, m), 1.95 (1 H, dd, J 14, 8), 2.07 (3 H, s), 2.13 (1 H, d, J 4), 2.25 (1 H, dd, J 4, 4) 3.46 (1 H, d, J 9), 4.77 (1 H, dd, J 7, 3), 5.19 (1H, d, J 9), 6.93 (1 H, d, J 4), 7.40 (1 H, d, J 4); m/z 374, 372 ($\text{M}+\text{Na}^+$).

15

Example 119. (*syn, exo*)-7-[[5-Chlorothiophen-2-yl)sulfonyl]amino)bicyclo[2.2.1]hept-2-yl 2-(methylthio)nicotinate




20

(a) A mixture of the product from Example 118 (0.483 g, 1.38 mmol) and K_2CO_3 (0.19 g, 1.38 mmol) in MeOH (20 mL) was stirred at room temperature for 2.5 h. The mixture was concentrated and the residue was partitioned between water (50 mL) and CH_2Cl_2 (50 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated to give a colourless gum. Trituration and washing with Et_2O gave (*syn, exo*)-5-chloro-*N*-(2-hydroxybicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide as a white solid (0.337 g, 79%). ^1H NMR (CDCl_3 , 360 MHz) δ 0.94–1.09 (2 H, m), 1.47–1.61

(2 H, m), 1.68 (1 H, dd, J 14, 2), 1.82 (1 H, dd, J 14, 7), 1.09 (1 H, d, J 1), 2.01 (1 H, d, J 4), 2.23–2.25 (1 H, m) 3.47–3.49 (1 H, m), 3.94 (1 H, d, J 6), 6.25 (1H, d, J 9), 6.91 (1 H, d, J 4), 7.40 (1 H, d, J 4); m/z 310, 308 ($M+H^+$).

(b) A solution of potassium bis(trimethylsilyl)amide (0.5 M in toluene, 5 0.25 mL) was added to a solution of (*syn, exo*)-5-chloro-*N*-(2-hydroxybicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide (0.015 g, 0.05 mmol) in dry THF (0.5 mL) in a septum-sealed glass reaction tube. After 20 min a solution of 2-thiomethyl-3-pyridinecarbonyl chloride (0.06 mmol) in dry THF (0.1 mL) was added. After 3 h at room temperature HCl (0.05 10 M, 1.5 mL) and CH_2Cl_2 (1.5 mL) were added. The mixture was vortex mixed and the organic layer was separated by filtration through a Teflon membrane. Solvent was removed by evaporation. Purification of half of the sample by preparative HPLC-MS gave the title compound (0.0051 g, 44%). 1H NMR (h_6 -DMSO, 400 MHz, DMSO and H_2O signals suppressed) δ 0.90–15 1.05 (2 H, m), 1.30–1.50 (2 H, m), 1.75 (1 H, dd, J 13, 7), 1.90–1.96 (1 H, m), 2.09–2.12 (1 H, m), 3.00 (1 H, br s), 4.60–4.65 (1 H, m), 7.12 (1 H, d, J 4), 7.18 (1 H, dd, J 8, 5), 7.38 (1 H, d, J 4), 7.90–7.92 (1 H, m), 8.25 (1 H, dd, J 8, 2), 8.58 (1 H, dd, J 5, 2); m/z 361, 359 ($M+H^+$).


20 **Example 120.** (*syn, exo*)-7-[(5-Chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl 3,4-dimethoxybenzoate



Prepared as for Example 119 using 3,4-dimethoxybenzoyl chloride in place of 2-thiomethyl-3-pyridinecarbonyl chloride. 1H NMR (h_6 -DMSO, 400 MHz, 25 DMSO and H_2O signals suppressed) δ 1.07–1.20 (2 H, m), 1.46–1.62 (2 H, m), 1.92 (1 H, dd, J 13.4, 7.6), 2.01–2.07 (2 H, m), 2.22 (1 H, br s), 3.07 (1 H, br s), 3.83 (6 H, br s), 4.79 (1 H, dd, J 7.3, 2.6), 7.05 (1 H, d, J 8.4), 7.21


(1 H, d, J 4.0), 7.47 (1 H, d, J 4.0), 7.54 (1 H, d, J 1.7), 7.63 (1 H, dd, J 8.4, 1.8), 8.01 (1 H, br s); m/z 496, 494 ($M+Na^+$).

**Example 121. (*syn, exo*)-7-(5-Chlorothiophene-2-sulfonylamino)-
5 bicyclo[2.2.1]hept-2-yl 2-nitrobenzoate**



Prepared as for Example 119 using 2-nitrobenzoyl chloride in place of 2-thiomethyl-3-pyridinecarbonyl chloride. 1H NMR (h_6 -DMSO, 400 MHz, DMSO and H_2O signals suppressed) δ 1.07–1.21 (2 H, m), 1.46–1.63 (2 H, m), 1.92 (1 H, dd, J 13.6, 7.6), 2.04–2.07 (2 H, m), 2.24 (1 H, br s), 3.07 (1 H, br s), 4.77–4.80 (1 H, m), 7.21 (1 H, d, J 4.0), 7.46 (1 H, d, J 4.0), 7.80–7.86 (2 H, m), 7.95–8.03 (3 H, m); m/z 479, 481 ($M+Na^+$).


Example 122. (*syn, exo*)-7-[(5-Chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl methyl carbonate



Prepared as for Example 119 using methyl chloroformate in place of 2-thiomethyl-3-pyridinecarbonyl chloride. 1H NMR (h_6 -DMSO, 400 MHz, DMSO and H_2O signals suppressed) δ 0.90–1.00 (2 H, m), 1.30–1.45 (2 H, m), 1.70 (1 H, dd, J 14, 7), 1.82–1.90 (1 H, m), 2.05–2.10 (1 H, m), 2.22 (1 H, d, J 5), 3.56 (3 H, s), 4.30–4.35 (1 H, m),


7.23 (1 H, d, J 4), 7.45 (1 H, d, J 4), 7.82 (1 H, d, J 5). m/z 390, 388 (M+Na⁺).

Example 123. (*syn, exo*)-7-(5-Chlorothiophene-2-sulfonylamino)-
5 bicyclo[2.2.1]hept-2-yl methanesulfonate




To a solution of (*syn, exo*)-5-chloro-*N*-(2-hydroxybicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide [Example 119 step (a)] (48 mg, 0.16 mmol) in CH₂Cl₂ (3 mL) were added Et₃N (33 μ L, 0.24 mmol), methanesulfonyl chloride (14 μ L, 0.18 mmol) and 4-(dimethylamino)pyridine (10 mg, 0.08 mmol). The mixture was stirred at room temperature under N₂ for 18 h. The mixture was then partitioned between H₂O and EtOAc. The layers were separated and the aqueous phase extracted a second time with EtOAc. The combined organic extracts were dried (MgSO₄) and concentrated. Purification by flash chromatography (15% EtOAc / hexane) afforded the title compound as a white solid (54 mg, 90%). ¹H NMR (CDCl₃, 400 MHz) δ 1.10–1.17 (2 H, m), 1.56–1.73 (2 H, m), 1.98–2.09 (2 H, m), 2.39 (1 H, br s), 2.44 (1 H, br d, J 4.8), 3.05 (3 H, s), 3.44 (1 H, d, J 7.0), 4.72 (1 H, dd, J 7.0, 3.3), 5.29 (1 H, d, J 7.0), 6.95 (1 H, d, J 4.0), 7.43 (1 H, d, J 4.0); m/z 292, 290 ([M – OSO₂Me]⁺).

Example 124. (*syn, exo*)-7-(5-Chlorothiophene-2-sulfonylamino)-
25 bicyclo[2.2.1]hept-2-yl toluene-4-sulfonate



Prepared as for Example 123 using toluene-4-sulfonyl chloride in place of methanesulfonyl chloride. ¹H NMR (CDCl₃, 400 MHz) δ 0.98–1.08 (2 H, m), 1.49–1.66 (2 H, m), 1.78–1.88 (2 H, m), 2.21 (1 H, br d, *J* 4.6), 2.29 (1 H, br s), 2.47 (3 H, s), 3.43 (1 H, d, *J* 7.7), 4.55 (1 H, dd, *J* 6.8, 3.5), 5.17 (1 H, d, *J* 7.7), 6.93 (1 H, d, *J* 3.9), 7.36–7.40 (3 H, m), 7.75–7.78 (2 H, m); *m/z* 462, 460 ([M+H]⁺); 292, 290 ([M – OSO₂PhMe]⁺).

Example 125. (syn)-5-Chloro-*N*-(2-methylenebicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide



(a) Pyridinium dichromate absorbed on alumina (20% wt/wt 0.5 g) was added to a stirred solution of (*syn, exo*)-5-chloro-*N*-(2-hydroxybicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide [Example 119 step (a)] (0.121 g, 0.393 mmol) in dry CH₂Cl₂ (4 mL) at room temperature. After 3.5 h, further pyridinium dichromate–alumina (0.5 g) was added. After a further 4.5 h, the mixture was diluted with CH₂Cl₂ (10 mL) and filtered through a pad of silica gel, eluting with EtOAc (200 mL). The filtrate was concentrated to give (*syn*)-5-chloro-*N*-(2-oxobicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide as a white powder (0.100 g, 83%). ¹H NMR (CDCl₃, 360 MHz) δ 1.52–1.55 (2 H, m), 1.87–1.92 (3 H, m), 2.42 (1 H, dd, *J* 18, 4), 2.54–2.56 (1 H, m), 2.77–2.79 (1 H, m), 3.50–3.52 (1 H, m), 4.94 (1


H, s), 6.96 (1 H, d, J 4), 7.41 (1 H, d, J 4); m/z 330 and 328 ($M+Na^+$), 308 and 306 ($M+H^+$).

(b) A mixture of (*syn*)-5-chloro-*N*-(2-oxobicyclo[2.2.1]hept-7-yl)thiophene-2-sulfonamide (0.100 g, 0.313 mmol),

- 5 methyl(triphenylphosphonium) bromide (0.125 g, 0.35 mmol) and potassium *tert*-butoxide (1M in THF, 1.0 mL) in dry toluene (2 mL) was relaxed under N_2 for 4 h. The mixture was cooled, diluted with 1M citric acid (15 mL) and extracted with EtOAc (2 x 15 mL). The extracts were dried (Na_2SO_4), filtered and concentrated. Flash column chromatography, eluting with 10% then 20% EtOAc–isohexane, gave the title compound as a pale yellow solid (0.027 g, 28%). 1H NMR ($CDCl_3$, 360 MHz) δ 1.30–1.34 (2 H, m), 1.69–1.73 (2 H, m), 1.96 (1 H, d, J 15), 2.26–2.35 (2 H, m), 2.41 (1 H, d, J 3), 3.42 (1 H, d, J 6), 4.55 (1 H, d, J 6), 4.83 (1 H, s), 4.95 (1 H, s), 6.92 (1 H, d, J 4), 7.39 (1 H, d, J 4); m/z 306 and 304 ($M+H^+$).

15

Example 126. (*syn*, *endo*)-7-[(5-Chlorothiophen-2-yl)sulfonylamino]bicyclo[2.2.1]hept-2-yl acetate



- 20 (a) Sodium hydride (55% wt/wt dispersion in oil; 1.75 g, 40 mmol) was added portionwise to a stirred solution of (*endo*)-2-hydroxybicyclo[2.2.1]heptan-7-one dimethyl acetal (M. E. Jung, J. P. Hudspeth, *J. Am. Chem. Soc.* 1977, 5508) (6.07 g, 36 mmol) and benzyl bromide (5.1 mL, 43 mmol) in dry DMF (100 mL) at room temperature under N_2 . The gently effervescent mixture was warmed to 50°C for 3.25 h. The mixture was cooled, diluted with H_2O (300 mL) and NH_4Cl (100 mL), and extracted with Et_2O (4 x 100 mL). The extracts were dried (Na_2SO_4), filtered and concentrated. Flash column chromatography, eluting with
- 25

20% EtOAc–isohexane, gave (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one dimethyl acetal as an orange oil (7.25 g, 78%). ¹H NMR (CDCl₃, 360 MHz) δ 1.03 (1 H, dd, *J* 12, 2), 2.23 (1 H, ddd, *J* 12, 8, 4), 2.84 (1 H, dd, *J* 4, 4), 3.14 (3 H, s), 3.16 (3 H, s), 3.17–3.19 (1 H, m), 4.30–4.35 (1 H, m), 4.45 (1 H, d, *J* 12), 4.48 (1 H, d, *J* 12), 6.02 (1 H, dd, *J* 6, 3), 6.35 (1 H, ddd, *J* 6, 3, 1), 7.26–7.33 (5 H, m).

(b) 50% H₂SO₄ (30 mL) was added dropwise to a vigorously stirred solution of (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one dimethyl acetal (7.13 g, 27.4 mmol) in CH₂Cl₂ (300 mL) at room temperature. After 3.5 h, further 50% H₂SO₄ (30 mL) was added. After 24 h, conc H₂SO₄ (10 mL) was added and stirring was continued for 2 h. The mixture was diluted with H₂O (100 mL) and neutralised with NaHCO₃ (s). The mixture was further diluted with H₂O (200 mL) and extracted with CH₂Cl₂ (2 x 150 mL). The extracts were dried (Na₂SO₄), filtered and concentrated. The residual oil was filtered through a plug of silica, eluting with 20% EtOAc–isohexane, to give (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one (6.20 g, 100%). ¹H NMR (CDCl₃, 400 MHz) δ 1.28 (1 H, dd, *J* 13, 3), 2.32 (1 H, ddd, *J* 13, 8, 4), 2.91–2.94 (1 H, m), 3.30–3.32 (1 H, m), 4.33–4.37 (1 H, m), 4.47 (1 H, d, *J* 12), 4.53 (1 H, d, *J* 12), 6.35–6.37 (1 H, m), 6.68–6.71 (1 H, m), 7.27–7.37 (5 H, m).

(c) A solution of (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one (3.0 g, 14 mmol), hydroxylamine hydrochloride (2.1 g, 30 mmol) and sodium acetate (2.5 g, 30 mmol) in EtOH–H₂O (3:1, 50 mL) was stirred under N₂ at room temperature for 18 h. The mixture was diluted with water (200 mL) and extracted with CH₂Cl₂ (2 x 100 mL). The extracts were dried (Na₂SO₄), filtered and concentrated. Flash column chromatography, eluting 50% EtOAc–isohexane, gave (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one oxime as a straw-coloured liquid (3.02 g, 94%). ¹H NMR (CDCl₃, 400 MHz) 1:1 mixture of oxime isomers δ 1.19–1.27 (1 H, m), 2.19–2.29 (1 H, m), 3.11–3.12 and 3.72–3.74 (1 H, 2 x m), 3.41–3.43 and 4.15–4.16 (1 H, 2 x m), 4.26–4.30 (1 H, m), 4.45–4.54 (2 H, m), 6.12–6.14 and 6.19–6.22 (1 H, 2 x

m), 6.44–6.46 and 6.52–6.54 (1 H, 2 x m), 7.25–7.36 (5 H, m) 7.60–8.10 (1 H, br s); m/z 230 ($M+H^+$).

(d) Lithium aluminium hydride (1M in THF, 14 mL) was added to a stirred solution of (*endo*)-2-benzyloxybicyclo[2.2.1]heptan-7-one oxime (3.0 g, 13.1 mmol) in dry THF (60 mL) at -78°C under N_2 . After 45 min the mixture was warmed to room temperature and stirred for 1 h. The reaction was recooled to -78°C and further lithium aluminium hydride (1M in THF, 14 mL) was added. The orange solution was warmed to room temperature and stirred for a further 18 h. The reaction was quenched by cautious addition of saturated aqueous ammonium chloride (10 mL) then poured into saturated aqueous ammonium chloride (100 mL) and diluted with water (100 mL). Saturated aqueous Rochelle salt (100 mL) and EtOAc (200 mL) were added. After standing for 15 min the two phases were separated and the aqueous phase was extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried (Na_2SO_4), filtered and concentrated. Flash column chromatography, eluting with 90:9:1 CH_2Cl_2 –MeOH– NH_3 (aq), gave (*syn, endo*)-7-amino-2-benzyloxybicyclo[2.2.1]heptane as a pale yellow oil (0.67 g, 24%). ^1H NMR (CDCl_3 , 360 MHz) δ 1.15 (1 H, ddd, J 13, 3, 2), 1.30–1.50 (2 H, br s), 2.23 (1 H, ddd, J 12, 8, 4), 2.48–2.50 (1 H, m), 2.84–2.87 (1 H, m), 2.99 (1 H, d, J 2), 4.41 (1 H, ddd, J 8, 4, 3), 4.47 (2 H, s), 6.01 (1 H, dd, J 6, 3), 6.31 (1 H, ddd, J 6, 3, 1), 7.25–7.37 (5 H, m); m/z 216 ($M+H^+$).

(e) A solution of (*syn, endo*)-7-amino-2-benzyloxybicyclo[2.2.1]heptane (0.66 g, 3.07 mmol), di-*tert*-butyldicarbonate (0.74 g, 3.4 mmol) and triethylamine (0.84 mL, 6 mmol) in dry CH_2Cl_2 (10 mL) was stirred at room temperature under N_2 for 18 h. The solution was poured into water (100 mL) and extracted with CH_2Cl_2 (100 mL). The extract was dried (Na_2SO_4), filtered and concentrated. Flash column chromatography, eluting with 10% EtOAc–isohexane, gave (*syn, endo*)-7-(*tert*-butyloxycarbonyl)amino-2-benzyloxybicyclo[2.2.1]heptane as a white solid (0.885 g, 92%). ^1H NMR (CDCl_3 , 360 MHz) δ 1.15–1.21 (1 H, m), 1.43 (9 H,

s), 2.05–2.12 (1 H, m), 2.70 (1 H, br s), 3.10 (1 H, br s), 3.55 (1 H, br s), 4.45–4.48 (1 H, m), 4.44–4.49 (2 H, m), 6.02–6.04 (1 H, m), 6.31–6.33 (1 H, m), 7.26–7.24 (5 H, m).


- (f) A mixture of (*syn, endo*)-7-(*tert*-butyloxycarbonyl)amino-2-benzyloxybicyclo[2.2.1]heptane (0.74 g, 2.35 mmol), ammonium formate (1.6 g, 24 mmol) and 5% palladium on carbon (0.2 g) in MeOH (20 mL) was refluxed under N₂. After 18 h, further ammonium formate (1.6 g) and palladium catalyst (0.2 g) were added. After 3 days the mixture was cooled, filtered and concentrated. The material was redissolved in MeOH (30 mL) with 5% palladium on carbon (0.5 g) and hydrogenated at 40 psi H₂ in a Parr apparatus. When H₂ uptake was complete (ca. 2 h) the mixture was filtered and the filtrate was concentrated to give (*syn, endo*)-7-(*tert*-butyloxycarbonyl)amino-2-hydroxybicyclo[2.2.1]heptane as a white solid (0.471 g, 88%). ¹H NMR (CDCl₃, 400 MHz) δ 1.05–1.11 (1 H, m), 1.35–1.40 (1 H, m), 1.45 (9 H, s), 1.50–1.55 (1 H, m), 1.65–1.75 (1 H, m), 1.80–1.95 (1 H, m), 2.10–2.20 (2 H, m), 2.30–2.35 (1 H, m), 3.70–3.75 (1 H, m), 4.45–4.50 (1 H, m).
- (g) A solution of (*syn, endo*)-7-(*tert*-butyloxycarbonyl)amino-2-hydroxybicyclo[2.2.1]heptane (0.147 g, 0.647 mmol), acetyl chloride (0.055 mL, 0.78 mmol) and Et₃N (0.28 mL, 2 mmol) in dry CH₂Cl₂ (5 mL) was stirred for 18 h at RT under N₂. The mixture was diluted with H₂O (20 mL) and extracted with CH₂Cl₂ (2 x 25 mL). The extracts were dried (Na₂SO₄), filtered and concentrated. Flash column chromatography, eluting with 20% EtOAc, gave the partly purified ester as a colourless oil (0.109 g). This material was dissolved in Et₂O (1 mL) with 2M HCl in Et₂O (4 mL) and heated gently for 5 min. After stirring for 1.5 h at room temperature the solution was concentrated to give a yellow solid (0.058 g). The solid was resuspended in CH₂Cl₂ (2 mL) and 5-chlorothiophene-2-sulfonyl chloride (0.13 g, 0.6 mmol) and Et₃N (0.14 mL, 1.0 mmol) were added. After stirring for 18 h at room temperature, the mixture was diluted with CH₂Cl₂ (20 mL), washed with 1M citric acid (20 mL), dried

(Na₂SO₄), filtered and concentrated. Flash column chromatography, eluting 20% EtOAc-isohehexane, gave (*syn*, *endo*)-7-[(5-chlorothiophen-2-yl)sulfonyl]amino}bicyclo[2.2.1]hept-2-yl acetate (0.034 g, 24%) as a colourless gum that solidified to a white powder on trituration with Et₂O.

5 ¹H NMR (CDCl₃, 400 MHz) δ 1.17–1.26 (1 H, m), 1.34–1.47 (2 H, m), 1.64–1.82 (2 H, m), 2.05 (3 H, s), 2.23–2.34 (2 H, m), 2.40–2.50 (1 H, m), 3.36–3.39 (1 H, m), 4.88–4.90 (1 H, m), 5.14–5.17 (1 H, m), 6.94 (1 H, d, *J* 4), 7.41 (1 H, d, *J* 4); *m/z* 390, 388 (M+K⁺), 374, 372 (M+Na⁺), 352, 350 (M+H⁺).

10

Example 127. (*syn*)-5-Chloro-*N*-(5,6,7,8,9,10-hexahydro-5,9-methanobenzo[*a*][8]annulen-11-yl)thiophene-2-sulfonamide




15 (5,6,7,8,9,10-Hexahydro-5,9-methanobenzo[*a*][8]annulen-11-one (Muratake and Natsume, *Tetrahedron Lett.*, 1997, 7581) was converted to the oxime and then to the corresponding amine as described in the general procedures. The amine (0.062 g) was dissolved in dry CH₂Cl₂ (1 mL) and Et₃N (0.14 mL, 1 mmol) and 5-chlorothiophene-2-sulfonyl chloride

20 (0.086 g, 0.4 mmol) were added. The solution was stirred at room temperature under N₂ for 26 h, then diluted with CH₂Cl₂ (10 mL), washed with H₂O (10 mL), dried, filtered and concentrated. Preparative thin layer chromatography, eluting with 10% EtOAc-isohehexane, gave the title compound as a white solid (0.033 g, 27%). ¹H NMR (CDCl₃, 400 MHz) δ

25 0.95–1.10 (1 H, m), 1.20–1.30 (1 H, m), 1.60–1.80 (4 H, m), 2.29–2.35 (1 H, m), 2.65 (1 H, d, *J* 18), 2.85–2.90 (1 H, m), 3.10 (1 H, dd, *J* 18, 8), 3.65–3.70

(1 H, m), 4.55 (1 H, d, J 8), 6.92 (1 H, d, J 4), 7.10–7.18 (3 H, m), 7.37 (1 H, d, J 4); m/z 392, 390 ($M+Na^+$), 370, 368 ($M+H^+$).

Example 128. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide




(a) N-(5-Nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one oxime
 5-Nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (*J. Org. Chem.*
 1982, 47, 4329-4334) was converted to the oxime as described in the
 General Procedures.

m/z 247 ($M+H^+$).

(b) *endo*-N-(5-Nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-hydroxylamine

The oxime was reduced to the hydroxylamine using sodium
 cyanoborohydride by the procedure of Example 108 step 1
 m/z 249 ($M+H^+$).


(c) *endo*-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-triene-5,13-diamine



Activated zinc dust (excess) was added to a rapidly stirring solution of N-(5-nitro-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-hydroxylamine (2.0 g) in 1:1 tetrahydrofuran:2N aqueous HCl (100 mL). After two hours the reaction mixture was filtered and reduced to half volume under reduced pressure. The residue was basified to pH 9 with 4N NaOH and extracted into ether (4 x 100 mL). The organic extracts were combined, dried over


MgSO₄, filtered and the solvent removed under reduced pressure to afford the title compound as a clear oil. (1.6 g). *m/z* 203 (M+H⁺).

(d) *endo*-(5-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-carbamic acid tert-butyl ester



5 A solution of di-tertbutyldicarbonate (864 mg) in dichloromethane (20 mL) was added over four hours to a stirred solution of tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-triene-5,13-diamine (800 mg) in dichloromethane (50 mL) at -20°C. After a further two hours the solution was warmed to room temperature
10 and the solvent removed under reduced pressure. The residual oil was purified by chromatography on silica gel (30% EtOAc/isohexane) to afford the product as a white solid (500 mg). ¹H NMR (CDCl₃ 400 MHz) δ 1.20-1.25 (2H, m), 1.46 (9H, s), 1.65-1.69 (2H, m), 2.40-2.46 (4H, m), 2.86-2.90 (2H, m), 4.05 (1H, brs), 5.29 (1H, brs), 6.41-6.44 (2H, m), 6.84 (1H, d, J =
15 5.0 Hz).


(e) *endo*-(13-tert-Butoxycarbonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl) carbamic acid allyl ester



20 Allyl chloroformate (75 μL) was added to a stirred solution of (5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-carbamic acid tert-butyl ester

(213 mg) in dry dichloromethane (10 mL) containing 4-methylmorpholine (140 mg). After one hour the reaction was dilute with citric acid (10% aq, 20 mL) and the organic layer separated, dried over MgSO_4 , filtered and the solvent removed under reduced pressure to afford the title compound as a white solid. (264 mg). ^1H NMR (CDCl_3 400 MHz) δ 1.17-1.24 (2H, m), 1.46 (9H, s), 1.67-1.70 (2H, m), 2.45-2.59 (4H, m), 2.93-3.00 (2H, m), 4.00 (1H, brs), 4.65 (2H, dd, $J = 4.0$ and 1.0 Hz), 5.25 (1H, dd, $J = 8.0$ and 1.0 Hz), 5.37 (1H, dd, $J = 16.0$ and 1.0 Hz), 5.96 (1H, m), 6.57 (1H, brs), 7.02 (1H, d, $J = 8.0$ Hz), 7.10 (2H, m).


10 (f) *endo*-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-carbamic acid allyl ester



Dry HCl gas was passed through a cooled solution of (13-tert-butoxycarbonylamino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl) carbamic acid allyl ester (264 mg) in dry ether for ten minutes. At the end of this time a white precipitate had formed which was filtered off to afford the amine hydrochloride. (204 mg) m/z 286 ($\text{M}+\text{H}^+$). The recovered material was re-suspended in dry dichloromethane and treated with 4-methylmorpholine (160 μL) and 5-chlorothiophene-2-sulfonyl chloride (159 mg). After 18 hours a polyamine scavenger resin (1.0 g, Novobiochem 4.61 mmol/g) was added and the solution stirred for a further six hours. The reaction was filtered to remove the resin and the resin pad washed sequentially with dichloromethane, methanol, ether 20 mL each). The filtrate and washings were combined and the solvent removed under reduced pressure. The residue was partitioned between dichloromethane


and water, the organic layer separated, dried, MgSO_4 , filtered and the solvent removed under reduced pressure. Chromatography on silica gel (20% EtOAc/isohexane) afforded the title compound as a white solid. (180 mg). ^1H NMR (CDCl_3 400 MHz) δ 1.17-1.25 (2H, m), 1.62-1.65 (2H, m), 2.34-2.37 (2H, m), 2.50-2.56 (2H, m), 2.95 (1H, d, $J = 12$ Hz), 3.00 (1H, d, $J = 12$ Hz), 3.74 (1H, dt, $J = 8.0$ and 1.0 Hz), 4.65 (2H, m), 5.24 (1H, d, $J = 8.0$ Hz), 5.27 (1H, d, $J = 12$ Hz), 5.37 (1H, d, $J = 16$ Hz), 5.95 (1H, m), 6.55 (1H, brs), 6.93 (1H, d, $J = 4.0$ Hz), 6.98 (1H, d, $J = 8.0$ Hz), 7.08 (2H, m), 7.44 (1H, d, $J = 4.0$ Hz). m/z 466 ($\text{M}+\text{H}^+$).

(g) endo-5-Chloro-thiophene-2-sulfonic acid (5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide



A catalytic amount of $\text{Pd}(\text{PPh}_3)_4$ was added to a stirred solution of [13-(5-chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-carbamic acid allyl ester (140 mg) in dichloromethane containing 10% PhSiH_3 . The resulting mixture was stirred at room temperature for two hours at which time the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (20% EtOAc/isohexane) to afford the title compound as a white solid. (74 mg). ^1H NMR (CDCl_3 400 MHz) δ 1.16-1.19 (2H, m), 1.56-1.66 (2H, m), 2.26-2.52 (4H, m), 2.76 (1H, d, $J = 12.0$ Hz), 2.85 (1H, d, $J = 12.0$ Hz), 3.72 (1H, dt, $J = 4.0$ and 1.0 Hz), 5.29 (1H, d, $J = 8.0$ Hz), 6.42 (2H, m), 6.81 (1H, d, $J = 8.0$ Hz), 6.92 (1H, d, $J = 4.0$ Hz), 7.44 (1H, d, $J = 4.0$ Hz). m/z 382 ($\text{M}+\text{H}^+$).

Example 129. *endo*-N-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-2-pyrrolidin-1-yl-acetamide



5 (a) *endo*-2-Chloro-N-[13-(5-chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-acetamide


Chloroacetyl chloride (75 μ L) was added to a stirred solution of *endo* 5-chloro-thiophene-2-sulfonic acid (5-amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide (Example 128) (360 mg) in dichloromethane (15
10 mL) containing 4-methylmorpholine (131 μ L). After 30 minutes at room temperature the reaction mixture was poured into 1N HCl (30 mL), and the organic layer separated off. The aqueous layer was then extracted with dichloromethane (2 x 15 mL) and the combined organic layers dried over MgSO₄, filtered and the solvent removed under reduced pressure to
15 afford the product as a gum (430 mg) which was used without further purification. ¹H NMR (CDCl₃ 400 MHz) δ 1.13-1.17 (2H, m), 1.61-1.68 (2H, m), 2.36-2.39 (2H, m), 2.51-2.59 (2H, m), 2.99 (1H, d, J = 12.0 Hz), 3.04 (1H, d, J = 12.0 Hz), 3.72 (1H, dt, J = 8.0 and 4.0 Hz), 4.12 (2H, s), 5.23 (1H, s), 6.94 (1H, d, J = 4.0 Hz), 7.04 (1H, d, J = 8.0 Hz), 7.28 (2H, m), 7.44
20 (1H, d, J = 4.0 Hz), 8.16 (1H, brs).

(b) *endo*-N-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-2-pyrrolidin-1-yl-acetamide

A solution of the chloroacetamide from step (a) (257 mg) in dichloromethane (5 mL) was added rapidly to a solution of pyrrolidine












(142 mg) in dichloromethane (20 mL). The resulting mixture was stirred at room temperature for 3 hours at which point the solvent was removed under reduced pressure. The residue was partitioned between dichloromethane and NaHCO₃ (aq), the organic layer separated, dried, 5 MgSO₄, filtered and the solvent removed under reduced pressure. Crystallization from methanol afforded the title compound as a white solid. (124 mg). ¹H NMR (CDCl₃ 400 MHz) δ 1.15-1.19 (2H, m), 1.50-1.62 (3H, m), 1.84-1.87 (4H, m), 2.35-2.38 (2H, m), 2.52-2.56 (2H, m), 2.70 (4H, brm), 2.95 (1H, d, J = 12.0 Hz), 3.01 (1H, d, J = 12.0 Hz), 3.27 (2H, s), 3.74 10 (1H, dt, J = 8.0 and 4.0 Hz), 5.09 (1H, d, J = 8.0 Hz), 6.93 (1H, d, J = 4.0 Hz), 7.01 (1H, d, J = 8.0 Hz), 7.32 (2H, m), 7.44 (1H, d, J = 4.0 Hz), 9.05 (1H, s). *m/z* 494 (M+H⁺)




The following compounds in accordance with formula A below were 15 prepared by the method of Example 129, substituting the appropriate amine for pyrrolidine in step (b). In all cases, purification was by mass directed HPLC.




20

| Example | R | <i>m/z</i> (M+H ⁺) |
|---------|---|--------------------------------|
| 130 | | 604 |

| Example | R | m/z ($M+H^+$) |
|---------|--|-------------------|
| 131 |  | 616 |
| 132 |  | 586 |
| 133 |  | 509 |
| 134 |  | 524 |
| 135 |  | 511 |
| 136 |  | 497 |
| 137 |  | 581 |
| 138 |  | 615 |
| 139 |  | 617 |
| 140 |  | 616 |
| 141 |  | 613 |

| Example | R | m/z (M+H ⁺) |
|---------|---|-------------------------|
| 142 |  | 623 |
| 143 |  | 545 |
| 144 |  | 616 |

Example 145. *endo*-N-{5-[2-(4-Fluorophenoxy)ethoxy]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-benzenesulfonamide



(a) *endo*-N-(5-Hydroxy-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide


Endo-N-(5-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-benzenesulfonamide (Example 42) (1.0 g, 2.92 mmol) in 2:1 water : concentrated sulphuric acid (100 mL) was stirred at 0°C for one hour to give an even dispersion. Sodium nitrite (0.242g, 3.51 mmol) in the minimum quantity of water was added below the surface of the reaction mixture, and stirred with ice cooling for one hour. The cold reaction mixture was added to water (400 mL) which had been pre-heated to 80°C, then allowed to cool to room temperature and extracted with ethyl acetate. The organic extract was washed with brine and concentrated to give a brown oil. The crude product was purified by flash chromatography on silica gel (isohexane:ethyl acetate) to give a yellow solid. 656 mg. ¹H NMR

(CDCl₃, 400 MHz) δ 7.93 (2H, m), 7.59 (1H, m), 7.53 (2H, m), 6.86 (1H, d, J = 7.8 Hz), 6.54 (2H, m), 5.08 (1H, d, J = 7.9 Hz), 3.65 (1H, m), 2.83-2.92 (2H, m), 2.32-2.42 (2H, m), 2.18-2.24 (2H, m), 1.56 (2H, m), 1.12 (2H, m). m/z 344 (M+H⁺).

5 (b) *endo*-N-{5-[2-(4-Fluoro-phenoxy)-ethoxy]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-benzenesulfonamide






The phenol from step (a) (200 mg, 0.583 mmol), 4-fluorophenoxyethyl bromide (134 mg, 0.612 mmol) and potassium carbonate (800 mg) in DMF (10 mL) were stirred and heated at 45°C for 64 hours, then allowed to cool
10 to room temperature and diluted with ethyl acetate and 1M hydrochloric acid. The organic phase was washed with water, brine and concentrated to give an orange oil. The crude product was purified twice by flash chromatography on silica gel (isohexane:ethyl acetate). The chromatographed material was further purified by mass-directed
15 preparative HPLC to give a white solid 65 mg. ¹H NMR (CDCl₃, 400 MHz) δ 7.93 (2H, m), 7.60 (1H, m), 7.53 (2H, m), 6.96 (3H, m), 6.88 (2H, m), 6.64 (2H, m), 4.95 (1H, d, J = 7.9 Hz), 3.68 (1H, m), 2.89-2.99 (2H, m), 2.38-2.47 (2H, m), 2.22-2.27 (2H, m), 1.13 (2H, m). m/z 482 (M+H⁺).

20 The following compounds, in accordance with formula B below, were prepared by the method of Example 145, substituting the appropriate bromoalkyl derivative for 4-fluorophenoxyethyl bromide in step (b). In each case, purification was by mass directed HPLC.




25

| Example | R | m/z (M+H ⁺) |
|---------|---|---------------------------|
|---------|---|---------------------------|

| Example | R | m/z (M+H ⁺) |
|---------|---|-------------------------|
| 146 |  | 468/470 |
| 147 |  | 464 |
| 148 |  | 498/500 |
| 149 |  | 435 |
| 150 |  | 435 |

Example 151. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-hydroxymethyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide

5



(a) *endo*-13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-triene-5-carboxylic acid methyl ester


This intermediate was prepared as in Example 1 using methyl 3,4-bis(bromomethyl)benzoate as the starting material for the precursor amine, and reacting said amine with 5-chlorothiophene-2-sulfonyl chloride.

¹H NMR (CDCl₃, 400 MHz) δ 7.74 (2H, m), 7.45 (1H, d, J = 4.0 Hz), 7.13 (1H, d, J = 8.3 Hz), 6.94 (1H, d, J = 4.0 Hz), 5.16 (1H, d, J = 7.2 Hz), 3.89 (3H, s), 3.72 (1H, m), 3.04-3.11 (2H, m), 2.63-2.70 (2H, m), 2.41-2.44 (2H, m), 1.64-1.69 (2H, m), 1.12-1.15 (2H, m). m/z 426/428 (M+H⁺).

Step (b)

1M DIBAL-H in toluene (28.8 mL, 28.8 mmol) was added to a stirred solution the intermediate ester (3.07 g, 7.21 mmol) in toluene (60 mL) at such a rate to maintain the reaction temperature below -70°C , and stirred at this temperature for 2 hours. The reaction mixture was quenched with
5 methanol at -78°C and allowed to warm to room temperature. The mixture was diluted with ethyl acetate and washed with 1M hydrochloric acid, saturated sodium bicarbonate solution, brine and the organic phase was concentrated to give a white solid. 2.79g. ^1H NMR (CDCl_3 , 400
10 MHz) δ 7.44 (1H, d, $J = 4.1$ Hz), 7.06 (3H, m), 6.94 (1H, d, $J = 3.9$ Hz), 5.19 (1H, d, $J = 7.6$ Hz), 4.62 (2H, s), 3.74 (1H, m) 2.99-3.04 (2H, m), 2.54-2.61 (2H, m), 2.39 (2H, m), 1.62-1.68 (2H, m), 1.16 (2H, m).

Example 152. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-styryltricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide



15
(a) *endo*-5-Chloro-thiophene-2-sulfonic acid (5-formyltricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide


Pyridinium dichromate (1.77g, 4.7 mmol) was added to a stirred solution of *endo*-5-chloro-thiophene-2-sulfonic acid (5-hydroxymethyltricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide (Example 151) (1.25g, 3.1 mmol) in DCM (50 mL). The mixture was stirred at room temperature for two hours and then filtered through silica washing thoroughly with ethyl acetate. The solution was concentrated to give an orange oil. The crude product was purified by flash chromatography on silica gel
25 (isohexane:ethyl acetate) to give a colourless oil 1.10g. ^1H NMR (CDCl_3 , 400 MHz) δ 9.93 (1H, s), 7.59 (2H, m), 7.45 (1H, d, $J = 4.0$ Hz), 7.23 (1H, d, $J = 7.5$ Hz), 6.94 (1H, d, $J = 4.1$ Hz), 5.41 (1H, d, $J = 6.8$ Hz), 3.71 (1H, m),

3.11-3.17 (2H, m), 2.65-2.72 (2H, m), 2.44-2.47 (2H, m), 1.64-1.70 (2H, m), 1.12-1.15 (2H, m).





Step (b)

1M Potassium *t*-butoxide in THF (0.379, 0.379 mmol) was added dropwise
 5 to a stirred suspension of benzyltriphenylphosphonium chloride (147 mg, 0.379 mmol) in THF (0.5 mL). Stirred at room temperature for 30 minutes. The ylide mixture was then added to a stirred solution of the formyl intermediate from step (a) (50 mg, 0.126 mmol) in THF (0.5 mL) and stirred at room temperature for one hour. The reaction mixture was
 10 quenched with 2M hydrochloric acid and extracted with ethyl acetate. The organic phase was concentrated to dryness, and the crude product purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) [1:1 mixture of *cis* and *trans* isomers] δ 7.50 (1H, d, *J* = 7.2 Hz), 7.44 (1H, m), 7.35 (1H, t, *J* = 7.8 Hz), 7.18-7.28 (4H, m), 7.06 (2H, m), 6.94 (2H, m), 6.54
 15 (1H, m), 5.09 (1H, d, *J* = 7.7 Hz), 3.76 (1H, m), 2.90-3.07 (2H, m), 2.51-2.65 (2H, m), 2.31-2.42 (2H, m), 1.63-1.68 (2H, m), 1.15-1.26 (2H, m) for *cis* isomer. *m/z* 470/472 (M+H⁺).

The following compounds, in accordance with formula C below, were
 20 prepared by the method of Example 152, using the appropriate alkyltriphenylphosphonium bromide in step (b) :




| Example | R | <i>m/z</i> (M+H ⁺) |
|---------|---|--------------------------------|
| 153* | | 500/502 |

| Example | R | m/z (M+H ⁺) |
|---------|---|-------------------------|
| 154* |  | 488/490 |
| 155* |  | 548/550/562 |
| 156* |  | 498/500 |
| 157 |  | 394/396 |

* - mixture of *cis* and *trans* isomers

Example 158. *endo*-3-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-acrylic acid methyl ester



A solution of *endo*-5-chloro-thiophene-2-sulfonic acid (5-formyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide [Example 152 step (a)] (2.33g, 5.88 mmol) in DCM (20 mL) was added to a stirred solution of methyl (triphenylphosphoranylidene)acetate (5.90g, 17.65 mmol) in DCM (40 mL), then stirred at room temperature for 18 hours. Reaction mixture was quenched with 2M hydrochloric acid and the organic phase concentrated to dryness. The crude product was purified by flash chromatography on silica gel eluting with 3:1 isohexane : ethyl acetate to give a white solid 2.1g. ¹H NMR (CDCl₃, 400 MHz) a 10:1 mixture of *trans* and *cis* isomers δ 7.62 (1H, d, J = 16.0Hz), 7.45 (1H, d, J = 4.0 Hz), 7.24 (2H, m), 7.08 (1H, d, J = 7.7 Hz), 6.94 (1H, d, J = 3.9 Hz), 6.38 (1H, d, J = 16.0 Hz), 5.18 (1H, d, J = 6.2 Hz), 3.73 (1H, m), 3.05 (2H, d, J = 16.2 Hz),

2.57-2.64 (2H, m), 2.40 (2H, m), 1.67 (2H, m), 1.17 (2H, m) for trans isomer.
 m/z 452/454 ($M+H^+$).

Following the procedure of Example 158, and using the appropriate ylide,
5 there were also prepared:

Example 159. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(3-oxo-3-phenyl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide.

10


m/z 498/500 ($M+H^+$);

and

15 **Example 160.** *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(2-cyano-vinyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide.

m/z 419/421 ($M+H^+$).


20 **Example 161.** *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(3-hydroxypropenyl)tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



1M DIBAL-H in toluene (18.6 mL, 18.6 mmol) was added to a stirred
25 solution of *endo*-3-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-acrylic acid methyl ester (Example 158) (2.10g, 4.65 mmol) in toluene (80 mL) at such a rate to maintain the reaction temperature below -70°C . After stirring at this

temperature for 2 hours, the reaction mixture was quenched with methanol at -78°C and allowed to warm to room temperature. The mixture was diluted with ethyl acetate and washed with 1M hydrochloric acid, saturated sodium bicarbonate solution, brine and the organic phase was concentrated to give a white solid. 1.90g. ^1H NMR (CDCl_3 , 400 MHz) 10:1 mixture of trans and cis isomers δ 7.44 (1H, d, $J = 3.9$ Hz), 7.11 (1H, m), 7.01 (1H, d, $J = 7.8$ Hz), 6.93 (1H, d, $J = 4.0$ Hz), 6.54 (1H, d, $J = 15.9$ Hz), 6.29-6.36 (1H, m), 5.11 (1H, d, $J = 7.6$ Hz), 4.30 (1H, d, $J = 5.3$ Hz), 3.75 (1H, m), 3.01 (2H, m), 2.54-2.61 (2H, m), 2.38 (2H, m), 1.64 (2H, m), 1.16 (2H, m) for trans isomer.


Example 162. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-[3-(4-fluoro-phenoxy)-propyl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



(a) *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(3-hydroxypropenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide (Example 161) (50 mg, 0.118 mmol) and platinum dioxide (5 mg) in glacial acetic acid (5 mL) were stirred at room temperature under a balloon of hydrogen for three hours. The mixture was filtered through Celite® and concentrated to dryness. The crude product was purified by flash chromatography on silica gel (isohexane:ethyl acetate) to give a colourless oil 18 mg. ^1H NMR (CDCl_3 , 400 MHz) δ 7.44 (1H, d, $J = 4.0$ Hz), 6.89-6.99 (4H, m), 5.13 (1H, d, $J = 7.8$ Hz), 3.75 (1H, m), 3.66 (2H, t, $J = 6.5$ Hz), 2.98-3.02 (2H, m), 2.62 (2H, t, $J = 7.4$ Hz), 2.51-2.59 (2H, m), 2.37 (2H, m), 1.82-1.89 (2H, m), 1.63 (2H, m), 1.17 (2H, m).

(b) Methanesulphonyl chloride (5.6 mg, 0.049 mmol) in DCM (0.1 mL) was added dropwise to an ice-cooled solution of the 3-hydroxypropyl derivative from step (a) (19 mg, 0.045 mmol) and triethylamine (6.8 mg, 0.067 mmol) in DCM (0.9 mL). After stirring at 0°C for 90 minutes, more triethylamine
5 (3.4 mg) and methanesulphonyl chloride (2.8 mg) were added and stirred for a further hour at 0°C. After dilution with DCM and washing with 0.1M hydrochloric acid and water (x2), the organic phase was concentrated to give the crude mesylate as a colourless oil (17 mg) which was used immediately in the next step. The mesylate (17 mg, 0.0334 mmol), 4-
10 fluorophenol (3.8 mg, 0.0334 mmol, tris(3,6-dioxaheptyl)amine (109 mg, 0.337 mmol) and potassium carbonate (7.0 mg, 0.051 mmol) in toluene (1 mL) were stirred and heated at 100°C for 18 hours, cooled to room temperature and diluted with ethyl acetate. Washed with 1M hydrochloric acid, 5% sodium bicarbonate solution and brine. The organic phase was
15 concentrated to dryness. The crude product was purified by flash chromatography on silica gel (isohexane:ethyl acetate) to give a colourless oil. This was further purified by mass-directed preparative HPLC to give the title compound (4.3 mg). ¹H NMR (CDCl₃, 400 MHz) δ 7.44 (1H, d, J = 4.0Hz), 6.90- 6.99 (6H, m), 6.81 (2H, m), 5.05 (1H, d, J = 7.8 Hz), 3.90 (2H, t, J = 6.3 Hz), 3.76 (1H, m), 2.95-3.01 (2H, m), 2.72 (2H, t, J = 7.7 Hz), 2.49-
20 2.59 (2H, m), 2.36 (2H, m), 2.05 (2H, m), 1.63 (2H, m), 1.16 (2H, m). *m/z* 520/522 (M+H⁺).


Example 163. *endo-N*-(5-Hydroxymethyl-tricyclo[8.2.1.0^{3,8}]trideca-
25 3,5,7-trien-13-yl)benzenesulfonamide



Lithium Aluminium Hydride (300μl of 1.0M in THF) was added dropwise to a solution of *endo*-13-(benzenesulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-

3(8),4,6-triene-5-carboxylic acid methyl ester* (116 mg, 0.3mmol) in dry THF (5 mL) stirring under a nitrogen atmosphere at 0°C with stirring. The reaction was allowed to warm to room temperature and stirring continued for 1 hour. Water (2.0 mL) and 1.0M sodium hydroxide solution (2.0 mL) were added to the reaction mixture and stirred for 30 minutes. Reaction mixture was extracted into dichloromethane, dried with anhydrous magnesium sulphate, filtered and the solvent removed by evaporation to yield a colourless oil. Purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) δ 1.08-1.13 (2H, m), 1.55-1.58 (2H, m), 2.27 (2H, m), 2.46-2.53 (2H, m), 2.95-3.00 (2H, dd, J=16Hz and 4Hz), 3.66-3.71 (1H, q), 4.61 (2H,s), 5.01 (1H, d, J=8Hz), 7.01-7.06 (3H, m), 7.51-7.55 (2H, m), 7.58-7.62 (1H, m), 7.92-7.95 (2H, m). m/z 380 (M+Na⁺).
* - prepared as in Example 151 step (a), using benzenesulfonyl chloride.


Example 164. *endo*-N-(5-Bromomethyl-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl)benzenesulfonamide



endo-N-(5-Hydroxymethyl-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl)-benzenesulfonamide (Example 163) (107 mg, 0.3mmol) and carbon tetrabromide (1.05 eq. 104 mg) were combined in dry diethyl ether (10 mL) and cooled to 0°C under nitrogen. To this was added triphenyl phosphine (1.05 eq. 83 mg) and the reaction was continued at 0°C for 1 hour. Reaction was then allowed to warm to room temperature, after 4 hours a further 1 equivalent of carbon tetrabromide and triphenyl phosphine was added and the reaction progressed for 5 hours. Solvent was removed by evaporation and the crude product purified by flash chromatography (10 → 20% EtOAc in isohexane), and then further purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) δ 1.08-1.13 (2H, m), 1.56-


1.61 (2H, m), 2.25-2.30 (2H, m), 2.44-2.53 (2H, m), 2.94-2.99 (2H, dd, $J=16\text{Hz}$ and 4Hz), 3.66-3.71 (1H, q), 4.42 (2H, s), 4.93 (1H, d, $J=8\text{Hz}$), 6.99-7.09 (3H, m), 7.51-7.62 (3H, m), 7.92-7.95 (2H, m). m/z 421 ($M+H^+$).

5 **Example 165. *endo*-N-[5-(4-Chloro-phenoxy)methyl]-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl]benzenesulfonamide**













4-Chlorophenol (12.2 mg, 0.095mmol), sodium hydride 60% w/w in mineral oil (3.8 mg, 0.095mmol) and dry DMF (1.5 mL) were combined in a test
 10 tube and stirred at room temperature for 30 minutes. To this was added
endo-N-(5-bromomethyl-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl)-benzenesulfonamide (Example 164) (20 mg, 0.0475mmol) and the reaction continued at room temperature for 2 hours. Reaction mixture was then
 heated to 60°C for 4 hours. Solvent was removed by evaporation and the
 15 crude product was purified by mass-directed preparative HPLC. m/z 468 ($M+H^+$).


The following compounds in accordance with formula D below were
 prepared by the method of Example 165, substituting the appropriate
 20 phenol for 4-chlorophenol:



| Example | R | m/z ($M+H^+$) |
|---------|---|-------------------|
|---------|---|-------------------|

| Example | R | m/z (M+H ⁺) |
|---------|--|-------------------------|
| 166 |  | 434 |
| 167 |  | 452 |
| 168 |  | 452 |
| 169 |  | 464 |
| 170 |  | 502 |
| 171 |  | 490 |
| 172 |  | 501 |
| 173 |  | 485 |
| 174 |  | 518 |
| 175 |  | 560 |

Example 176. *endo*-5-Chloro-thiophene-2-sulfonic acid (5-cyano-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl)amide




The compound of Example 152 step (a) (100 mg, 0.253mmol), hydroxylamine hydrochloride (23 mg, 0.328mmol) and formic acid (5 mL) were combined and heated to reflux under nitrogen for 2 hours. Reaction mixture was allowed to cool to room temperature and then poured onto 5 iced water (20 mL), neutralized with aqueous sodium hydroxide with the temperature maintained at 0°C. The solution was then extracted with diethyl ether, and the combined organic solution dried over anhydrous magnesium sulphate. Filtered and evaporated to yield a white solid.


10 Purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) δ 1.07-1.15 (2H, m), 1.65-1.72 (2H, m), 2.41-2.48 (2H, m), 2.57-2.67 (2H, m), 3.07-3.15 (2H, t, J=16Hz), 3.66-3.71 (1H, q, J=6Hz), 5.28-5.30 (1H, d, J=6Hz), 6.95 (1H, d, J=4Hz), 7.17 (1H, m), 7.35-7.38 (2H, m), 7.45 (1H, d, J=4Hz). m/z 393 (M+H⁺).

15

Example 177. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(5-pyridin-2-yl-[1,2,4]oxadiazol-3-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl]amide




20 (a) *endo*-13-(5-Chloro-thiophene-2-sulfonylamino)-N-hydroxy-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-triene-5-carboxamidine




- endo*-5-Chloro-thiophene-2-sulfonic acid (5-cyano-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl)-amide (Example 176) (50 mg, 0.127mmol), triethylamine (32μl, 0.229mmol), hydroxylamine hydrochloride (13 mg, 0.19mmol) and ethanol (5 mL) were combined and heated to reflux under nitrogen overnight. The solvent was removed by evaporation and the residue was partitioned between 1M HCl solution and ethyl acetate. The organic layer was separated, dried over anhydrous magnesium sulphate, filtered and evaporated to give a pale gum which was used without further purification. *m/z* 426 (M+H⁺).
- (b) The product of step (a) (15 mg, 0.0352mmol), sodium hydride 60% w/w (1.5 mg) and THF (1.5 mL) were combined in a test tube and stirred at room temperature for 1 hour. To this was added ethyl picolinate (5.3 mg, 0.0352mmol) and the reaction was heated to 65°C for 3 hours and then allowed to cool to room temperature. Water (2 mL) and 1M HCl solution (2 mL) were added to the reaction and the whole mixture was extracted with 3 x 3 mL of ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated to give a yellow gum. Purified by mass-directed preparative HPLC. ¹H NMR (CDCl₃, 400 MHz) δ 1.16-1.25 (2H, m), 1.66-1.73 (2H, m), 2.45 (2H, m), 2.64-2.76 (2H, m), 3.08-3.15 (2H, m), 3.73-3.78 (1H, q, J=6Hz), 5.27 (1H, d, J=6Hz), 6.95 (1H, d, J=4Hz), 7.22 (2H, d, J=8Hz), 7.46 (1H, d, J=4Hz), 7.54 (1H, m), 7.92-7.96 (3H, m), 8.29-8.31 (1H, m). *m/z* 513 (M+H⁺).

Example 178. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(5-phenyl-[1,2,4]oxadiazol-3-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3,5,7-trien-13-yl]amide



Prepared by the method of Example 177, substituting benzoic anhydride for ethyl picolinate. Pale gum, m/z 512 ($M+H^+$).

5 **Example 179. [11-*endo*]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-yl)ethenesulfonamide**



To a solution of the amine* (700 mg) in dry DCM (8 ml) under nitrogen was added triethylamine (1.2 ml) and slowly, 2-chloroethanesulfonyl chloride (0.4 ml). The reaction was stirred at room temperature for 18 h. The reaction was then diluted with DCM, washed with water, brine, dried over $MgSO_4$, filtered and evaporated *in vacuo*. The crude product was purified by flash chromatography (silica, 5% methanol in DCM) to give a white solid (400 mg, 40%).

10 (360 MHz, 1H , $CDCl_3$) 1.21(2H, m), 1.77 (2H, m), 2.48 (2H, m), 2.64 (2H, m), 3.07 (2H, d, $J=14$), 3.75 (1H, m), 4.74 (1H, br), 5.96 (1H, d, $J=3.5$), 6.32 (1H, d, $J=15$), 6.61 (1H, m), 7.01 (4H, s)


* [11-*endo*]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine, also known as *endo*-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine (General Procedures).

20

brine, dried over MgSO_4 , filtered and evaporated *in vacuo*. Purified by flash column chromatography (silica, 25% EtOAc in iso-hexane) to give a colourless glassy solid (65 mg, 70%).

(360MHz, ^1H , CDCl_3) 1.20 (5H, m), 1.69 (2H, m), 2.44-2.69 (6H, m), 2.96
5 (2H, m), 3.10 (2H, d, $J=16.1$), 3.32 (2H, m), 3.85 (1H, m), 4.87 (1H, d), 7.08
(4H, s)

Example 182. [11-*endo*]-3-chloro-*N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)propanesulfonamide




10

To a solution of the [11-*endo*]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8] annulen-11-amine (2.5g) in dry DCM (20 ml) at 0°C and under nitrogen were added triethylamine (2 ml) and 3-chloropropanesulfonyl chloride (1.6 ml) over 10 min. The reaction was
15 allowed to warm to room temperature and stirred for 18 h., then washed with water (x2), brine, dried over MgSO_4 , filtered and evaporated. Crude product was purified by flash column chromatography (silica, DCM) to give a white solid (1.6g, 45%).

(360MHz, ^1H , CDCl_3) 1.21 (2H, quin), 1.71 (2H, m), 2.33 (2H, m), 2.50 (2H, m), 2.68 (2H, m), 3.05 (2H, d, $J=15.9$), 3.27 (2H, t, $J=7.7$), 3.71 (2H, t, $J=7.7$), 3.89 (1H, m), 4.72 (1H, br), 7.01 (4H, s)
20 MS(ES+) $[\text{MH}]^+ 328$, $[\text{M}-\text{Cl}(\text{CH}_2)_3\text{SO}_2\text{NH}]^+ 171$

Example 183. [11-*endo*]-2,2,2-trifluoro-*N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)ethanesulfonamide

25




To a solution of the [11-*endo*]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (100 mg) in dry DCM (2 ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and 2,2,2-trifluoroethanesulfonyl chloride (100 mg), and the reaction stirred at room temperature for 18 h., diluted with DCM, washed with water and brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by flash column chromatography (silica, DCM) to give a white solid (98 mg, 57%).

(360MHz, ¹H, CDCl₃) 1.25 (2H, m), 1.73 (2H, m), 2.50 (2H, m), 2.73 (2H, m), 3.01 (2H, d, J=15.1), 3.90 (3H, m), 5.06 (1H, br), 7.11 (4H, s)

MS(ES+) [M-SO₂CF₃]⁺ 188, [M-NHSO₂CF₃]⁺ 171

Example 184. [11-*endo*]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-yl)cyclopentanesulfonamide




To a solution of the [11-*endo*]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (100 mg) in dry DCM (2ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and cyclopentylsulfonyl chloride (89 mg) (prepared from cyclopentanethiol *via* a literature procedure; *Chemistry Letters*, **1992**, 1483). The reaction was stirred at room temperature for 18h., diluted with DCM, washed with water and brine, dried over MgSO₄, filtered and evaporated. The crude product was

purified by flash column chromatography (silica, DCM) to give a white solid (80 mg, 52%).


(360MHz, ^1H , CDCl_3) 1.21 (2H, m), 1.62 (2H, m), 1.84 (4H, m), 2.07 (4H, m), 2.47 (2H, m), 2.65 (2H, dd, $J=7.9, 7.8$), 3.06 (2H, d, $J=15.5$), 3.53 (1H, m), 3.91 (1H, m), 4.55 (1H, br), 7.09 (4H, s)

Example 185. [11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl)-furan-2-sulfonamide




To a solution of the [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (100 mg) in dry DCM (2 ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and furan-2-sulfonyl chloride (90 mg) (prepared from furan *via* a literature procedure; *Synthesis*, 1986, 852). After stirring at room temperature for 18 h., the reaction was diluted with DCM, washed with water and brine, dried over MgSO_4 , filtered and evaporated. The crude product was purified by flash column chromatography (silica, DCM) to give a white solid (120 mg, 58%). (360MHz, ^1H , CDCl_3) 1.16 (2H, m), 1.63 (2H, m), 2.31 (2H, m), 2.57 (2H, dd, $J=7.8, 7.8$). 3.01 (2H, d, $J=15.3$), 3.78 (1H, q), 5.12 (1H, d, $J=8.1$), 6.53 (1H, m), 7.06 (5H, m), 7.59 (1H, m). MS(EI+): $[\text{MH}]^+ 318$, $[\text{M-furanSO}_2\text{NH}]^+ 171$

Example 186. [11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl)-1,3-thiazole-2-sulfonamide



To a solution of the [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (100 mg) in dry DCM (2 ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and thiazole-2-sulfonyl
5 chloride (99 mg) (prepared from thiazole *via* a literature procedure; *Synthesis*, 1986, 852). After stirring at room temperature for 18 h., the reaction was diluted with DCM, washed with water and brine, dried over MgSO_4 , filtered and evaporated. The crude product was purified by flash
10 column chromatography (silica, DCM) to give a white solid (50 mg, 45%).
(360MHz, ^1H , CDCl_3) 1.15 (2H, m), 1.63 (2H, m), 2.38 (2H, m), 2.56 (2H, dd, $J=7.9, 7.9$), 3.05 (2H, d, $J=15.8$), 3.91 (1H, quar, $J=7.6$), 5.45 (1H, br), 7.06 (4H, m), 7.65 (1H, d, $J=3.1$), 8.00 (1H, d, $J=3.1$)
MS(CI+) [MH]⁺ 335, [M-thiazoleSO₂NH]⁺ 171

15 **Example 187. [11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl)-thiophene-3-sulfonamide**




To a solution of the [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (100 mg) in dry DCM (2 ml) under
20 nitrogen were added 4-methylmorpholine (0.1 ml) and thiophene-3-sulfonyl chloride (100 mg) (prepared from 3-bromothiophene *via* a literature procedure; *Synthesis*, 1986, 852). After stirring at room

temperature for 18 h., the reaction was diluted with DCM, washed with water and brine, dried over MgSO_4 , filtered and evaporated. The crude product was purified by flash column chromatography (silica, DCM) to give a white solid, (82 mg, 52%).

- 5 (360MHz, ^1H , CDCl_3) 1.13 (2H, m), 1.62 (2H, m), 2.30 (2H, m), 2.51 (2H, dd, $J=7.8, 7.8$), 2.99 (2H, d, $J=15.9$), 3.73 (1H, m), 5.04 (1H, d, $J=7.7$), 7.07 (4H, m), 7.42 (2H, m), 8.01 (1H, m)
MS(ES+) [MH] $^+$ 334, [M-thiophene SO_2] $^+$ 188, [M-thiophene SO_2NH] $^+$ 171


- 10 **Example 188. [11-endo]-2-chloro-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-yl)-1,3-thiazole-5-sulfonamide**



- To a solution of the [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8] annulen-11-amine (100 mg) in dry DCM (2 ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and 2-chloro-thiazole-5-sulfonyl chloride (120 mg) (prepared from 2-chlorothiazole *via* a literature procedure; *Synthesis*, 1986, 852). After stirring at room temperature for 18 h., the reaction was diluted with DCM, washed with water and brine, dried over MgSO_4 , filtered and evaporated. The crude product was
15 purified by flash column chromatography (silica, DCM) to give a white solid (95 mg, 48%).


- (360MHz, ^1H , CDCl_3) 1.21 (2H, m), 1.68 (2H, m), 2.42 (2H, m), 2.60 (2H, dd, $J=8.0, 8.0$), 3.01 (2H, d, $J=15.8$), 3.81 (1H, quar, $J=7.6$), 5.16 (1H, br), 7.08 (4H, s), 8.02 (1H, s)
20 MS (ES+) [MH] $^+$ 369, [M-chlorothiazole SO_2] $^+$ 188, [M-chlorothiazole SO_2NH] 171

Example 189. [11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl)-pyridyl-3-sulfonamide



- 5 To a solution of the [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-amine (120 mg) in dry DCM (2 ml) under nitrogen were added 4-methylmorpholine (0.1 ml) and pyridine-3-sulfonyl chloride (117 mg) (prepared from pyridine-3-sulfonic acid *via* a literature procedure; *J. Org.Chem.*, **1989**,54, 389). After stirring at room
- 10 temperature for 18 h., the reaction was diluted with DCM, washed with water and, brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by flash column chromatography (silica, DCM) to give a white solid (152 mg, 72%).
- 15 (360MHz, ¹H, CDCl₃) 1.15 (2H, m), 1.62 (2H, m), 2.32 (2H, m), 2.54 (2H, dd, J=7.9, 7.9), 2.97 (2H, d, J=15.8), 3.74 (1H, quar, J=7.5), 5.08 (1H, br), 7.06 (4H, m), 7.49 (1H, m), 8.22 (1H, dd, J=4.1,4.1), 8.88 (1H, s), 9.15 (1H, s). MS(ES+) [MH]⁺ 329, [M-pyridylSO₂]⁺ 186

- Example 190. endo-5-Chloro-thiophene-2-sulfonic acid [5-(3-piperidin-1-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide**
- 20




(a) *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(3-bromo-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide

- A solution of 1M phosphorous tribromide in DCM (29 μ L, 0.0294 mmol) was added to a stirred solution of 5-chloro-thiophene-2-sulfonic acid [5-(3-hydroxy-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide (Example 161) (25 mg, 0.0589 mmol) in DCM (1ml) at -20°C . The mixture was allowed to warm to $\sim 10^{\circ}\text{C}$ gradually at which point it was diluted with DCM and water. The organic phase was washed with dilute sodium bicarbonate solution, dried and concentrated under reduced pressure to give a white solid 24 mg. ^1H NMR (CDCl_3 , 360MHz) δ 7.44 (1H, d, $J = 3.9$ Hz), 7.10 (2H, m), 7.03 (1H, d, $J = 6.9$ Hz), 6.94 (1H, d, $J = 4.0$ Hz), 6.57 (1H, d, $J = 15.6$ Hz), 6.31-6.39 (1H, m), 5.09 (1H, br d, $J = 7.5$ Hz), 4.15 (2H, d, $J = 7.6$ Hz), 3.74 (1H, m), 3.10 (2H, d, $J = 16.2$ Hz), 2.54-2.61 (2H, m), 2.39 (2H, m), 1.65 (2H, m), 1.17 (2H, m)
- (b) The recovered bromide (24 mg, 0.0492 mmol), piperidine (40 mg, 0.4705 mmol) and potassium carbonate (17 mg, 0.125 mmol) in DMF (1 ml) were stirred at 80°C for 18 hours. The mixture was allowed to cool to rt. and concentrated under reduced pressure. The residue was treated with acetic acid (gl.) with stirring and then concentrated under reduced pressure. The crude product was purified by mass-directed preparative HPLC. ^1H NMR (CDCl_3 , 400MHz) δ 7.45 (1H, d, $J = 4.0$ Hz), 7.09 (2H, m), 7.03 (1H, d, $J = 7.6$ Hz), 6.94 (1H, d, $J = 3.9$ Hz), 6.62 (1H, d, $J = 15.8$ Hz), 6.19 (1H, m), 5.33 (1H, d, $J = 7.2$ Hz), 3.74 (3H, m), 3.63 (2H, br d, $J = 11.7$ Hz), 3.04 (2H, m), 2.68-2.47 (6H, m), 2.40 (2H, m), 2.00 (1H, m), 1.89 (2H, m), 1.65 (2H, m), 1.38 (1H, m), 1.15 (2H, m). m/z 491/493 ($\text{M}+\text{H}^+$).


The following compounds in accordance with formula E were prepared by the method of example 190, substituting the appropriate amine for piperidine in step (b). In all cases, purification was by mass-directed HPLC.

138




| Example | R | <i>m/z</i> (M+H ⁺) |
|---------|---|--------------------------------|
| 191 | | 493/495 |
| 192 | | 474/476 |
| 193 | | 475/477 |
| 194 | | 506/508 |
| 195 | | 568/570 |
| 196 | | 495/497 |

Example 197. *endo*-5-Chloro-N-[5,6,7,8,9,10-hexahydro-6,9-
 5 methanocycloocta[*b*]pyridin-11-yl]thiophene-2-sulfonamide
 trifluoroacetate



10

Step (a) (6*S*/*R*,9*R*/.*S*,11*E*/*Z*)-5,6,7,8,9,10-hexahydro-6,9-
 methanocycloocta[*b*]pyridin-11-one oxime



Diisopropylethylamine (6.6mL, 38 mmol) and 1-pyrrolidinocyclopentene (2.8mL, 19 mmol) were added to a stirred solution of freshly prepared 2,3-bis(chloromethyl)pyridine [K. Tsuda et al; *Pharm. Bull.* **1**, 1953, 142] (2.6g, 15 mmol) in dry acetonitrile (50mL) at 0°C under nitrogen. The reaction was stirred for 15 minutes at this temperature, then 1 hour at room temperature. The mixture was then stirred and heated at reflux for 2 hours. The reaction was allowed to cool, the volatiles removed *in vacuo*, and the residue taken up in water (40mL). Concentrated hydrochloric acid was added to give pH 1, and the mixture heated at reflux for 24 hours. The reaction was cooled to 0°C and basified with 4N aqueous sodium hydroxide, and the dark mixture extracted with dichloromethane (x4). The combined extracts were dried (Na₂SO₄), filtered and evaporated, and the residue purified by chromatography on silica gel, eluting with 80% ethyl acetate/hexanes to 100% ethyl acetate to give (6S/R,9R/S)-5,6,7,8,9,10-hexahydro-6,9-methanocycloocta[b]pyridin-11-one (700mg) as a dark oil (~75% pure); MS (ES+) 188 ([MH]⁺). This material was used without further purification.


A solution of the above ketone (840mg), hydroxylamine hydrochloride (625mg, 9 mmol) and sodium acetate trihydrate (1.2g, 8.8 mmol) in ethanol/water (2:1, 15mL) was stirred and heated at reflux for 45 minutes. The reaction was allowed to cool and the ethanol was removed *in vacuo*. The residue was basified with 4N aqueous sodium hydroxide. This aqueous mixture was extracted with dichloromethane (x4). The combined extracts were dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography on silica, eluting with 75% ethyl acetate/hexanes to 100% ethyl acetate to give the title oxime (487mg, 50%) as a colourless foam; MS (ES+) 203 ([MH]⁺).

Step (b)

The oxime from step (a) was converted to the corresponding amine by sequential treatment with sodium cyanoborohydride and activated zinc as described in Example 108 steps 1 and 2. The product, a yellow oil; MS (ES+) 189 [MH]⁺, was used without further purification.

- 5 5-Chlorothiophene-2-sulfonyl chloride (150mg, 0.7 mmol) was added to a solution of a portion of the above amine (~100mg, 0.5mmol) and 4-(dimethylamino)pyridine (84mg, 0.7 mmol) in dry dichloromethane (5mL) at room temperature under nitrogen. After stirring at this temperature overnight, the mixture was partitioned between dichloromethane and
- 10 saturated aqueous sodium hydrogen carbonate. The aqueous layer was extracted with dichloromethane (x2). The combined extracts were dried (Na₂SO₄), filtered. The residue was purified by chromatography on silica gel eluting with 30% ethyl acetate/dichloromethane to give the sulphonamide (140mg, colourless solid). A portion of this material was
- 15 further purified by preparative HPLC to give the title compound (7mg) as a colourless solid; (400MHz ¹H, δ-d₆-DMSO) 0.89-0.96 (2H,m), 1.65-1.73 (2H, m); 2.33-2.45 (2H, m); 2.76 (1H, dd, J=16.4, 7.4), 2.99 (1H, dd, J=16.4, 7.5), 3.22 (1H, d, J=16.2), 3.40 (1H, d, J=16.5), 3.57 (1H, q, J=6.2), 7.29 (1H, d, J=4.0), 7.57 (1H, d, J=4.0), 7.65 (1H, br t, J=6), 8.15 (1H, d, J=7.6),
- 20 8.45 (1H, d, J=6.1), 8.55 (1H, d, J=5.2); MS (ES+) 369, 371 ([MH]⁺).

Example 198. *endo*-5-Chloro-N-[5,6,7,8,9,10-hexahydro-6,9-methanocycloocta[*c*]pyridin-11-yl]thiophene-2-sulfonamide




25

This material was prepared according to the procedure described in Example 197, substituting 3,4-bis(chloromethyl)pyridine for 2,3-bis(chloromethyl)pyridine in step (a).


The final product was purified by preparative tlc (10% ethyl acetate - dichloromethane) to give 5-chloro-N-[(6S/R,9S/R,11R/S)-5,6,7,8,9,10-hexahydro-6,9-methanocycloocta[c]pyridin-11-yl]thiophene-2-sulfonamide (59mg) as a colourless foam; (360MHz ¹H, δ-d₆-DMSO) 0.85-0.94 (2H, m), 1.22-1.29 (1H, m); 1.50-1.56 (2H, m); 2.27-2.32 (2H, m), 2.51-2.58 (1H, m), 3.05-3.16 (2H, m), 3.59-3.65 (1H, m), 7.20 (1H, br s), 7.28 (1H, d, J=4.0), 7.52 (1H, d, J=4.0), 8.25 (2H, br s), 8.36 (1H, d, J=7); MS (ES⁺) 369, 371 ([MH]⁺).

Example 199. [N-(11-endo)]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-yl)pyrrolidine-1-sulfonamide.



A mixture of [11-endo]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-amine (180mg, 0.96mmol), 1-pyrrolidinesulfonyl chloride (FR 2678935 A1) (320mg; 1.9 mmol) and triethylamine (300μL, 2.2 mmol) in dry acetonitrile (3mL) was stirred and heated at reflux overnight under a nitrogen atmosphere. After cooling to room temperature the reaction mixture was partitioned between dichloromethane and saturated aqueous sodium hydrogen carbonate. The aqueous layer was further extracted with dichloromethane (x2). The combined organic extracts were dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography on silica gel eluting with 20% ethyl acetate / hexanes to give the title compound (44mg, 14%) as a cream solid, δ (¹H, 360MHz, CDCl₃) 1.15-1.21 (2H, m), 1.66-1.72 (2H, m), 1.92-1.98 (4H, m), 2.46-2.51 (2H, m), 2.61 (2H, dd, J=16.1, 7.6), 3.09 (2H, d, J=16.0), 3.33-3.37 (4H, m), 3.78-3.84 (1H, m), 4.63 (1H, br d, J=8), 7.09 (4H, br s).

Example 200. *endo*-5-chloro-*N*-[2-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl]thiophene-2-sulfonamide



5 Step 1.

Potassium t-butoxide (1.0M in THF; 1.33ml, 1.33mmol) was added to a solution of 5-chloro-*N*-(2-cyano-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)thiophene-2-sulfonamide (Example 176) (350mg, 0.89mmol) in THF (10ml) and stirred for 20 mins. Chloromethyl methyl ether (108μl, 1.42mmol) was added and the reaction stirred overnight at RT. More reagents were added as necessary until the reaction was complete by NMR. The reaction mixture was poured into water (25ml) and extracted with ethyl acetate (2 x 25ml). The combined organic layers were washed with brine, dried over MgSO₄ and evaporated to give 5-chloro-*N*-(2-cyano-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)-*N*-(methoxymethyl)thiophene-2-sulfonamide (388mg, quant.).

¹H NMR (400MHz, CDCl₃) δ 7.49 (d, *J* 4, 1H), 7.40-7.35 (m, 2H), 7.17 (d, *J* 7.7, 1H), 6.95 (d, *J* 4, 1H), 4.88 (q, *J* 9, 2H), 3.48-3.39 (m, 2H), 3.36 (s, 3H), 3.36-3.33 (m, 1H), 2.81-2.77 (m, 2H), 2.68-2.58 (m, 2H), 1.62-1.59 (m, 2H), 1.14-1.11 (m, 2H).

20 Step 2

The nitrile from Step 1 (388mg, 0.89mmol) was converted to the corresponding N-hydroxycarboximide as described in Example 177 step (a). Yield (396mg, 95%).

¹H NMR (400MHz, DMSO) δ 9.50 (s, 1H), 7.67 (d, *J* 4.2, 1H), 7.39-7.36 (m, 2H), 7.31 (d, *J* 4.2, 1H), 7.02 (d, *J* 7.8, 1H), 5.72 (s, 2H), 4.84 (s, 2H), 3.28 (s, 3H), 3.28-3.23 (m, 3H), 2.73 (m, 2H), 2.59-2.53 (m, 2H), 1.55-1.53 (m, 2H), 1.02 (d, *J* 10.2, 2H).

Step 3

Isonicotinic acid (29mg, 0.24mmol) was dissolved in DMF (4ml) under nitrogen and carbonyl diimidazole (38mg, 0.24mmol) added. The reaction was stirred at RT for 1h. A solution of the product from step 2 (120mg, 0.26mmol) in DMF (2ml) was added and the reaction stirred for 4h. The reaction mixture was poured into water (25ml) and extracted with ethyl acetate (2 x 25ml). The combined organic layers were washed with water (3 x 25ml), citric acid (10% aq; 25ml), NaHCO₃ (sat. aq; 25ml) and brine, dried over Na₂SO₄ and evaporated. Without further purification, 75mg of the residue was dissolved in DMF (2ml) and toluene (4ml), *p*-toluenesulphonic acid (5mg) was added and the reaction heated to 70°C for 3h. The cooled reaction mixture was poured into NaHCO₃ (25ml) and extracted with ethyl acetate (25ml). The organic layer was washed with water (3 x 25ml) and brine, dried over Na₂SO₄ and evaporated to give 5-chloro-*N*-(methoxymethyl)-*N*-[2-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl]thiophene-2-sulfonamide (67mg, 92%).

¹H NMR (400MHz, DMSO) δ 8.88 (s, 2H), 8.07 (d, *J* 5, 2H), 7.89 (d, *J* 7.9, 2H), 7.51 (d, *J* 4.1, 1H), 7.26-7.22 (m, 1H), 6.96 (d, *J* 4.1, 1H), 4.92 (q, *J* 10, 2H), 3.51-3.45 (m, 2H), 3.37 (s, 3H), 3.39-3.36 (m, 1H), 2.79-2.78 (m, 2H), 2.75-2.65 (m, 2H), 1.70-1.60 (m, 2H), 1.26-1.21 (m, 2H).

Step 4


Trifluoroacetic acid (0.5ml) was added to a solution of the product from step 3 (65mg, 0.12mmol) in DCM (2ml) and stirred for 1h at RT. Ethyl

acetate (20ml) was added and washed with Na_2CO_3 (10% aq; 20ml) and brine, dried over Na_2SO_4 and evaporated. The residue was purified by flash column chromatography on silica, eluting with 1:1 isohexane:EtOAc, to give the title product (30mg, 49%).

- 5 ^1H NMR (400MHz, CDCl_3) δ 9.90 (d, J 1.6, 2H), 8.08 (dd, J 1.6, 4.4, 2H), 7.90 (s, 1H), 7.90-7.88 (m, 1H), 7.47 (d, J 3.9, 1H), 7.26-7.23 (m, 1H), 6.97 (d, J 3.9, 1H), 5.05 (d, J 7.4, 1H), 3.77 (q, J 6.4, 1H), 3.14-3.10 (m, 2H), 2.78-2.67 (m, 2H), 2.49-2.44 (m, 2H), 1.72-1.68 (m, 2H), 1.24-1.20 (m, 2H). m/z 513, 514, 515, 516.

10

Example 201. *endo*-5-chloro-*N*-[2-(5-pyridin-3-yl-1,2,4-oxadiazol-3-yl)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl]thiophene-2-sulfonamide




15

Prepared as described in Example 200, substituting nicotinic acid for isonicotinic acid in step 3.

- 20 ^1H NMR (400MHz, DMSO) δ 9.34 (d, J 0.8, 1H), 8.90 (dd, J 1.2, 4.7, 1H), 8.57-8.54 (m, 1H), 8.42 (d, J 7, 1H), 7.83 (s, 1H), 7.82-7.79 (m, 1H), 7.73-7.69 (m, 1H), 7.57 (d, J 3.9, 1H), 7.33 (d, J 7.8, 1H), 7.29 (d, J 3.9, 1H), 3.63-3.57 (m, 1H), 3.27-3.23 (m, 2H), 2.69-2.57 (m, 2H), 2.36-2.29 (m, 2H), 1.65-1.60 (m, 2H), 1.02-0.97 (m, 2H). m/z 513, 514, 515, 516.


Example 202. *endo-N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8] annulen-11-yl)pentanesulfonamide



Prepared as described in Example 184, substituting n-pentanesulfonyl
5 chloride for cyclopentanesulfonyl chloride. The crude product was purified
by flash column chromatography (silica, 20% EtOAc in iso-hexane) to give
a glassy solid (30%).

(360 MHz, ¹H, CDCl₃) 0.92 (3H, q, J=7), 1.20 (2H, m), 1.41 (4H, m), 1.71
(2H, m), 1.86 (2H, m), 2.44 (2H, m), 2.64 (2H, dd, J=7.5, 7.5), 3.09 (4H, m),
10 3.85 (1H, quar, J=6.3), 4.82 (1H, d, J=8.3), 7.09 (4H, m)

Example 203. *endo-N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8] annulen-11-yl)-isothiazole-5-sulfonamide




15

Prepared as in Example 202 using isothiazole-5-sulfonyl chloride
(prepared from 5-bromoisothiazole by the method described in *Synthesis*,
1986, 852). The crude product was purified by flash column
20 chromatography (silica, 3:1 iso-hexane/ethyl acetate) to give a white solid
(53%).

(360 MHz, ¹H, CDCl₃) 1.15 (2H, m), 1.61 (2H, m), 2.38 (2H, m), 2.55 (2H,
dd, J=7.6, 7.6), 3.00 (2H, d, J=16), 3.85 (1H, quar, J=6.9), 4.75 (1H, d,
J=7.3), 5.29 (1H, d, J=7.0), 7.09 (4H, m), 7.67 (1H, s), 8.52 (1H, s)

MS (ES+) [MH]⁺ 335, [M-isothiazoleSO₂NH]⁺ 171


5 Example 204. *endo-N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-yl)-pyrrole-3-sulfonamide



Prepared as in Example 202 using 1-triisopropylsilylpyrrole-3-sulfonyl chloride (prepared from the corresponding 3-bromide by the method described in *Synthesis*, 1986, 852), followed by removal of the silyl group by treatment with t-butylammonium fluoride in dry THF at 0 °C under N₂. Purified by flash chromatography (SiO₂, 50% ethyl acetate in isohexane) to give a white solid.

(360 MHz, ¹H, CDCl₃) 1.13 (2H, m), 1.61 (2H, m), 2.35 (2H, m), 2.52 (2H, dd, J=6.7, 6.8), 3.07 (2H, d, J=14), 3.70 (1H, quar, J=6.0), 4.82 (1H, d, J=6.8), 6.55 (1H, m), 6.85 (1H, m), 7.06 (4H, m), 7.36 (1H, m). 8.60 (1H, br).
15 MS (ES+) [MH]⁺ 317, [M-pyrroleSO₂NH]⁺ 171


20 Example 205. *endo*-1-methyl-*N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8] annulen-11-yl)-pyrrole-3-sulfonamide



Prepared from the product of Example 204 by treatment with sodium hydride and iodomethane.

(360 MHz, ^1H , CDCl_3) 1.14 (2H, m), 1.61 (2H, m), 2.36 (2H, m), 2.53 (2H, dd, $J=7.6$, 7.6), 3.08 (2H, d, $J=16$), 3.69 (4H, m), 4.75 (1H, d, $J=7.3$), 6.45 (1H, m), 6.63 (1H, m), 7.06 (4H, m), 7.16 (1H, m)
MS (ES+) $[\text{MH}]^+$ 330


10 **Example 206. *endo*-6-chloro-*N*-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8] annulen-11-yl)-pyridine-3-sulfonamide**



Prepared as in Example 1 using 6-chloropyridine-3-sulfonyl chloride.

^1H NMR (CDCl_3 , 360 MHz) δ 8.92 (1 H, d, $J = 2.5$ Hz, PyH), 8.15 (1 H, dd, $J = 2.5$ & 8.4 Hz, PyH), 7.50 (1H, d, $J = 8.4$ Hz), 7.10-7.03 (4H, m, aromatic), 5.17 (1H, d, $J = 7.9$ Hz, NH), 3.72 (1H, q, $J = 6.3$ & 14.2 Hz), 2.96 (2H, d, $J = 16$ Hz, aliph), 2.59-2.52 (2H, m, aliph), 2.35-2.29 (2H, m, aliph), 1.65-1.59 (2H, m, aliph), 1.19-1.13 (2H, m, aliph), m/z 362.

20 **Example 207. *endo*-5-chloro-*N*-(2-pyridin-2-yl-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)thiophene-2-sulfonamide**



Step 1

[6S/R,9R/S] 2-Hydroxy-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-one (J.Org.Chem 1982, 47, 4329) was converted to the oxime and thence to the 11-amine by the process described in the General Procedures. The amine (10.90 g) and di-*tert*-butyl dicarbonate (24 g) in dry THF (400 ml) were stirred at r.t. under nitrogen for 4 hours. *Unsymm*-N,N-dimethyl ethylenediamine (6 ml) was added and the mixture was stirred for a further 1.5 hours. Water (500 ml) was added and the mixture was extracted with ethyl acetate (2 x 200 ml). The organic layers were washed with 0.2M citric acid (200 ml), brine (100 ml), dried and concentrated. The residue was filtered through charcoal, eluting with dichloromethane, and the filtrate concentrated to give [6S/R,9R/S,11S/R] *tert*-butyl 2-hydroxy-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-ylcarbamate (17.7 g, quantitative) as a beige solid.

15 Step 2

The product of step 1 (0.463 g), diisopropylethylamine (0.32 ml) and N-phenylbis(trifluoromethanesulfonamide) (0.65 g) in acetonitrile (20 ml) were stirred at 0°C under nitrogen, warming slowly to room temperature. After 18 hours the suspension was diluted with ethyl acetate (50 ml) and washed with water (50 ml), 1M citric acid (50 ml), dried and concentrated. Flash column chromatography, eluting with 5% then 10% ethyl acetate-isohexane, gave [6S/R,9R/S,11S/R] 11-[(*tert*-butoxycarbonyl)amino]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-2-yl trifluoromethanesulfonate (0.497 g, 75%) as a white powder

25 Step 3


The product from step 2 (0.076 g), dipalladium (0) tris(dibenzylideneacetone) (0.008 g) and tri(2-furyl)phosphine (0.008 g) in dry DMF (1 ml) were stirred at 80°C under nitrogen, followed by addition of 2-pyridylzinc bromide (0.5M in THF, 0.2 ml). After 18 hours the mixture was poured into 1M citric acid (5 ml), neutralised with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate (20

ml). The organic extract was dried and concentrated. Flash column chromatography, eluting with 20% ethyl acetate-isohexane, gave [6S/R,9R/S,11S/R] *tert*-butyl 2-pyridin-2-yl-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-ylcarbamate (0.012 g, 19%) as an oil.

5 Step 4

The product of step 3 (0.020 g) and trifluoroacetic acid (1 ml) in dichloromethane (1 ml) was stood at room temperature for 1.5 hours then evaporated to dryness. The residue was redissolved in dry dichloromethane (1 ml) and triethylamine (1 ml) and 2-chlorothiophene-5-sulfonyl chloride (0.015 ml) were added. After 18 hours the mixture was diluted with water (5 ml) and extracted with dichloromethane (2 x 5 ml). The extracts were dried and concentrated. Preparative thin layer chromatography, eluting with 30% ethyl acetate-isohexane, gave the title compound (0.004 g, 16%) as a white solid. (360MHz ¹H, δ-CDCl₃) 1.20-1.26 (2H, m), 1.65-1.70 (2H, m), 2.40-2.45 (2H, m), 2.63-2.77 (2H, m), 3.07 (2H, d, J=16), 3.75-3.81 (1H, m), 5.04 (1H, d, J=7), 6.95 (1H, d, J=4), 7.17-7.23 (2H, m), 7.46 (1H, d, J=4), 7.67-7.76 (4H, m), 8.67 (1H, d, J=5). M/z (ES+) 445, 447 (M+H⁺).

20 **Example 208. *endo*-5-chloro-*N*-(2-(pyridin-4-yloxy)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-yl)thiophene-2-sulfonamide**




Sodium hydride (55% in oil, 0.26 g) was added to a stirred solution of [6S/R,9R/S] 2-Hydroxy-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-one (0.50 g; J. Org. Chem **1982**, *47*, 4329) in dry DMF at room temperature under nitrogen. When effervescence had subsided, 4-bromopyridine hydrochloride (0.57 g) was added and the mixture was stirred at 80°C for 18 hours. The mixture was diluted with water (100 ml), acidified with 1M hydrochloric acid and washed with EtOAc (20 ml). The aqueous layer was basified with 4M sodium hydroxide and extracted with dichloromethane-methanol (9:1, 2 x 100 mL). The extracts were dried and concentrated. Flash column chromatography, eluting with 90:9:1 dichloromethane-methanol-ammonia, gave a brown oil that was filtered through charcoal, eluting with dichloromethane, and concentrated to give [6S/R,9R/S] 2-(pyridin-4-yloxy)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-one (0.27 g) as a beige solid.

Step 2

The ketone from step 1 was converted to the oxime as described in the General Procedures, and this was reduced to the amine as described in Example 66, step 2. Treatment of the amine (0.04g) with 5-chlorothiophene-2-sulfonyl chloride by the procedure of Example 66 step 3 gave the title compound. Purification by flash column chromatography, eluting with 5% methanol-dichloromethane, gave a beige solid that was washed with ethyl acetate to give the final product (0.010 g, 12%) as an off-white powder. (400MHz ¹H, δ -d₆-DMSO) 0.98-1.06 (2H, m), 1.57-1.66 (2H, m), 2.23-2.32 (2H, m), 2.43-2.50 (2H, m), 3.15-3.22 (2H, m), 3.55-3.62 (1H, m), 6.84-6.90 (3H, m), 6.91-6.96 (1H, m), 7.19 (1H, d, J=8), 7.29 (1H, d, J=4), 7.56 (1H, d, J=4), 8.32-8.38 (1H, broad m), 8.44-8.48 (2H, m). m/z (ES+) 461, 463 (M+H⁺).

Example 209. *endo*-Thiophene-2-sulfonic acid{5-[2-(4-fluorophenoxy)-ethoxy]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide






Step 1. 5-[2-(4-fluoro-phenoxy)-ethoxy]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one


A mixture of 2-hydroxy-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[*a*][8]annulen-11-one (21.7g; J. Org. Chem **1982**, 47, 4329), K₂CO₃ (17.7g) and 1-(2-Bromo-ethoxy)-4-fluoro-benzene (40.3g) in DMF (400 ml) were stirred for 72 hours at 120 °C. The reaction was then cooled to room temperature and the solvent removed *in vacuo*. The residue was then washed with saturated NaHCO₃ solution and the organics extracted with EtOAc (3x200ml). The organics were then combined, dried (MgSO₄) and the solvent removed *in vacuo* yielding a dark brown oil which was purified by flash chromatography on silica eluting 20% EtOAc in isohexane giving the title alkylated ketone (15.97 g, 44%). MS (ES+) 341 [M+H]⁺.

Step 2

The ketone from step 1 was converted to the oxime and thence to the corresponding amine as described in the General Procedures. The amine (0.3g) was reacted with thiophene-2-sulfonyl chloride by the procedure of Example 1 to provide the title compound which was purified by flash chromatography on silica eluting 20% EtOAc in isohexane. The product isolated from this purification was then recrystallized from EtOAc and isohexane yielding 250 mg of the desired sulfonamide as a white crystalline solid. (400MHz ¹H, δ-CDCl₃), 1.16-1.18 (2H, d), 1.60-1.65 (2H, m), 2.31-2.32 (2H, m), 2.44-2.53 (2H, benzylic, m), 2.92-2.96 (1H, benzylic, d), 2.99-3.03 (1H, benzylic, d), 3.76 (1H, CH-N, m), 4.26 (4H, s), 5.01 (1H, NH-SO₂ s), 6.68 (2H, aromatic, m), 6.88 (2H, aromatic, m), 6.97 (3H, aromatic, m), 7.10 (1H, thiophenyl, m), 7.60 (1H, thiophenyl, m), 7.66 (1H, thiophenyl, m). MS (ES+) 488 [M+H]⁺.


Following the procedure of Example 209, using the appropriate alkyl
halide in step 1 and the appropriate sulfonyl chloride in step 2, the
following compounds of formula VA were prepared, wherein R¹ is H and R³
5 and R^{4b} are as indicated:

| Example | R ³ | R ^{4b} | m/z [M+H] ⁺ |
|---------|---|---------------------------|------------------------|
| 210 | 4-fluorophenyl | 2-(4-fluorophenoxy)ethoxy | 500 |
| 211 | 4-chlorophenyl | 2-(4-fluorophenoxy)ethoxy | 516 |
| 212 | 4-nitrophenyl | 2-(4-fluorophenoxy)ethoxy | 527 |
| 213 | 4-methoxyphenyl | 2-(4-fluorophenoxy)ethoxy | 512 |
| 214 | n-propyl | 2-(4-fluorophenoxy)ethoxy | 448 |
| 215 |  | 2-(4-fluorophenoxy)ethoxy | 618 |
| 216 | 2-fluorophenyl | 2-(4-fluorophenoxy)ethoxy | 500 |
| 217 | 2,4-difluorophenyl | 2-(4-fluorophenoxy)ethoxy | 518 |
| 218 | 3-fluorophenyl | 2-(4-fluorophenoxy)ethoxy | 500 |
| 219 | 5-bromo-2-thienyl | 2-(4-fluorophenoxy)ethoxy | 568 |
| 220 |  | 2-(4-fluorophenoxy)ethoxy | 486 |
| 221 |  | 2-(4-fluorophenoxy)ethoxy | 500 |
| 222 | 4-cyanophenyl | 2-(4-fluorophenoxy)ethoxy | 507 |
| 223 | 3-pyridyl | 2-(4-fluorophenoxy)ethoxy | 483 |
| 224 | n-butyl | 2-(4-fluorophenoxy)ethoxy | 462 |
| 225 | 5-chloro-2-thienyl | 2-(4-fluorophenoxy)ethoxy | 523 |
| 226 | 3-pyridyl | benzyloxy | 435 |

| Example | R ³ | R ^{4b} | m/z [M+H] ⁺ |
|---------|---|-----------------|------------------------|
| 227 |  | benzyloxy | - |

Example 228. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(2-morpholin-4-yl-ethoxy)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide

5



Step 1

endo-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo [8.2.1.0^{3,8}] trideca-3(8),4,6-trien-5-yloxy]-acetic acid ethyl ester was prepared by the method of Example 209 using ethyl bromoacetate in step 1 and 5-chlorothiophene-2-sulfonyl chloride in step 2.

10

Step 2 : *endo*-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo [8.2.1.0^{3,8}] trideca-3(8),4,6-trien-5-yloxy]-acetic acid.

15

Lithium hydroxide monohydrate (84 mg) was added to a stirred solution of the ester from step 1 (870 mg) in THF:H₂O (20 ml 1:1) and the resulting solution stirred at room temperature for 16 hours. After this time the solvent was removed under reduced pressure and the residue partitioned between 2N HCl (aq.) and DCM, the organic layer separated, dried over MgSO₄, filtered and the solvent removed under reduced pressure to afford the acid as a white powder. (820 mg).


20

Step 3

HBTU (17.08 mg) was added to a stirred solution of the acid from step 2 (20 mg), morpholine (3.94 mg) and diisopropylethylamine (15 μ l) in acetonitrile (2.0 ml). After 18 hours the reaction was quenched by the







addition of water (2 ml) and solvent removed by lyophilisation. The residue was taken up in DMSO (1.0 ml) and purified by mass-directed preparative HPLC m/z 512 ($M+H^+$). The recovered amide intermediate was taken up in dry THF (0.5 ml) and treated with $BH_3:THF$ (0.5 ml/1.0 M) for 4 hours. The reaction was then quenched with 1N HCl (0.5 ml) and the solvents removed under reduced pressure. The residue was taken up in DMSO (1.0 ml) and purified by mass-directed preparative HPLC m/z 498 ($M+H^+$). 1H NMR ($CDCl_3$ 400 MHz) (TFA salt) δ 1.19 (2H, m), 1.62 (2H, m), 2.36 (2H, m), 2.48-2.61 (6H, m), 2.78 (2H, t, $J = 8.0$ Hz), 2.93 (1H, d, $J = 16.0$ Hz), 3.00 (1H, d, $J = 16$ Hz), 3.74 (5H, m), 4.06 (2H, t, $J = 8.0$ Hz), 5.10 (1H, d, $J = 12.0$ Hz), 6.61 (2H, m), 6.94 (2H, m), 7.44 (2, m).

The following compounds in accordance with formula F below were prepared by the above method, substituting the appropriate amine for morpholine in the amide formation step. In all cases, purification was by mass directed HPLC.




F

| Example No | NR ₂ | m/z ($M+H^+$). |
|------------|-----------------|--------------------|
| 229 | | 610 |
| 230 | | 626 |
| 231 | | 640 |

| Example No | NR ₂ | m/z (M+H ⁺). |
|------------|---|--------------------------|
| 232 |  | 640 |
| 233 |  | 624 |
| 234 |  | 496 |
| 235 |  | 498 |
| 236 |  | 512 |
| 237 |  | 510 |

Example 238. *endo*-Pyridine-3-sulfonic acid [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}] trideca-3(8),4,6-trien-13-yl]-amide



5 Step 1

endo-13-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-triene-5-carboxylic acid methyl ester was prepared as described in the General Procedures using methyl 3,4-bis(bromomethyl)benzoate as starting material, and converted to the BOC derivative as described in Example 207 step 1. The methyl ester was reduced to the benzyl alcohol as in Example 151 step (b), then oxidised to the aldehyde as in Example 152 step (a), and converted to the 3-hydroxypropenyl derivative by the procedures of Example 158 and Example 161.

Step 2


15 1-Bromo-N,N,2-trimethylpropenylamine (171 mg, 0.962 mmol) in DCM (0.5 ml) was added to a stirred suspension of the alcohol of step 1 (300mg, 0.875 mmol) in DCM (4.5 ml) with ice cooling. After stirring at room

temperature for 1 hour, morpholine (3 ml) was added, with stirring for a further 30 minutes. The mixture was diluted with DCM and washed with water. The organic phase was dried over sodium sulphate, filtered and concentrated to dryness. The crude product was purified by column chromatography on silica eluting with 20 : 1 DCM : methanol to give [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-carbamic acid tert-butyl ester as a colourless oil 156 mg (43%).

Step 3


The BOC group was removed by treatment with trifluoroacetic acid as described in Example 207 step 4.. The resulting amine (32 mg, 0.103 mmol), pyridine-3-sulphonyl chloride (27mg, 0.154 mmol), triethylamine (15mg, 0.154 mmol) and DMAP (cat.) in DCM (3 ml) were stirred at room temperature for 18 hours at which point more pyridine-3-sulphonyl chloride (20mg) and triethylamine (30mg) were added and the mixture stirred for a further 6 hours. The mixture was diluted with DCM and washed with 1M sodium hydroxide (aq). The organic phase was dried over sodium sulphate, filtered and concentrated to dryness. The crude product was purified twice by column chromatography firstly on silica eluting with 20 : 1 DCM : 2M ammonia in methanol and then on silica eluting with 40 : 1 DCM : 2M ammonia in methanol. Finally the product was purified by mass-directed preparative HPLC to give the title compound 20mg (43%).
¹H NMR (CDCl₃, 400 MHz) δ 9.14 (1 H, s), 8.82 (1 H, m), 8.22 (1 H, m), 7.49 (1 H, m), 7.10 (1 H, d, J = 7.8 Hz), 7.05 (1 H, s), 6.99 (1 H, m), 6.45 (1 H, d, J = 15.8 Hz), 6.16 – 6.23 (1 H, m), 5.21 (1 H, d, J = 7.8 Hz), 3.72 (5 H, m), 3.13 (2 H, d, J = 7.6 Hz), 2.94 – 2.99 (2 H, dd, J = 16.1 + 6.6 Hz), 2.50 (3 H, m), 2.31 (2 H, m), 1.62 (2 H, m), 1.14 (2 H, m).

Example 239. *endo*-2-Morpholin-4-yl-thiazole-5-sulfonic acid [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



Prepared as described in Example 238, using 2-morpholin-4-yl-thiazole-5-sulfonyl chloride in step 3. m/z 545 ($M+H^+$).

5 **Example 240. *endo*-Pyridine-3-sulfonic acid [5-(2-morpholin-4-ylethoxy)-tricyclo [8.2.1.0^{3,8}] trideca-3(8),4,6-trien-13-yl]-amide**



Step 1

Diethyl azodicarboxylate (1.07 g, 6.16 mmol) in DCM (5 ml) was added at a dropwise rate to a stirred solution of 2-hydroxy-11-oxo-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene (J. Org. Chem. **1982** 4329, 829 mg, 4.10 mmol), triphenylphosphine (1.61 g, 6.16 mmol) and 4-(2-hydroxyethyl)morpholine (806 mg, 6.16 mmol) in DCM (45 ml). The mixture was stirred at room temperature for 2 hours and then concentrated to dryness. The crude product was purified by column chromatography on silica eluting with 40 : 1 DCM : 2M ammonia in methanol. The chromatographed material was taken up in the minimal volume of ethyl acetate and diluted with diethyl ether. 1M HCl in diethyl ether was added. The precipitate was filtered washing the solid with ethyl acetate and diethyl ether. The white solid was taken up in DCM and washed with 1M sodium hydroxide (aq). The organic phase was dried over sodium sulphate, filtered and concentrated to dryness to give 5-(2-morpholin-4-yl-ethoxy)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one as a colourless oil 740 mg (57%).


25 Step 2

The ketone from step 1 was converted to the amine as described in the General Procedures, then reacted with pyridine-3-sulfonyl chloride by the process of Example 237 step 3 to provide the title compound which was isolated as its dihydrochloride salt.


- 5 ^1H NMR ($\text{CDCl}_3 + [\text{CD}_3\text{OD}]$, 400 MHz) δ 9.34 (1 H, s), 8.98 (1 H, s), 8.73 (1 H, br d, $J = 7.2$ Hz), 7.98 (1 H, m), 6.97 (1 H, d, $J = 7.9$ Hz), 6.63 (2 H, m), 4.46 (2 H, m), 4.15 (2 H, br t, $J = 12.3$ Hz), 4.03 (2 H, m), 3.59 (1 H, m), 3.50 (2 H, m), 3.39 (1 H, br d, $J = 16.2$ Hz), 3.06 - 3.16 (4 H, m), 2.47 (2 H, m), 2.33 (2 H, m), 1.61 (2 H, m), 1.14 (2H, m).

10


Example 241. *endo*-4-[13-(5-Chloro-thiophene-2-sulfonylamino)tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yloxy]-piperidine-1-carboxylic acid tert-butyl ester



Example 242 *endo*-5-Chloro-thiophene-2-sulfonic acid [5-[3-(4-oxymorpholin-4-yl)-propenyl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



- 5 *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide (Example 191) (20 mg, 0.041 mmol) and *m*-chloroperoxybenzoic acid (7 mg, 0.041 mmol) in DCM (2 ml) were stirred at room temperature for 18 hours. The mixture was diluted with DCM and washed with sodium bicarbonate solution (aq, sat.).
- 10 The organic phase was dried over sodium sulphate, filtered and concentrated to dryness. The crude product was purified by mass-directed preparative HPLC and further purified by reverse-phase preparative HPLC to provide 1.5 mg of the title compound. ¹H NMR (CDCl₃, 400 MHz) δ 7.45 (1 H, d, J = 4.1 Hz), 7.15 (2 H, m), 7.08 (1 H, d, J = 8.2 Hz), 6.95 (1
- 15 H, d, J = 4.0 Hz), 6.81 (1 H, d, J = 15.8 Hz), 6.30 - 6.37 (1 H, m), 5.07 (1 H, br d, J = 7.2 Hz), 4.55 (2 H, d, J = 7.4 Hz), 4.31 (2 H, t, J = 11.7 Hz), 3.94 (4 H, m), 3.74 (1 H, m), 3.39 (2 H, m), 3.05 (2 H, d, J = 16.1 Hz), 2.58 - 2.65 (2 H, m), 2.43 (2 H, m), 1.69 (2 H, m), 1.17 (2 H, m).
- 20 **Example 243.** *endo*-5-Chloro-*N*-[2-(morpholin-4-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-yl]thiophene-2-sulfonamide




A solution of the allylic alcohol from Example 161 (155 mg, 0.37 mmol) in CH_2Cl_2 (10 ml) was placed under N_2 and cooled to -15°C . Diethylzinc solution (1.83 ml of a 1.0 M solution in hexanes, 1.83 mmol) was added dropwise with care and this was followed by addition of diiodomethane (0.15 ml, 1.86 mmol). The reaction mixture was allowed to warm to room temperature over 3 h and then stirred for a further 2 h. The reaction mixture was quenched by addition of satd. NH_4Cl solution and then Et_2O and 1M HCl (aq.) were added. The layers were separated and the organic extract washed sequentially with Na_2SO_3 (sat. aq.), NaHCO_3 (sat. aq.) and brine before being dried (MgSO_4) and concentrated. Trituration with Et_2O afforded the cyclopropyl alcohols as a mixture of diastereomers (155 mg, 97%). ^1H NMR (CDCl_3 , 400 MHz) δ 0.87-0.95 (2H, m), 1.15-1.20 (2H, m), 1.37-1.46 (1H, m), 1.61-1.67 (2H, m), 1.73-1.77 (1H, m), 2.34-2.38 (2H, m), 2.49-2.57 (2H, m), 2.93-3.00 (2H, m), 3.61 (2H, d, $J = 6.7$ Hz), 3.75 (1H, app dd, $J = 13.9, 6.4$ Hz), 5.04 (1H, d, $J = 7.8$ Hz), 6.76-6.78 (2H, m), 6.93-6.96 (2H, m), 7.44 (1H, d, $J = 4.0$ Hz).

Example 246. *endo*-5-Chloro-*N*-[2-(3-morpholin-4-ylpropoxy)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[α][8]annulen-11-yl]thiophene-2-sulfonamide


was extracted with dichloromethane (2x2ml). The combined organics were evaporated and purified by mass-directed preparative HPLC. m/z 349 ($M+H^+$). 1H NMR ($CDCl_3$, 360MHz) δ 1.4-1.6 (m, 2 H), 1.7-1.8 (m, 2 H), 2.03 - 2.35 (m, 4 H), 2.43-2.50 (m, 2 H), 2.90-2.96 (m, 2 H), 3.42-3.47 (m, 1 H), 3.82 (s, 3H), 4.94 (d, 1 H, $J = 5.4$ Hz), 6.94 (d, 1H, $J = 4.0$ Hz), 7.43 (d, 1H, $J = 4.0$ Hz).

Example 248. *endo*-Butane-1-sulfonic acid (3-methylene-bicyclo[3.2.1]oct-8-yl)-amide



A solution of *endo*-3-methylene-bicyclo[3.2.1]oct-8-ylamine [Example 108, Step 2] (25mg, 0.18mmol) in dichloromethane (0.8ml) containing N,N -diisopropylethylamine (0.2ml) was added to a stirred solution of 1-butan Sulphonyl chloride in dichloromethane (1ml) at $0^\circ C$ and allowed to warm to room temperature over 18 hours. The solution was evaporated and purified by mass-directed preparative HPLC. m/z 258 ($M+H^+$). 1H NMR ($CDCl_3$, 400MHz) δ 0.96 (s, 3 H, $J=7.4$ Hz), 1.42-1.52 (m, 2 H), 1.68-1.73 (m, 2 H), 1.78-1.87 (m, 2 H), 1.99-2.04 (m, 2 H), 2.18-2.22 (m, 2 H), 2.38-2.44 (m, 2H), 3.02-3.08 (m, 2H), 3.54-3.60 (m, 1 H), 4.54 (d, 1H, $J = 7.5$ Hz), 4.77-4.80 (m, 2 H).


Following the procedure of Example 248 using the appropriate sulphonyl chloride, the following compounds of formula G were prepared and purified by mass-directed preparative HPLC:



G

| Example | R | m/z (M+H ⁺) |
|---------|-------------------|-------------------------|
| 249 | phenyl | 278 |
| 250 | 2-thienyl | 284 |
| 251 | 4-methylphenyl | 292 |
| 252 | 4-fluorophenyl | 296 |
| 253 | 2-fluorophenyl | 296 |
| 254 | 3-fluorophenyl | 296 |
| 255 | 4-chlorophenyl | 312 |
| 256 | 4-bromophenyl | 356 |
| 257 | 5-bromo-2-thienyl | 362 |
| 258 | 4-iodophenyl | 404 |

5 **Example 259. *endo*-5-Chloro-thiophene-2-sulfonic acid (3-benzylidene-bicyclo[3.2.1]oct-8-yl)-amide**



Step 1

10 *endo*-3-Methylene-bicyclo[3.2.1]oct-8-ylamine (example 108 step 2) was converted to the BOC derivative as described in Example 207 step 1. This compound (305mg), tetrabutylammonium chloride(360mg), sodium hydrogen carbonate (220mg), iodobenzene (505mg) and palladium acetate (90mg) were combined in DMF(10ml) and heated at 100°C for 80 hours. The reaction mixture was evaporated and *endo*-3-benzylidene-

15 bicyclo[3.2.1]oct-8-yl)-carbamic acid tert-butyl ester was isolated, after

column chromatography on silica using 10% ethyl acetate in isohexane as the eluant, as a mixture of isomers including the desired compound and endo-(3-benzyl-bicyclo[3.2.1]oct-2-en-8-yl)-carbamic acid tert-butyl ester (220mg).

5 Step 2


The product from step 1 (120mg) in dichloromethane (4 ml) was treated with trifluoroacetic acid (4ml) and stirred at room temperature for 1 hour. The reaction mixture was evaporated, basified using saturated potassium carbonate solution (4ml) and extracted using dichloromethane (6x1ml)

- 10 The dichloromethane solution was treated with N,N-dimethylethylenediamine (0.4ml), cooled to 0°C and treated with 5-chlorothiophene sulphonyl chloride in dichloromethane (2ml) at 0°C. The reaction mixture was allowed to warm to room temperature over 18 hours. The reaction mixture was washed with 1N hydrochloric acid (2ml),
- 15 evaporated and purified by chromatography on silica using 5-10% ethyl acetate in isohexane as eluant followed by mass-directed preparative HPLC to give the desired compound (7.5mg)

- ¹H NMR (CDCl₃, 360MHz) δ 1.28-1.37 (m, 1 H), 1.50-1.73 (m, 3H), 2.0-2.25 (m, 2H) 2.30-2.40 (m, 1H) 2.50-2.56 (m, 1H), 2.61-2.66 (m, 1H), 3.46 (dd, 20 1H, J₁=11.2Hz, J₂=5Hz), 5.11 (d, J=6.7Hz), 6.38 (s, 1H), 6.93 (d, 1H, J=4Hz), 7.15-7.21 (m, 3H), 7.28-7.33 (m, 2H), 7.44 (d, 1H, J=4Hz).


Example 260. endo-5-Chloro-thiophene-2-sulfonic acid {5-[2-(4-fluorophenoxy)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide

25




endo-N-[13-(5-Chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-yl]-2-(4-fluorophenoxy)-acetamide was prepared by the method of Example 44, substituting 4-fluorophenoxyacetic acid for benzoic acid. The amide (35mg) was treated with borane-tetrahydrofuran complex in tetrahydrofuran (1M,1.5ml) and stirred at room temperature for 18 hours. Methanol (1ml) was added and the mixture was stirred at room temperature overnight. The reaction mixture was evaporated and purified to give the desired compound (27mg) by mass-directed preparative HPLC *m/z* 521 (M+H⁺). ¹H NMR (CDCl₃, 360MHz) δ 0.90–1.07 (m, 2H), 1.52-1.60 (m,2H), 2.27-2.45(m,4H), 2.83-2.92 (m,2H), 3.40-3.46 (m,1H), 3.54-3.66 (m,2H), 4.06-4.18 (m, 2H), 6.20 (br d,1H), 6.82-6.99(m,8H), 7.43 (d, 1H, J=4.1Hz).

15 **Example 261.** *endo*-5-Chloro-thiophene-2-sulfonic acid {5-[2-(4-chlorophenoxy)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide



Prepared as for Example 260, using 4-chlorophenoxyacetic acid in the first
20 step, and purified by mass-directed preparative HPLC. m/z 537 ($M+H^+$).

Example 262. *endo*-5-Chloro-thiophene-2-sulfonic acid {5-[4-(4-fluorophenyl)-piperazin-1-yl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide



Step 1

5-Amino-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (ref. *J.Org.Chem.*, 1982, 47, 4329-4334) (7.45g, 37mmol) in 40% sulphuric acid was cooled to 0°C and treated with sodium nitrite (3.06g, 44mmol) in water (16ml) keeping the temperature below 5°C. Meanwhile copper(I) bromide (57g) in water was treated with 48% hydrobromic acid at 0°C. The diazonium solution was added to this solution, keeping the temperature below 5°C. After addition the reaction mixture was allowed to warm to room temperature and stirred at room temperature overnight. Water (500ml) was added and the aqueous mixture extracted using dichloromethane (9x200ml). The combined organics were washed with brine (200ml), dried using sodium sulphate, filtered and the filtrate evaporated. 5-Bromo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (5.1g) was purified by column chromatography on silica using 9:1 to 5:1 isohexane:ethyl acetate as the eluant.

Step 2


An oven dried flask was charged with caesium carbonate (912mg), *rac*-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (racemic BINAP) (56mg), and palladium (II) acetate (13.6mg) and flushed with nitrogen. A solution of the bromo-derivative of step 1 (530mg, 2mmol) and 1-(4-fluorophenyl)-piperazine (432mg, 2.4mmol) in toluene (4ml) was added via canula and the mixture degassed using nitrogen. The reaction was stirred at room temperature for 30 minutes and then heated at 80°C for 18 hours. After cooling to room temperature, ether was added and a precipitate formed. This was filtered and the filtrate was evaporated and purified by column

chromatography on silica using 9:1 to 5:1 isohexane:ethyl acetate as the eluant to give 5-[4-(4-fluorophenyl)-piperazin-1-yl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-one (290mg, 40%). m/z 365 ($M+H^+$).

5 Step 3


The ketone from step 2 was converted to the oxime as described in Example 107 step 1 and reduced to the amine as described in Example 108 steps 1 and 2. The amine (250mg, 0.68mmol) in dichloromethane (2ml) and pyridine (0.5ml) was cooled to 0°C and treated with 5-chlorothiophene
10 sulphonyl chloride (223 mg, 1.03mmol) followed by a catalytic amount of 4-dimethylaminopyridine. The mixture was allowed to warm to room temperature and stirred at room temperature for 18 hours. Water (25ml) was added and the aqueous layer extracted using dichloromethane (3x30ml). The combined organics were dried using sodium sulphate,
15 filtered and the filtrate evaporated to dryness. The residue was purified by column chromatography on silica using 4:1 isohexane:ethyl acetate followed by purification on alumina using 5:1 to 4:1 isohexane: ethyl acetate to give the title compound (124mg). m/z 546 ($M+H^+$).
¹H NMR (CDCl₃, 360MHz) δ 1.20–1.29 (m, 2H), 1.60-1.67 (m, 2H), 2.31-
20 2.43(m, 4H), 2.51(d, 1H, J=16.2Hz), 2.53(d, 1H, J=16.2Hz), 2.93 (d, 1H, J=16.3Hz), 3.04(d, 1H, J=16.4Hz), 3.74-3.80 (m, 1H), 5.02 (d, 1H, J=7.9Hz), 6.91-7.02(m, 4H), 7.44 (d, 1H, J=4.1Hz).

Example 263. *endo*-5-Chloro-thiophene-2-sulfonic acid {5-[4-(2-methoxyphenyl)-piperazin-1-yl]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide
25




Prepared as for Example 262, using 1-(2-methoxyphenyl)piperazine in step 2, and purified by mass-directed preparative HPLC. m/z 558 ($M+H^+$).

- 5 **Example 264.** *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(4-pyridin-2-yl-piperazin-1-yl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



- 10 Prepared as for Example 262, using 1-(2-pyridyl)piperazine in step 2, and purified by mass-directed preparative HPLC. m/z 529 ($M+H^+$).

Example 265. *endo*-5-Chloro-thiophene-2-sulfonic acid {5-[2-(4-fluorophenylamino)-ethylamino]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide




Step1: *Endo*-2-[13-(5-chloro-thiophene-2-sulfonylamino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-5-ylamino]-N-(4-fluorophenyl)-acetamide

5 The amine from Example 128 step (g) (100mg) in dichloroethane was treated with N,N-diisopropylethylamine (0.4ml) followed by α -chloro-4-fluoroacetanilide (50mg) and heated at 65°C for 40 hours. Further α -chloro-4-fluoroacetanilide (100mg) was added and the mixture heated for a further 8 days. The mixture was evaporated and purified by column
10 chromatography on silica using 2:1 to 1:1 isohexane: ethyl acetate as the eluant to give the title compound (48mg) m/z 534 ($M+H^+$).

Step 2

The product from Step 1 was reduced to the title compound by the process described in Example 260. m/z 520 ($M+H^+$).

15 **Example 266. *endo*-5-Chloro-thiophene-2-sulfonic acid [5-(2-morpholin-4-ylethylamino) tricyclo [8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide**



20 Step 1


The amine from Example 128 step G (100mg) in dichloroethane was treated with N,N-diisopropylethylamine (0.4ml) followed by 4-(2-chloroacetyl)morpholine (63mg, 0.39mmol) in dichloroethane (1ml) and

was heated at 70°C for 72 hours. The mixture was evaporated and purified by column chromatography on silica using 1:1 isohexane: ethyl acetate as the eluant to give *endo*-5-chlorothiophene-2-sulfonic acid [5-(2-morpholin-4-yl-2-oxoethyl amino)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide (63mg) *m/z* 510 (M+H⁺).

Step 2

The product from step 1 was reduced as described in Example 260 to give the title compound. *m/z* 496 (M+H⁺).

10 Example 267. *endo*-Pyridine-3-sulfonic acid (2-hydroxy-2-methyl-tricyclo-[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide



Step 1

Chromium trioxide (2.61 g, 26.12 mmol) was dissolved in a solution of sulfuric acid (100 ml) and water (225 ml). *endo*-Tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine (General Procedures) (as the acetic acid salt, 3.23g, 13.06 mmol) was added, and the mixture was heated to reflux for 2.5 h. After cooling in an ice-water bath, sodium hydroxide (73 g, 1.83 mol) was added slowly over 30 min [CARE!], and ammonium hydroxide was added to pH 10. The mixture was extracted with DCM (3 x 120 ml), the combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure to give a yellow oil (1.77g), which was converted to the BOC derivative as follows:

The crude amino ketone (1.77 g) was dissolved in DCM (30 ml), and di-*tert*butyldicarbonate (9.60 g, 43.97 mmol), triethylamine (2.45 ml, 17.59 mmol) and DMAP (100 mg) were added. After stirring at room temperature for 96 h, the mixture was quenched with 1 M HCl (10 ml). The aqueous phase was extracted with DCM (3 x 20 ml) and the combined

organic phases were washed with saturated NaHCO_3 (aq), dried (Na_2SO_4) and concentrated under reduced pressure. The orange oil was purified by flash chromatography (isohexane / diethyl ether 7:3) to give *endo*-(2-oxo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-carbamic acid tert-butyl ester
5 as a white foam (920 mg, 23%). m/z 202.

Step 2

The product of step 1 (920 mg, 3.05 mmol) was treated with TFA (10 ml) in DCM (15 ml) for 1 h. The volatiles were removed under reduced pressure, and the residue was dissolved in DCE (15 ml). Triethylamine (1.27 ml,
10 9.16 mmol), DMAP (50 mg), and 3-pyridylsulfonyl chloride were added, and the mixture was heated to reflux for 16 h. After cooling to room temperature, the precipitate was filtered, washing the residue with EtOAc (50 ml). The filtrate was concentrated, and the orange oil was subjected to flash chromatography (gradient elution from EtOAc / isohexane 1:1 to 1:0)
15 to give *endo*-pyridine-3-sulfonic acid (2-oxo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl)-amide as a white solid (334 mg, 30%). m/z 343 ($M+H$)⁺.

Step 3

To a stirred suspension of the product of step 2 (150 mg, 0.44 mmol) in
20 THF (20 ml) was added 3 M MeMgBr in diethyl ether (409 μl , 1.23 mmol). The mixture was heated to reflux for 3 h and then quenched with EtOH (1 ml). The volatiles were removed under reduced pressure and the residue was partitioned between pH 7 buffer (10 ml) and EtOAc (20 ml). The aqueous phase was extracted with EtOAc (4 x 20 ml) and the combined
25 organic phases were washed with brine (30 ml), dried (Na_2SO_4) and concentrated to dryness. Purification by flash chromatography (gradient elution from EtOAc / isohexane 2:3 – 1:0) gave white solids:


Major diastereoisomer (110 mg, 70%). ^1H NMR (CDCl_3 , 360 MHz) δ 9.16 (1H, s), 8.77-8.79 (1H, m), 8.26-8.20 (1H, m), 7.91 (2H, d, $J = 8.5$ Hz), 7.49 (1H, dd, $J = 8.0, 4.9$ Hz), 7.31 (1H, dd, $J = 6.8, 1.9$ Hz), 7.19-7.10 (2H, m),
30 3.74-3.69 (1H, m), 3.54 (1H, d, $J = 15.5$ Hz), 2.52 (1H, dd, $J = 15.5, 8.2$ Hz),

2.41-2.35 (1H, m), 2.05 (1H, t, $J = 6.6$ Hz), 1.91-1.67 (4H, br s), 1.47-1.57 (2H, m), 1.06-0.99 (1H, m), 0.81-0.74 (1H, m). m/z 359 ($M+H$)⁺.

Minor diastereoisomer (11 mg, 7%). ¹H NMR (CDCl₃, 360 MHz) δ 9.15 (1H, s), 8.77-8.79 (1H, m), 8.23-8.20 (1H, m), 7.72 (1H, dd, $J = 7.8, 1.0$ Hz), 7.51 (1H, dd, $J = 8.0, 4.9$ Hz), 7.22 (1H, t, $J = 7.5$ Hz), 7.12 (1H, td, 7.4, 1.2 Hz), 7.01 (1H, d, $J = 7.4$ Hz), 5.22 (1H, d, $J = 7.5$ Hz), 3.68-3.63 (1H, m), 3.44 (1H, d, $J = 16.2$ Hz), 2.62 (1H, dd, $J = 16.1, 7.9$ Hz), 2.38-2.30 (2H, m), 1.90 (1H, br s), 1.68-1.61 (2H, m), 1.58 (3H, m), 1.22-1.13 (2H, m). m/z 359 ($M+H$)⁺.

10


Example 268. *endo*-Pyridine-3-sulfonic acid (2-methylene-tricyclo[8.2.1.0^{3,8}]-trideca-3(8),4,6-trien-13-yl)-amide



The product from Example 267 (20 mg, 55.8 μ mol) was treated with TFA (1 ml) in DCM (5 ml) for 1 h. Concentration under reduced pressure gave a yellow foam, which was dissolved in DCM (20 ml) and washed with saturated NaHCO₃ (aq) (10 ml). The aqueous phase was extracted with DCM (2 x 20 mL) and the combined organic phases were dried (Na₂SO₄) and concentrated under reduced pressure to give a cream solid which was purified by flash chromatography (eluent: EtOAc / isohexane 1:1) to give a white solid (17 mg, 89%). ¹H NMR (CDCl₃, 360 MHz) δ 9.16 (1H, s), 8.77-8.79 (1H, m), 8.23-8.20 (1H, m), 7.49 (1H, dd, $J = 8.0, 4.9$ Hz), 7.22-7.14 (3H, m), 7.08-7.04 (1H, m), 5.22 (1H, d, $J = 1.7$ Hz), 5.08 (1H, d, $J = 8.8$ Hz), 4.89 (1H, d, $J = 1.7$ Hz), 3.84-3.79 (1H, m), 2.95 (1H, d, $J = 15.9$ Hz), 2.76 (1H, t, $J = 6.8$ Hz), 2.48 (1H, dd, $J = 15.9, 7.2$ Hz), 2.41-2.35 (1H, m), 1.80-1.69 (2H, m), 1.13-1.35 (2H, m). m/z 341 ($M+H$)⁺.


25

Example 269. *endo*-5-Chloro-thiophene-2-sulfonic acid {6-[2-(4-fluoro-phenoxy)-ethoxy]-2-oxo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide




5 The product of Example 225 was oxidised to the title compound using chromium trioxide in sulphuric acid as described in Example 267 step 1. The product was purified by flash chromatography (gradient elution from EtOAc / isohexane 1:4 – 1:1) to give a white foam (41 mg, 35%). ¹H NMR (CDCl₃, 360 MHz) δ 7.51 (1H, d, J = 8.6 Hz), 7.46 (1H, d, J = 4.0 Hz), 7.02-6.95 (3H, m), 6.91-6.85 (2H, m), 6.80 (1H, dd, 8.6, 2.4 Hz), 6.72 (1H, d, J = 2.2 Hz), 5.27 (1H, d, J = 6.2 Hz), 4.35-4.27 (4H, m), 3.90-3.85 (1H, m), 3.39 (1H, d, J = 15.0 Hz), 2.99 (1H, t, J = 7.7 Hz), 2.80-2.73 (2H, m), 2.04-1.95 (1H, m), 1.92-1.82 (1H, m), 1.77-1.59 (2H, m). *m/z* 536 (M+H)⁺.

15 **Example 270.** *endo*-Pyridine-3-sulfonic acid {6-[2-(4-fluoro-phenoxy)-ethoxy]-2-oxo-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide



Prepared by oxidation of the product of Example 223 as described in
20 Example 269. Purification by flash chromatography (eluant: EtOAc / isohexane 1:1) gave a white solid. *m/z* = 497 (M+H)⁺.

Example 271. Pyridine-3-sulfonic acid {6-[2-(4-fluoro-phenoxy)-ethoxy]-2-hydroxy-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide
25 amide




The product from Example 270 (18 mg, 36.2 μ mol) in methanol (5 ml) was treated with NaBH_4 (22 mg, 0.59 mmol) at room temperature for 3 h. The solvent was removed under reduced pressure and the residue was

5 partitioned between EtOAc (10 ml) and pH 7 buffer (5 ml). The aqueous phase was extracted with EtOAc (3 x 10 ml), and the combined organic phases were washed (brine), dried (Na_2SO_4) and concentrated under reduced pressure to give a white solid. Purification by flash

10 chromatography (gradient elution from EtOAc / isohexane 1:1 – 1:0) gave a white solid (13.7 mg, 76%). ^1H NMR (CDCl_3 , 360 MHz) δ 9.15 (1H, s), 8.78-8.81 (1H, m), 8.24-8.21 (1H, m), 7.74 (1H, d, $J = 7.4$ Hz), 7.48 (1H, dd, $J = 7.9, 4.8$ Hz), 7.05-6.95 (3H, m), 6.91-6.87 (2H, m), 6.75-6.69 (2H, m), 4.78 (1H, d, $J = 6.8$ Hz), 4.28 (4H, s), 3.79-3.73 (1H, m), 3.50 (1H, d, $J = 14.8$ Hz), 2.56-2.38 (3H, m), 1.73-1.48 (2H, m), 1.25-1.17 (2H, m), 0.93-0.88 (1H, m). m/z 499 ($\text{M}+\text{H}$) $^+$.

15

Example 272. *endo*-Pyridine-3-sulfonic acid {6-[2-(4-fluorophenoxy)-ethoxy]-2-methyl-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl}-amide



Step 1

endo-5-[2-(4-Fluoro-phenoxy)-ethoxy]-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-ylamine (1.00 g, 2.93 mmol) (Example 209 step 2) was oxidised to the 2-oxo derivative by the procedure of Example 267 step 1. Trituration

of the crude product with Et₂O furnished a cream solid (282 mg, 27%).
m/z 356 (M+H)⁺.


Step 2

To a stirred suspension of Ph₃PCH₃Br (377 mg, 1.06 mmol) in anhydrous
5 dioxane (3.5 ml) at 0 °C was added, dropwise, 1.6 M *n*-BuLi in diethyl
ether (555 µl, 0.88 mmol). Stirring was continued for a further 30 min.,
prior to warming to room temperature. The ketone from step 1 (150 mg,
0.423 mmol) was added, and after stirring at room temperature for a
further 30 min., the mixture was heated to reflux for 90 min., and then
10 stirred at room temperature for a further 16 h. The solvent was removed
under reduced pressure, and the residue was partitioned between CHCl₃
(20 ml) and water (10 ml). The layers were separated and the aqueous
phase was extracted with CHCl₃ (4 x 20 ml), and the combined organic
phases were dried (Na₂SO₄) and concentrated to give an orange oil.
15 Purification by flash chromatography (CHCl₃ / MeOH / ammonium
hydroxide 95:3:0.3) gave the 2-methylene derivative as a cream solid (115
mg, 77%). *m/z* 354 (M+H)⁺.

Step 3


The product of step 2 (25 mg, 70.7 µmol) and 10% Pd/C (25 mg) were
20 stirred in methanol (3 ml) under an atmosphere of H₂ for 4 h. The mixture
was filtered and concentrated under reduced pressure to give the 2-methyl
derivative as a white solid (25 mg, 100%). Sulfonylation of this compound
with pyridine-3-sulfonyl chloride by the procedure of Example 1 gave the
title compound. ¹H NMR (CDCl₃, 400 MHz) δ 9.17 (1H, d, *J* = 2.0 Hz), 8.84
25 (1H, s), 8.24-8.21 (1H, m), 7.52-7.48 (1H, m), 7.04 (1H, d, *J* = 8.5 Hz), 6.99-
6.95 (2H, m), 6.90-6.86 (2H, m), 6.71 (1H, dd, *J* = 8.5, 2.8 Hz), 6.66 (1H, d,
J = 2.8 Hz), 5.42 (1H, d, *J* = 6.9 Hz), 4.26 (4H, s), 3.66-3.61 (1H, m), 3.04-
2.99 (2H, m), 2.44-2.38 (1H, m), 2.26 (1H, q, *J* = 7.1 Hz), 1.98 (1H, t, *J* = 6.4
Hz), 1.55-1.35 (2H, m), 1.11 (3H, d, *J* = 7.1 Hz), 1.10-1.03 (1H, m), 0.96-
30 0.88 (1H, m). *m/z* 497 (M+H)⁺.

Example 273. *endo*-Pyridine-3-sulfonic acid {6-[2-(4-fluorophenoxy)-ethoxy]-2-methylene-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide




- 5 Prepared by reacting the product of Example 272 step 2 with pyridine-3-sulfonyl chloride by the procedure of Example 1. *m/z* 495 (M+H)⁺.

Example 274. Enantiomers of *endo*-5-chloro-thiophene-2-sulfonic acid [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide



and




- 15 A 25 mg / ml solution in ethanol of racemic *endo*-5-chloro-thiophene-2-sulfonic acid [5-(3-morpholin-4-yl-propenyl)-tricyclo[8.2.1.0^{3,8}]trideca-3(8),4,6-trien-13-yl]-amide (Example 191) was purified by chiral HPLC. The HPLC system was a Chiralcel OD column (250 x 10 mm i.d.), using 8% ethanol in isohexane, with a flow rate of 5 ml / min and detection at 260 nm. Loadings of 80 µl onto the column (i.e. 2 mg of material) were achieved. The two enantiomers were eluted with retention times of 15 minutes for enantiomer A and 22 minutes for enantiomer B.
- 20 Enantiomer A TFA salt : ¹H NMR (CDCl₃, 400 MHz) δ 7.45 (1 H, d, J = 3.9 Hz), 7.10 (2 H, m), 7.04 (1 H, d, J = 7.6 Hz), 6.95 (1 H, d, J = 4.0 Hz), 6.66 (1 H, d, J = 15.9 Hz), 6.13 - 6.21 (1 H, m), 5.15 (1 H, br d, J = 7.2 Hz), 3.99

(4 H, m), 3.78 (2 H, d, $J = 7.4$ Hz), 3.72 (1 H, m), 3.56 (2 H, m), 3.04 (2 H, m), 2.87 (2 H, m), 2.55 - 2.63 (2 H, m), 2.42 (2 H, m), 1.67 (2 H, m), 1.17 (2 H, m). m/z 493 / 495 ($M+H^+$).

Enantiomer B TFA salt : 1H NMR ($CDCl_3$, 400 MHz) δ 7.45 (1 H, d, $J = 3.9$ Hz), 7.10 (2 H, m), 7.04 (1 H, d, $J = 7.9$ Hz), 6.95 (1 H, d, $J = 3.9$ Hz), 6.67 (1 H, d, $J = 15.6$ Hz), 6.14 - 6.23 (1 H, m), 5.20 (1 H, br d, $J = 7.2$ Hz), 3.99 (4 H, m), 3.78 (2 H, br d, $J = 6.9$ Hz), 3.72 (1 H, m), 3.56 (2 H, m), 3.04 (2 H, m), 2.87 (2 H, m), 2.55 - 2.63 (2 H, m), 2.41 (2 H, m), 1.66 (2 H, m), 1.17 (2 H, m). m/z 493 / 495 ($M+H^+$).




CLAIMS

1. A pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a therapeutically effective amount of one or more compounds of formula I:



wherein:

- A and B are independently selected from $-(CXY)_p-$; $-(CXY)_qCY = CY(CXY)_r-$; $-(CXY)_xNR^{13}(CXY)_y-$;



- X represents halogen, R^9 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where t is 1 or 2, $-OSO_2R^9$, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-OCO_2R^{10}$, $-CON(R^9)_2$, $-SO_2N(R^9)_2$, $-OSO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$ or $-NR^9SO_2R^{10}$;

Y represents H or C_{1-6} alkyl;

or X and Y together represent $=O$, $=S$, $=N-OR^{11}$ or $=CHR^{11}$;

provided neither A nor B comprises more than one -CXY- moiety which is other than -CH₂-;

Z completes an aromatic ring system of 5 to 10 atoms, of which 0 to 3 are selected from nitrogen, oxygen and sulfur and the remainder are carbon, or Z completes a non-aromatic ring system of 5 to 10 atoms, of which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon;

Z¹ completes a non-aromatic ring system of 5 to 10 atoms, of which 0 to 3 are independently selected from oxygen, nitrogen and sulphur and the remainder are carbon;

Z² completes a 5- or 6-membered heteroaryl ring;

m and n are independently 1 or 0;

p is an integer from 1-6;

q and r are independently 0, 1 or 2;

x and y are independently 0, 1 or 2;

provided that when m = n = 0, at least one of A and B comprises a chain of 2 or more atoms, such that the ring completed by A and B contains at least 5 atoms;

R¹ represents H, C₁₋₄alkyl, or C₂₋₄alkenyl;

R² represents H, C₁₋₆alkyl, C₆₋₁₀aryl, C₆₋₁₀arylC₁₋₆alkyl, C₃₋₆cycloalkyl or C₂₋₆acyl which is optionally substituted with a carboxylic acid group or with an amino group;

R³ represents C₁₋₁₆alkyl, C₃₋₁₀cycloalkyl, C₂₋₁₆alkenyl, C₂₋₁₆alkynyl, C₆₋₁₀arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, C₆₋₁₀arylC₂₋₆alkenyl, heteroarylC₂₋₆alkenyl, C₆₋₁₀aryl, bi(C₆₋₁₀aryl), heteroaryl, bi(heteroaryl) or heterocyclyl; wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups represented by R³ or forming part of a group represented by R³ optionally bear up to 3 substituents independently selected from halogen, CN, NO₂, -OR⁷, -SR⁷, -S(O)_tR⁸ where t is 1 or 2, -N(R⁷)₂, -COR⁷, -CO₂R⁷, -OCOR⁸, -CON(R⁷)₂, -NR⁷COR⁸, -C₁₋₆alkylNR⁷COR⁸, -NR⁷CO₂R⁸ and -NR⁷SO₂R⁸; and the aryl, heteroaryl and heterocyclic groups represented by R³ or forming part of a

group represented by R^3 optionally bear up to 5 substituents independently selected from R^8 , halogen, CN, NO_2 , $-OR^7$, $-SR^7$, $-S(O)_tR^8$ where t is 1 or 2, $-N(R^7)_2$, $-COR^7$, $-CO_2R^7$, $-OCOR^8$, $-CON(R^7)_2$, $-NR^7COR^8$, $-C_{1-6}alkylNR^7COR^8$, $-NR^7CO_2R^8$ and $-NR^7SO_2R^8$;

5 R^4 , R^5 and R^6 independently represent R^9 , halogen, CN, NO_2 , $-OR^9$, $-SR^9$, $-S(O)_tR^{10}$ where t is 1 or 2, $-N(R^9)_2$, $-COR^9$, $-CO_2R^9$, $-OCOR^{10}$, $-CON(R^9)_2$, $-SO_2N(R^9)_2$, $-NR^9COR^{10}$, $-NR^9CO_2R^{10}$, $-NR^9SO_2R^{10}$, $-CH=CHCH_2N(R^{16})_2$, $-CH_2OR^{10}$, $-CH_2N(R^{16})_2$, $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$;

10 R^7 represents H or R^8 ; or two R^7 groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring;

R^8 represents $C_{1-10}alkyl$, perfluoro $C_{1-6}alkyl$, $C_{3-10}cycloalkyl$, $C_{3-6}cycloalkylC_{1-6}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, Ar or $-C_{1-6}alkylAr$;

15 R^9 represents H or R^{10} ; or two R^9 groups together with a nitrogen atom to which they are mutually attached may complete a pyrrolidine, piperidine, piperazine or morpholine ring which is optionally substituted by R^{12} , $-COR^{12}$ or $-SO_2R^{12}$;

R^{10} represents $C_{1-10}alkyl$, perfluoro $C_{1-6}alkyl$, $C_{3-10}cycloalkyl$,
20 $C_{3-6}cycloalkylC_{1-6}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{6-10}aryl$, heteroaryl, heterocyclyl, $C_{6-10}arylC_{1-6}alkyl$, heteroaryl $C_{1-6}alkyl$, $C_{6-10}arylC_{2-6}alkenyl$, or heteroaryl $C_{2-6}alkenyl$, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups optionally bear one substituent selected from halogen, CF_3 , NO_2 , CN, $-OR^{11}$, $-SR^{11}$, $-SO_2R^{12}$, $-COR^{11}$, $-CO_2R^{11}$, $-CON(R^{11})_2$, $-OCOR^{12}$, $-N(R^{11})_2$
25 and $-NR^{11}COR^{12}$; and the aryl, heteroaryl and heterocyclic groups optionally bear up to 3 substituents independently selected from halogen, NO_2 , CN, R^{12} , $-OR^{11}$, $-SR^{11}$, $-SO_2R^{12}$, $-COR^{11}$, $-CO_2R^{11}$, $-CON(R^{11})_2$, $-OCOR^{12}$, $-N(R^{11})_2$ and $-NR^{11}COR^{12}$;

R^{11} represents H or R^{12} ;

30 R^{12} represents $C_{1-6}alkyl$, perfluoro $C_{1-6}alkyl$, $C_{3-7}cycloalkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, Ar, $-C_{1-6}alkylAr$ or $ArOC_{1-6}alkyl$; or two R^{12} groups

together with a nitrogen atom to which they are mutually attached may complete a heterocyclic ring system of 3-10 atoms, 0-2 of which (in addition to said nitrogen atom) are selected from O, N and S, said ring system bearing 0-2 substituents selected from halogen, CN, NO₂, R¹², OR¹¹,
5 NHR¹¹, and COR¹¹.

R¹³ represents R⁹, -COR¹⁰, -CO₂R¹⁰, -SO₂R¹⁰, -CON(R⁹)₂ or -SO₂N(R⁹)₂;

each R¹⁶ independently represents H or R¹⁰, or two R¹⁶ groups together with the nitrogen to which they are mutually attached complete a
10 mono- or bicyclic heterocyclic ring system of 5-10 ring atoms selected from C, N, O and S, said ring system optionally having an additional aryl or heteroaryl ring fused thereto, said heterocyclic system and/or additional fused ring bearing 0-3 substituents independently selected from halogen, NO₂, CN, R¹², -OR¹¹, -SR¹¹, -SO₂R¹², -COR¹¹, -CO₂R¹¹, -CON(R¹¹)₂,
15 -OCOR¹², -N(R¹¹)₂ and -NR¹¹COR¹²;

Ar represents phenyl or heteroaryl either of which optionally bears up to 3 substituents independently selected from halogen, CF₃, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;

"heterocyclyl" at every occurrence thereof means a cyclic or
20 polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein none of the constituent rings is aromatic and wherein at least one ring atom is other than C; and

"heteroaryl" at every occurrence thereof means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein at
25 least one of the constituent rings is aromatic and wherein at least one ring atom is other than C;

or a pharmaceutically acceptable salt thereof.










2. A compound of formula I as defined in claim 1, or a
30 pharmaceutically acceptable salt thereof, with the proviso that:

when $A = B = -CH_2CH_2-$, $R^1 = R^2 = H$, $R^3 = \text{phenyl}$ and $m = 0$, $(CXY)_n$ is other than $-CH_2-$, $-CH(Br)-$ or $-CH(SPh)-$; and




when $m = n = 0$, $R^1 = R^2 = H$, $R^3 = \text{phenyl}$ and $B = -CH_2CH_2-$, A is other than $-CH(Br)CH_2CH_2-$.




5

3. A compound according to claim 2 selected from:




10





and

5




where w is 1 or 2; or a pharmaceutically acceptable salt thereof.

10

4. A compound according to claim 2 or claim 3 wherein m and n are both 0, and R¹ and R² are both H.

5. A compound according to claim 2 of formula II:



II

wherein:


w is 1 or 2; and

A¹ represents -CH₂CXY-, -CH₂CH₂CH₂CH₂-, -CH₂CH=CHCH₂- or -CH₂CXYCH₂-;

5 or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 5 wherein w is 1; R¹ and R² are both H; Y is H or together with X represents =O, =N-OR¹¹ or =CH₂; and X is selected from H, C₁₋₆alkyl, -CO₂R⁹, -OCOR¹⁰, -OCO₂R¹⁰, -OSO₂R⁹,
10 and -CON(R⁹)₂, or together with Y represents =O, =N-OR¹¹ or =CH₂.

7. A compound according to claim 2 of formula IIA:




IIA

wherein:


15 w is 1 or 2; and

A² represents -CH₂-NR¹³-CXY-CH₂- or



20 or a pharmaceutically acceptable salt thereof.


8. A compound according to claim 2 of formula III:



wherein w is 1 or 2;

5 or a pharmaceutically acceptable salt thereof.


9. A compound according to claim 8 of formula IV:



10

or a pharmaceutically acceptable salt thereof.


10. A compound according to claim 9 of formula V:



wherein R^{4a} represents $-N(R^9)_2$, $-NR^9COR^{10}$ or $-NR^9CO_2R^{10}$,
or a pharmaceutically acceptable salt thereof.

5

11. A compound according to claim 9 of formula VA:




10 wherein R^{4b} represents C_{2-6} alkenyl (which is optionally substituted by halogen, CN, OR^{11} , $-CO_2R^{11}$, $-COR^{11}$ or $-CON(R^{11})_2$), C_{6-10} aryl C_{2-6} alkenyl, heteroaryl C_{2-6} alkenyl, $-CH=CHCH_2N(R^{16})_2$, $-OR^{10}$, $-CH_2OR^9$, $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$;
or a pharmaceutically acceptable salt thereof.

15

12. A compound according to claim 11 wherein R^{4b} represents $-CH=CH_2$, $-CH=CHCN$, $-CH=CH-CH_2OR^{11}$, $-CH=CH-CO-Ar$, $-CH=CH-CO_2R^{11}$, $-CH=CHAr$, $-CH=CHCH_2N(R^{16})_2$, $-OCH_2Ar$, $-OCH_2CH_2OR^{12}$, $-OCH_2CON(R^{12})_2$, $-OCH_2CH_2N(R^{12})_2$, $-CH_2OR^9$,
20 $-NHCOCH_2OR^{10}$ or $-NHCOCH_2N(R^{16})_2$.

13. A compound according to claim 2 of formula IIIC:



IIIC

5 wherein

V represents $\mathbb{C}R^4$ or \mathbb{N} ;

W represents CH or N;

a is 0 or 1;

b is 0 or 1; and

10 w is 1 or 2;

or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 9 wherein:

w is 1;

15 R^1 is H ;

R³ is selected from n-propyl, n-butyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-chlorophenyl, 2-thienyl, 5-chloro-2-thienyl, 5-bromo-2-thienyl, 3-pyridyl, 6-chloro-2-pyridyl and 5-isothiazolyl; and

20 R⁴ is in the β -position with respect to the ring junction and is
selected from pyridine-2-carboxamido, phenoxyacetamido,
4-chlorophenoxyacetamido, 2,4-dichlorophenoxyacetamido,
4-fluorophenoxyacetimido, morpholin-4-ylacetamido, pyrrolidin-1-
ylacetamido, piperidin-1-ylacetamido, 4-phenylpiperazin-1-ylacetamido,
25 4-(4-fluorophenyl)piperazin-1-ylacetamido, 2-(4-fluorophenoxy)ethoxy,

2-(morpholin-4-yl)ethoxy, 2-(morpholin-4-yl)ethylamino,
2-(4-fluorophenoxy)ethylamino, 2-(4-chlorophenoxy)ethylamino,
3-(4-fluorophenoxy)propenyl, 3-(imidazol-1-yl)propenyl, 3-(morpholin-4-
yl)propenyl, 5-(pyridin-2-yl)-1,2,4-oxadiazol-3-yl, 5-(pyridin-3-yl)-1,2,4-
5 oxadiazol-3-yl, 5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl, 3-(2-aza-5-
oxabicyclo[2.2.1]hept-2-yl)propenyl, 2-(2-aza-5-oxabicyclo[2.2.1]hept-2-
yl)ethoxy, 3-(4-fluoropiperidin-1-yl)propenyl, 2-(4-fluoropiperidin-1-
yl)ethoxy, 3-(4-trifluoromethylpiperidin-1-yl)propenyl and 2-(4-
trifluoromethylpiperidin-1-yl)ethoxy.

10

15. A compound of formula I as defined in claim 1, or a
pharmaceutically acceptable salt thereof, for use in a method of treatment
of the human or animal body.

15

16. The use of a compound of formula I as defined in claim 1, or a
pharmaceutically acceptable salt thereof, in the manufacture of a
medicament for the treatment or prevention of Alzheimer's disease.

20

17. A method of treatment of a subject suffering from or prone to
Alzheimer's disease which comprises administering to that subject an
effective amount of a compound of formula I as defined in claim 1, or a
pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/ 1/01154

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C311/07 C07C311/09 C07C311/11 C07C311/14 C07C311/20
 C07C311/24 C07C323/67 C07D207/36 C07D211/14 C07D213/38
 C07D213/70 C07D213/71 C07D213/81 C07D215/20 C07D233/84

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BEILSTEIN Data, WPI Data, EPO-Internal, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 5 703 129 A (P. CHATURVEDULA, ET AL.) 30 December 1997 (1997-12-30) the whole document --- | 1,16,17 |
| A | WO 98 38156 A (TAKEDA CHEMICAL INDUSTRIES) 3 September 1998 (1998-09-03) the whole document --- -/-- | 1,16,17 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the International search report

04/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

Application No
PCT/ 11/01154

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D249/08 C07D275/02 C07D277/36 C07D277/42 C07D295/18
C07D295/22 C07D307/64 C07D307/81 C07D319/18 C07D333/20
C07D333/34 C07D409/12 C07D413/12 C07D413/14 C07D417/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P, X | G.M. RISHTON, ET AL.: "Fenchylamine sulphoramide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease" JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 12, 23 May 2000 (2000-05-23), pages 2297-2299, XP002169798 American Chemical Society, Washington, DC, US ISSN: 0022-2623 table 1 --- -/-- | 1, 2, 16, 17 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/61/01154

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 C07D491/08 C07D491/10 A61K31/18 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | M. NARISADA, ET AL.: "Synthesis and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, (+/-)-(5Z)-7-(3-endo-(phenylsulphonyl)-amino!bicyclo[2.2.1]hept-2-exo-yl)-heptenoic acid" JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 9, September 1988 (1988-09), pages 1847-1854, XP002169870 American Chemical Society, Washington, DC, US ISSN: 0022-2623 the whole document --- -/-- | 1,2 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

PCT/G Application No.
11/01154

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | Y. YAMAGUCHI, ET AL.: "Sex differences in the metabolism of (+)-S-145, a novel thromboxane A2 receptor antagonist in rat" XENOBIOTICA, vol. 26, no. 6, June 1996 (1996-06), pages 613-626, XP001009742 Taylor and Francis, London, GB ISSN: 0049-8254 the whole document | 1,2 |
| X | --- R. HUISGEN, ET AL.: "1,3-Dipolare Cycloadditionen, XXII. Zur Anlagerung organischer Azide an winkelgespannte Doppelbindungen" CHEMISCHE BERICHTE, vol. 98, no. 12, December 1965 (1965-12), pages 3992-4013, XP002169799 Verlag Chemie, Weinheim, DE ISSN: 0009-2940 compound 34 | 2 |
| X | --- L.H. ZALKOW, ET AL.: "The solvolysis of 7-anti-bromo-2-exo-benzenesulphonamido-bicyclo[2.2.1]heptane. An example of solvolytic ring opening" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 86, no. 19, 5 October 1964 (1964-10-05), pages 4208-4209, XP002169800 American Chemical Society, Washington, DC, US ISSN: 0002-7863 compounds I,II,V,XI | 2 |
| X | --- S. ITSUNO, ET AL.: "Enantioselective synthesis of optically active homoallyl amines by nucleophilic addition of chirally modified allylboranes to N-silylimines" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, no. 10, 15 July 1999 (1999-07-15), pages 2011-2016, XP002168834 Royal Society of Chemistry, Letchworth, GB ISSN: 0300-922X compounds 16a-c,17,18 --- -/-- | 2 |

INTERNATIONAL SEARCH REPORT

| | |
|------------|---------------|
| Internatio | pplication No |
| PCT/6 | 1/01154 |

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | L.H. ZALKOW, ET AL.: "The reaction of benzenesulphonyl azide with bicyclo'2.2.1!-2-heptene" JOURNAL OF ORGANIC CHEMISTRY, vol. 28, no. 12, December 1963 (1963-12), pages 3303-3309, XP002169801 American Chemical Society, Washington, DC, US ISSN: 0022-3263 compounds III, IV, V, VI, VII, VIII, XVIII, XIX | 2 |
| X | J.E. FRANZ, ET AL.: "The structure and reactions of the 1:1 adduct of benzenesulphonyl azide and bicyclo'2.2.1!heptene" JOURNAL OF ORGANIC CHEMISTRY, vol. 29, no. 10, October 1964 (1964-10), pages 2922-2927, XP002169802 American Chemical Society, Washington, DC, US ISSN: 0022-3263 compounds IIa, IIb, IIc, IIIa, IIIb; figure 6 | 2 |
| X | K.B. SHARPLESS, ET AL.: "Allylic amination of olefins and acetylenes by imido sulphur compounds" JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 1, 9 January 1976 (1976-01-09), pages 176-177, XP002169803 American Chemical Society, Washington, DC, US ISSN: 0022-3263 example 6 | 2 |
| X | US 3 406 184 A (M.S. RAASCH) 15 October 1968 (1968-10-15) column 8, line 11 | 2 |
| X | US 3 715 362 A (S. DOMINIANNI) 6 February 1973 (1973-02-06) column 2, line 36 - line 41 | 2 |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-9,13,14 (partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which part(s) of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

For these reasons it appears impossible to execute a meaningful search and /or to issue a complete search report over the whole breadth of the claim(s). The search and the report for those claims can only be considered complete for compounds in which R1 is H, methyl, allyl and which contain the bridged ring systems as illustrated by the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ 1/01154

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|---|--|
| US 5703129 | A | 30-12-1997 | NONE | |
| WO 9838156 | A | 03-09-1998 | AU 6116698 A EP 0971878 A JP 11080098 A | 18-09-1998 19-01-2000 23-03-1999 |
| US 3406184 | A | 15-10-1968 | NONE | |
| US 3715362 | A | 06-02-1973 | NONE | |

This Page Blank (uspto)